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Introduction
10 Chapter 1
INTRODUCTION TO THIS THESIS
Inflammatory bowel disease (IBD) is an idiopathic chronic gastrointestinal disease 
with genetic susceptibility playing an important role 1. This is further explored in this 
thesis. The initiative for this thesis started within the departments of Gastroenterology 
and Hepatology, and Internal Medicine of the Erasmus MC University Medical Centre 
Rotterdam (UMCR).
AIM OF THIS THESIS
The primary research goal was to explore aspects of the genetic aetiology of IBD 
by searching for mutations in inflammation-related genes in patients with IBD. Many 
IBD-affected patients and (non-)affected relatives were recruited to set up a clinical 
and genetic IBD database. Initially, the research protocol focused on cytokine (recep-
tor) genes. This focus was extended to research on other polymorphic genes based 
on new findings in the literature. We have mainly focused on mutations within the 
interleukin-10 (IL-10) and caspase recruitment domain 15 (CARD15) genes, with 
emphasis on their prevalence, biological (dys)function, and association with disease 
phenotypes. Furthermore, genetic anticipation in IBD was studied. 
HIGHLIGHTS OF IBD
Definition
IBD is an idiopathic chronic relapsing disorder characterised by inflammation of 
the gastrointestinal tract. There are two well defined subtypes, Crohnʼs disease (CD) 
and ulcerative colitis (UC).
Crohnʼs disease
CD was launched as a defined disease in 1932 by Crohn, Ginzburg and 
Oppenheimer working at the Mount Sinai hospital in New York (United States). Initially 
they described the disease as ʻregional ileitisʼ 2. With later knowledge that the dis-
ease could also affect other sites of the gastrointestinal tract, the ʻCrohnʼs diseaseʼ 
became accepted.
Epidemiology  CD is a typical Western disease, with a rising incidence 3, 4. Lately, 
the incidence of CD also rose in non-western countries 5, 6. The incidence is char-
acterised by a north-south gradient. In Europe, the incidence of CD is 80% higher 
in northern countries compared with southern countries 7. In The Netherlands, the 
incidence is 4-8 cases per 100,000 and the prevalence around 0.05% 7-9. The dis-
ease is somewhat more common in females than in males, and the median age of 
diagnosis is 29 years 9. Appendectomy and smoking are associated with an increased 
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risk of developing CD 10, 11. The risk of small bowel and colorectal cancer is slightly 
increased in CD, but the overall survival is similar to the general population 12, 13. 
However, in a recent European multicentre study an overall increased mortality was 
seen ten years after diagnosis, especially in patients diagnosed with CD beyond the 
age of 40 years and mainly due to gastrointestinal causes 14.
Clinical aspects  CD is characterised by a focal or multifocal chronic transmu-
ral inflammatory process with lymphoid aggregates 15. Non-caseating granulomas 
can be found in 26-37% 16, 17, and may indicate a more aggressive disease 17. CD 
can affect any part of the gastrointestinal tract, of which the ileocecal region is 
most common (40%). In roughly one-third of patients CD is confined to the small 
bowel, another third has disease only affecting the colon, whereas in the remainder 
the disease affects both small and large bowel 18, 19. In 1998, the Vienna classifica-
tion was proposed to categorise patients with CD based on the age at diagnosis, 
the location of disease and the disease behaviour 20. CD can give rise to complica-
tions like stenosis and/or fistulas. Symptoms of CD are abdominal pain, diarrhoea, 
fever, rectal bleeding and weight loss. These symptoms are related to the location of 
inflammation and the disease behaviour 21. Several immune-related extra-intestinal 
manifestations are common in CD, such as arthritis, erythema nodosum, pyoderma 
gangrenosum, aphtous stomatitis and uveitis 22.
Diagnosis  In most cases the diagnosis is based on compatible symptoms, risk 
factors, physical findings, typical ileocolonoscopic features (Figure 1), histology of 
biopsies or surgical samples, and conventional radiology studies, like enteroclysis 
and abdominal ultrasonography 18, 23, 24. New diagnostic tools can be helpful, like 
capsule and double-balloon endoscopy, magnetic resonance imaging and computed 
tomography 25. Laboratory tests, especially C-reactive protein, and detection of spe-
cific antibodies like anti-Saccharomyces cerevisiae antibody (ASCA) and perinuclear 
anti-neutrophil cytoplasmic antibody (pANCA), can also be helpful 26, 27. Using sero-
diagnostic tests as the initial work up in patients suspected to have IBD might be 
cost-effective 28.
Treatment  In moderate active CD, sulfasalazine is effective in left-sided disease, 
while budesonide is first choice in right-sided and terminal ileum disease. In more 
severe active disease prednisone is indicated. Infliximab, a chimeric monoclonal anti-
body directed against tumour necrosis factor α (TNFα), is used for steroid-resistant 
patients, or when CD is complicated by perianal fistula. Immunomodulators, like 
azathioprine, 6-mercaptopurine and methotrexate, are effective to maintain remis-
sion after induction therapy, in particular with steroids. Most patients need surgery 
during their disease course 29-31.
Ulcerative colitis
Early reports about UC were published by Lockhart-Mummery from St. Markʼs 
Hospital in London (United Kingdom) in the beginning of the 20th century 32.
Epidemiology  The incidence of UC in The Netherlands is 7-13 cases per 100,000 
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inhabitants and the prevalence around 0.06% 7, 9, 33. Similar to CD, the incidence of 
UC shows a European north-south gradient and it is rising in both western and non-
western countries 5-7. Males are more often affected than females 7, 9. In contrast with 
CD, appendectomy and smoking reduce the risk of developing UC 10, 34. The overall 
risk for colorectal cancer is the same as in the general population, but patients with 
an extensive colitis have a considerably increases risk 12. Survival of UC-affected 
patients does not differ from the general population 13.
Clinical aspects  In UC, intestinal inflammation is continuous and superficial 
including the mucosa and submucosa. UC is a large bowel disease invariably involv-
ing the rectum, which can extend to the proximal colon. Based on the extend of 
inflammation, UC is classified as proctitis (rectum only), left-sided colitis (up to the 
splenic flexure) and extended or pancolitis (beyond the splenic flexure). Symptoms 
are rectal bleeding, urgency, diarrhoea, abdominal discomfort, loss of appetite and 
weight loss 15, 35. UC can also present with extra-intestinal manifestations. Most of 
them are similar to the manifestations associated with CD. Primary sclerosing chol-
angitis is a serious extra-intestinal manifestation, which is more common in UC- 
than in CD-affected patients 22.
Diagnosis  As UC is limited to the colon, (ileo)colonoscopy and mucosal sam-
pling are the most important tools to establish the diagnosis. The typical endoscopic 
mucosal appearances of UC (continuous mucosal inflammation starting from the 
dentate line with loss of vascular pattern, cryptitis, erosions, normal ileocecal valve 
and sometimes periappendicular inflammation) are different from those found in CD 
(skip lesions, cobblestoning, aphthous and longitudinal ulcers, ileocecal involvement 
and anal lesions). Endoscopic views are demonstrated in Figure 1. In severe disease, 
the endoscopic features of UC and CD may be difficult to distinguish 18, 24, 36. Non-
invasive test are also used in UC 26-28. 
Treatment  First-line treatment in mild to moderate UC consists of 5-amino-
salicylates (5-ASA, mesalazine), which can induce and maintain remission. In moder-
ate to severe active disease steroids are effective, usually combined with azathioprine 
or 6-mercaptopurine. Cyclosporine can be used in patients with severe active UC who 
are steroid-resistant 29, 30. Recently, infliximab was also proved to be effective (as 
rescue therapy) in moderate to severe active UC 37, 38. Surgical therapy is necessary 
in acute toxic colitis, intractable disease or colorectal cancer. Usually a total procto-
colectomy with ileostomy or an ileal pouch-anal anastomosis is performed 39.
Indeterminate colitis
In patients with exclusively colonic inflammation in who no differentiation can 
made between CD and UC, the disease is defined as indeterminate colitis (IC). 
Originally, the term IC was preserved for patients who had undergone colorectal 
surgery, but in whom subsequently no pathological diagnosis could be made on the 
resected specimen 40. In The Netherlands, the incidence of IC is around 0.001% 9. 
During follow-up of patients with the initial diagnosis IC, about 50% can be reclas-
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sified as having either CD or UC. It is assumed that the clinical course of IC is more 
similar to UC than CD. Medical treatment is based on the anatomical distribution, 
the severity and the relapse rate of the disease, including 5-amino-salicylates, ste-
roids, azathioprine or 6-mercaptopurine, and even infliximab. Surgical treatment 
involves total proctocolectomy with an ileal pouch-anal anastomosis. This procedure 
in patients with IC, however, is associated with more frequent occurrence of post-
operative complications than in patients with UC 41.
Pathogenesis 
Acquired immunity  The traditional concept regarding the cause of IBD is an 
abnormal response of cells from the acquired immune system, leading to an exag-
gerated aggressive activity of effector lymphocytes and pro-inflammatory cytokines 
in response to gut-derived antigens presented by antigen-presenting cells. The dis-
ease may also result from dysfunctional control mechanisms, such as an abnormal 
secretion of the anti-inflammatory cytokine IL-10 and transforming growth factor-β. 
The pro-inflammatory cytokines are secreted by T-helper (Th) cells, of which two 
types are identified. Th-1 cells mainly secrete IL-12, interferon γ (IFNγ) and TNFα. It 
is responsible for the cell-mediated immunity. Primary mediators of Th-2 cells are 
IL-4 and IL-5. They mediate the humoral immunity. Until recently, CD was thought 
to be Th-1 driven and UC a Th-2 driven disease.
Innate immunity  Recently, evidence has become available that the innate 
immune system is also involved in the aetiology of IBD. This immune system is a 
rapidly responding non-specific defence mechanism against pathogens. It recog-
nises molecular motifs of an antigen instead of the specific antigen itself. Toll-like 
receptors (TLRs) are well described surface receptors of several intestinal immune 
cells, sensing so-called pathogen-associated molecular patterns.
Bacteria  In the complex inflammatory mechanism of IBD, several responsible co-
factors are identified. For example, gut flora is important for inflammatory induction 
as deviation of the faecal stream 42, antibiotic and probiotic treatment especially in 
pouchitis 43 can lead to disease remission. Animal studies using normal and knock-
out models, such as IL-10 deficient mice, have demonstrated that a germ-free envi-
ronment leads to a quiescent immune system 44.
Epithelium  Otherwise, the intestinal epithelium which is part of the innate 
immune system is important as it is the first (anatomical) defence level. In CD, an 
increased intestinal permeability has been found 45. The epithelium harbours M-cells 
and dendritic cells, which are responsible for sampling components of luminal bac-
teria and to present these components to cells of the immune system.
Environment  Environmental influences in IBD susceptibility are well known. 
Accepted risk and preventive factors in IBD are smoking, appendectomy, perinatal 
events and socio-economic background. In general, these factors have an effect on 
the immune response, leading to up- or down-regulation of the intestinal inflam-
matory mucosal response 44, 46-48. In multiple CD-affected families, a trend was found 
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towards an excess of consecutive CD-affected sib-pairs as affected siblings were not 
randomly distributed within sibships as would be expected in case of a pure genetic 
disorder. Adjacent birth order of CD-affected siblings might involve a common envi-
ronment. Therefore, the excess of observed affected sibling clusters supports the 
hypothesis of environmental involvement in CD 49.
Genes  Genetic susceptibility to IBD and the search for disease-causing (altered) 
genes are of major interest since the first CD gene, the CARD15 gene, was identified 
in 2001 50, 51. This aspect will be described next in more detail.
Genetic susceptibility in IBD
Genetic epidemiology  Initial evidence for genetic involvement in IBD was based 
on epidemiological studies, including ethnic (Jews versus non-Jews) 52, 53 and racial 
differences (Caucasians versus non-Caucasians) 54. In five to ten percent of patients 
with IBD familial clustering exists, meaning that the largest risk to develop IBD dur-
ing life is having a family member with IBD 55. First-degree relatives of CD- and 
UC-affected probands have a 5.2 and 1.6% age-corrected lifetime risk to develop 
IBD, respectively. In Jewish families this risk is even higher 53. Evidence for a genetic 
role in IBD comes from the observed higher concordance rate for disease type in 
monozygotic twins than in dizygotic twins, especially in CD (around 40 versus four 
percent) 56-58. These data also support a reduced penetrance of IBD genes, as not 
100% disease concordance exists in the monozygotic twins and the disease risk in 
dizygotic twins is similar to siblings 59. In monozygous CD-affected twins, also high 
concordance rates were found for the three phenotypes as defined in the Vienna 
Classification 58. Otherwise, high concordance rates for type, location and behaviour 
of disease is reported in multiple IBD-affected families other than twins 60, suggest-
ing a common genetic risk factor.
Genetic anticipation  Some monogenic disorders have demonstrated genetic 
anticipation, meaning that in following generations the disease manifests at an ear-
lier age and/or with a more severe course. This phenomenon is thought to be the 
result of expansion of unstable trinucleotide repeats in the disease-causing gene. 
Although IBD is a multigenic disease, several studies have demonstrated remarkable 
differences in age at diagnosis between IBD generations. However, these retrospec-
tive studies involving disease-affected parent-child pairs included generations at 
different ages. This will lead to a preferential inclusion (ascertainment bias) in which 
the parent and child have a different completed risk period for their disease (fol-
low-up bias). Therefore, it is likely that genetic anticipation in IBD is explained by 
bias within the data 60.
Genetic research  Since the early 1990ʼs, various molecular genetic studies in 
IBD have been performed. Initially, studies using complex segregation analysis in 
IBD-affected families provided evidence for the involvement of a recessive gene with 
incomplete penetrance in CD and a dominant or additive gene in UC 61-63. Although 
simple Mendelian inheritance might be true in a subset of IBD patients (a major sin-
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gle mutation among several other involved genes with a limited individual impact), 
studies using segregation analysis cannot discriminate between inheritance models 
involving multiple genes or genetic heterogeneity (i.e. different genetic diseases 
with similar phenotype), which has become the accepted genetic model in IBD 59. 
Meanwhile, nine putative chromosomal IBD loci have been identified (IBD1-9, Figure 
2) 64, 65. The current genetic model for IBD includes a heterogeneous family of inflam-
matory disorders in which specific clinical disease manifestations in any individual 
are determined by interaction of genetic and environmental factors. In this type of 
complex disease, specific susceptibility genes can lead to either CD or UC. Other 
modifier genes are responsible for specific phenotypes once the disease is present 
(Figure 3) 64, 66.
GENE SEARCH TECHNIQUES
Markers
To search for DNA regions of interest including susceptibility genes or to evaluate 
susceptibility of already identified genes, genomic variations (alleles) are required. 
These DNA variations, also called polymorphic genetic markers, have to be located 
near or within the chromosomal region of interest or gene. These markers can for 
example consist of single nucleotide polymorphisms (SNPs), insertions or deletions 
of one or more base pairs, or microsatellites. Microsatellite markers are anonymous 
repeated DNA sequences with a variable length. Genetic markers are (more) useful 
when individuals in the study population have different alleles on the two homolo-
gous chromosomes carrying the particular marker and when a high heterozygosity 
exists, meaning much genetic variability. With this (flagging) technique two comple-
mentary genetic analyses are available, i.e. linkage and association studies 59, 65.
Linkage analysis
Linkage analysis is performed in multiple disease-affected families, usually 
affected sibling pairs or affected relative pairs. It evaluates whether a particular 
locus co-segregates with the presence or absence of the trait within families. One 
would expect that disease-causing loci are present in affected subjects. Especially, 
multi-point linkage analysis is informative as it tests for linkage between two or 
more proximal allele markers and a trait. A set of closely linked alleles inherited as 
a unit is called a haplotype. Two-point linkage analysis tests for segregation of only 
a single maker, and therefore its informative value depends highly on the hetero-
zygosity of the marker. Linkage is based on the frequency of co-segregation of the 
marker with the disease within families with multiple disease-affected members. In 
fact, the method compares the number of alleles which are shared between relatives. 
The outcome is expressed in a log odd (LOD) score. A LOD score of at least three is 
usually accepted as significant linkage 59, 65, 67.
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Association analysis
In an association based strategy, the frequency of specific alleles of a marker 
(indirect testing) is evaluated in patients with the disease (cases), and in (healthy) 
individuals without the disease. In contrast with linkage analysis, the chosen mak-
ers are usually much more close to the studied allele. Association analysis can also 
be performed by using a specific gene mutation (direct testing). The method is 
more powerful than linkage analysis with respect to gene (and any given locus) 
causality 59, 67, 68.
GENE FINDING
Genome-wide screening linkage mapping
In this type of genetic research the whole human genome is screened for chro-
mosomal regions that may contain susceptibility genes. This systematic mapping 
approach is based on linkage analysis using a large number of (highly) polymorphic 
markers, that are evenly spread across the genome. Traditionally, linkage analysis 
for genome screening is performed with microsatellite markers. Using a dense map 
of closely spaced SNPs is a new approach with a higher power to detect linkage 69.
In a complex disease like IBD, affected sib-pairs are mostly used and no restric-
tions are made regarding the mode of inheritance (non-parametric analysis). When 
a chromosomal region harbours a genetic factor involved in the aetiology of the 
disease, affected sib-pairs will share alleles at this region more often than expected 
by chance (identical-by-descent). During gamete formation, randomly one of the 
rearranged chromosomes due to meiosis is transmitted to offspring. Therefore, when 
more than 50% of the affected relatives co-inherit the specific chromosomal region 
linkage is present. 
Meanwhile, 11 genome scans in IBD have been performed using the traditional 
linkage method with microsatellite markers. The genome scans have identified seven 
chromosomal regions with confirmed and replicated IBD linkage (Figure 2). The IBD1 
locus, a pericentromeric region of chromosome 16, is the best known locus and was 
found to be significantly linked to CD. Within this locus the CARD15 gene has been 
discovered as the first susceptibility gene in CD 59, 65, 67, 70.
Positional mapping
The linkage peaks identified in genome scans usually cover large regions 
which may contain hundreds of biologically plausible candidate genes (see below). 
Positional mapping is a refining technique, in which a dense set of markers (SNPs) 
is tested for (the strongest) association throughout the linkage region. Its results 
depends on whether linkage dysequilibrium (LD) exists with the causal genetic vari-
ant. LD is a population genetic phenomenon by which alleles at different but closely 
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located genetic loci remain together on chromosomes throughout generations. 
Hopefully, ultimately a causal variant in a susceptibility gene is discovered. This 
technique has a greater power than linkage studies to identify genes with a small 
disease effect 59, 67.
Candidate gene analysis
Testing candidate genes is another approach to find disease genes in complex 
traits. It focuses on genes that are selected based on knowledge about their bio-
logical function that is likely to have an influence on the disease susceptibility. This 
approach is usually conducted in a case-control association study, but linkage analy-
sis with candidate genes is also possible 59, 67, 68.
Highly polymorphic and well studied candidate genes are those of the human leu-
kocyte antigen (HLA) region on chromosome 6. These genes play an important role 
in the presentation and recognition of antigens. Associations between several major 
histocompatibility complex (MHC) class II HLA alleles and CD and/or UC, specific IBD 
phenotypes, and extraintestinal manifestations have been found 71. The MHC complex 
is part of the IBD3 locus, which is one of the IBD-linked chromosomal regions found 
by genome screening 72. Other examples of associations with IBD have been found for 
promoter polymorphisms of the TNF gene 71, a specific allele of the variable number of 
tandem repeats sequence in intron 2 of the IL-1 receptor (IL-1R) antagonist gene 73, 
and polymorphisms of the TLR-4 gene 74. Associations between polymorphisms in 
the IL-10 gene will be discussed below. In addition, candidate gene studies with 
negative results have been published, showing no association between the studied 
gene and IBD. For example, the multidrug resistance 1 gene 75, the IL-4R gene 76, 77 
and the chemokine receptor CCR5 gene 77.
CARD15 GENE
Gene finding  In 2001, the first susceptibility gene in CD was discovered. This 
CARD15 gene (formerly called nucleotide binding oligomerisation domain 2 (NOD2)) 
is located on chromosome 16q12. It was found through fine mapping of the IBD1 
locus by one consortium group 50, and by a candidate gene approach with direct 
sequencing and transmission analysis within IBD families 51, 78, 79 by two other groups. 
CARD15 is a member of the Ced4 superfamily, a group of apoptosis regulating mol-
ecules, including apoptotic protease activating factor 1 80 and CARD4 81, 82 in humans. 
CARD15 is expressed in monocytes, macrophages, dendritic cells and intestinal epi-
thelial cells, especially in Paneth cells 83-86.
Mutations  In 2002, 67 nucleotide variations in the CARD15 gene were identified, 
of which 30 non-conservative missense mutations with a putative functional effect. 
Only three of these mutations independently appeared to be highly associated with 
CD in Caucasian populations from North America and Europe. These mutations were 
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2104C → T in exon 4 (SNP8, R702W, Arg702Trp), 2722G → C in exon 8 (SNP12, 
G908R, Gly908Arg), and 3020insC in exon 11 (SNP13, L1007fs, Leu1007fsinsC). 
These three common mutations represent more than 80% of all mutated alleles 
and are located near or in the leucine-rich region (LRR) 87. The frameshift mutation 
L1007fs leads to a truncated protein lacking the 33 distal amino acids. Since 2002, 
another 17 mutations have been reported 88-90. Mutations within the centrally located 
NOD (see below) show association with Blau syndrome, a rare monogenic highly 
penetrant granulomatous disease 91. No association was found between the three 
common CARD15 mutations and UC 87, except for one study which demonstrated 
a significantly increased prevalence of L1007fs in UC compared with controls 92. 
Several studies in Caucasian populations from different countries have been pub-
lished about the prevalences of the three common CARD15 mutations in IBD. The 
L1007fs is associated with the highest risk toward CD, corresponding with four-fold 
increased relative risk to develop CD in heterozygotes. Carriage of two mutations 
(homozygosity or compound heterozygosity) leads to a 17-fold increased relative 
risk for development of CD 93. In Scandinavian countries like Sweden with a high inci-
dence of CD, CARD15 mutations are less present even in (monozygous) twins, and a 
disease association was only found for R702W and G908R 94, 95. CARD15 mutations 
were also found to be less prevalent in African-Americans and Hispanics with CD 96. 
Furthermore, common CARD15 mutations are nearly absent in the Asian population 93. 
In a recent Dutch multicentre study, association with CD was found for R702W and 
L1007fs, and carriage of at least one variant in 36% of all CD-affected patients 97.
Phenotyping  CARD15 mutations may predispose to certain CD phenotypes, as 
associations have been reported between the common variants and specific clinical 
characteristics. In two large pooled studies, especially small bowel disease and to a 
lesser extent stricturing disease showed associations with carriage of at least one 
common variant. In the same analyses, a slightly increased odds ratio was found for 
a positive family history for IBD 93, 97. 
(Dys)function  CARD15 expression is increased through bacteria and pro-inflam-
matory cytokines 84, 85. CARD15 is an intracellular protein containing two N-terminal 
caspase recruitment domains (CARDs), a centrally located nucleotide oligomerisation 
domain (NOD), and a C-terminal leucine rich region (LRR). The LRR functions as a 
recognition receptor of muramyl dipeptide (MDP), which is a small component of cell 
wall peptidoglycan of gram-positive and gram-negative bacteria 98-100. It is thought 
to play a protective role in the innate and adaptive immunity as well 100. All three 
common CARD15 nucleotide variants are considered to be disease-associated muta-
tions. In vitro studies with transfection of CARD15 plasmids into human embryonic 
kidney cells and MDP stimulation leads to activation of transcription factor nuclear 
kappa-B (NFκB) in mononuclear cells 78. Increased levels and activity of NFκB have 
been observed in colonic mucosa of patients with active CD, and to a lesser extent in 
patients with active UC 101. NFκB comprises a family of inducible transcription factors. 
It is an important regulator of immune- and inflammation-related genes, such as 
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cytokines and anti-apoptotic genes 102. Especially, L1007fs has been demonstrated 
in vitro to be associated with a reduced NFκB activity 98, 99 103, 104. However, a L1007fs 
knock-in mouse model showed that carriage of L1007fs was associated with an 
elevated NFκB activity 105. This mouse model is more in line with the clinical observa-
tion of elevated NFκB activity in patients with active CD 101. Therefore, it is not clear 
whether CARD15 mutations lead to ʻgain-of-functionʼ or ʼloss-of-functionʼ 106.
A promising hypothesis is a decreased expression of intestinal-specific anti-
bacterial α-defensins (cryptdins) from Paneth cells 86, 100. Paneth cells are spe-
cialised epithelial cells located in the mucosal crypts of Lieberkühn and thought to 
play a protective role in the host against enteric flora 107. Paneth cells show a high 
CARD15 expression in CD-affected terminal ileum, but weak expression in nor-
mal ileal mucosa of CD-affected patients and non-IBD individuals 86. Moreover, in 
CD-affected terminal ileum a diminished expression was found of defensin-5 and 
defensin-6, which are secreted by Paneth cells. CARD15 L1007fs carriage showed a 
further defensin deficiency 108, 109.
Meanwhile, other CARD15 involving pathways are explored, for example syn-
ergy between CARD15 and specific TLRs, which are membrane bound and simi-
lar to CARD15 recognising conserved motifs from microbial pathogens. CARD15 
compound heterozygous CD-affected individuals show a loss of synergy between 
CARD15 and TLR-9 (expressed in Paneth cells) with respect to TNFα and IL-8 110, 111. 
Another possible disease pathway is an altered intestinal barrier function. This can 
be harmed due to an increased intestinal permeability, which is found in patients 
with CD and in their healthy relatives. Carriage of CARD15 L1007fs appeared to be 
associated with an increased intestinal permeability in healthy first-degree relatives 
45, 112, except for one study 113.
INTERLEUKIN-10
Function  IL-10 is usually expressed in response to a stimulus in macrophages, 
monocytes, dendritic cells, B lymphocytes and CD4+ regulatory T cells. It is an anti-
inflammatory cytokine and initially named as cytokine synthesis inhibitory factor. It 
influences the expression of several cytokines, soluble mediators and cell surface 
molecules by binding to the IL-10R of cells of the myeloid origin. For example, IL-10 
can down-regulate the production of pro-inflammatory cytokines TNFα, IFNγ, IL-1 
and IL-6, which are first-line cytokines in a Th-1 driven inflammatory response. IL-
10 also inhibits (the expression of) chemokines, prostaglandin E2 and MHC class II 
antigens. Furthermore, TLR-4 (LPS signal transducing receptor) is down-regulated 
and specific scavenger receptors are up-regulated. One of the transcriptional fac-
tors activated following stimulation of IL-10R is signal transducer and activator of 
transcription 3, which can inhibit NFκB. All together, IL-10 induces differentiation of 
macrophage-like cells limiting an ongoing immune response and inflammation, and 
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contributes to clearance of the infection through enhanced phagocytosis. It regulates 
the innate and adaptive immune response 114-116.
IL-10 is considered to play an important role in IBD based on animal studies. 
IL-10 gene knock-out mice spontaneously develop chronic enterocolitis, resembling 
CD in humans 117. However, in a germ-free environment these IL-10 -/- mice have 
no signs of disease 118. IL-10 is effective in preventing and treating spontaneous 
enterocolitis. Therefore, IL-10 seems to be an important cytokine for modulation of 
the immune response maintaining mucosal tolerance against the normal intestinal 
bacterial flora 115. Subcutaneously administered recombinant IL-10 has been evalu-
ated in four clinical trials in CD-affected patients with inconsistent results 119-122. It 
has been suggested that a subgroup of CD patients might benefit from IL-10 admin-
istration 120. Maybe treatment with genetically modified bacteria expressing IL-10 for 
mucosal delivery will in the future provide an alternative treatment option 123.
Gene  The IL-10 gene is located on chromosome 1q32.1. Three SNPs (-1082G/A, 
-819C/T and -592C/A) and two proximally located microsatellite polymorphisms 
(IL-10.G and IL-10.R) have been defined 124-127. The –1082G allele is associated with 
a higher IL-10 production of stimulated T cells and monocytes, and therefore its 
presence might protect against IBD 127. In IBD patients, the frequency of –1082G was 
lower compared with controls 128, particular in UC-affected patients 128, 129, which fits 
this hypothesis. However, these results could not be replicated 130-133. Allele –1082G 
was found to be associated with CD, especially with combined carriage of the IL-
10.G14 allele 134, which is a high IL-10 producing allele 135. The low IL-10 producing 
–1082 A/A genotype showed association with steroid dependency in CD and UC 129. 
Genotype –1082 G/G was associated with complicated disease behaviour in CD 136. 
Based on its function, the IL-10 gene seems to be a good candidate for susceptibility 
to IBD 114, 137. However, candidacy is unlikely concerning the conflicting results with 
respect to the polymorphisms and the microsatellite markers. Moreover, no linkage 
has been found between IL-10 and IBD 138.
There is support for a relation between IL-10 production and carriage of CARD15 
mutations. In vitro stimulation of mononuclear cells with a TLR-2 ligand results in a 
significantly reduced IL-10 production in patients with CD homozygous for CARD15 
L1007fs compared with CD-affected patients and healthy controls homozygous for 
the wild-type CARD15 allele 139. It is likely that this effect is not caused by differ-
ences in carriage of the high and low IL-10 producing alleles, as in a Spanish study 
with CD-affected patients no association was found between carriage of high IL-10 
producing alleles (-1082G, IL-10G14 or both) and at least one common CARD15 
mutation 140.
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GENES UNDER RESEARCH
Based on the results of the genome screens, several new putative IBD suscepti-
bility genes are being evaluated. The IBD5 locus (5q31), which showed to be associ-
ated with susceptibility to CD 141, 142, harbours the organic cation transporters genes 
OCTN1 and OCTN2. Their related proteins are transporters of carnitine and organic 
cations. Two mutations within these genes (1672C → T in exon 9 of OCTN1, and 
–207G → T in the promoter of OCTN2) are together as a two-allele risk haplotype 
associated with CD 143-145. Association of nucleotide variants within the Drosophila 
discs large homologue 5 (DLG5) gene with CD was found by positional cloning of 
the IBD linkage region 10q23 146. DLG5 is thought to play a role in maintaining the 
epithelial cell structure and transmitting transmembrane signals 147. DLG5 mutations 
might be involved in intestinal permeability, leading to an increased IBD risk 106. The 
CARD4 gene is part of an IBD susceptibility locus on chromosome 7p14. Its encoded 
protein is similar in structure and function to CARD15. Genetic variants of the CARD4 
gene are associated with IBD 148. Evaluation of TLRs in IBD is based on their key role 
in the innate immune system. Moreover, in a colitis mouse model TLR-4 antagonist 
can prevent development of colitis 149. Two polymorphisms within this candidate 
gene (Asp299Gly and Thr399Ile) have been evaluated in IBD with variable results 74. 
Very recently, in three case-control cohorts IBD showed association with nucleotide 
variants of the myosin IXB (MYO9B) gene, especially in UC-affected patients. This 
gene is thought to play a role in intestinal permeability and bacterial invasion of the 
epithelium 150. It is located on chromosome 19p13, which region is linked with IBD 
(IBD6 locus) 72, 142. 
New methods to identify susceptibility genes are genome-wide linkage and 
association studies using a very large amount of SNPs (up to 500,000) 69, 74, 151. 
These studies can be performed due to the outcome of the International Human 
Haploptype Map Project (HapMap). This project has determined common patterns of 
DNA sequence variations of the humane genome, including SNPs 152. With the use of 
microarrays these multiple SNPs can be genotyped (SNP chips) 153. Very recently, the 
first genome-wide association study in IBD have shown a highly significant associa-
tion between CD and the IL-23R gene 154.
Otherwise, microarrays can evaluate the expression of many genes of inter-
est, with studies in IBD performed on 1,000−20,000 genes 74. Another approach 
is proteomic analysis. It evaluates expressed proteins, and its related genes 74. The 
use of bioinformatic tools to combine large amounts of data resulting from vari-
ous approaches may lead to the identification of susceptibility and modifier genes 
in IBD 155.
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DESIGN OF THIS THESIS
Aim
The initiative for this thesis started within the departments of Gastroenterology 
and Hepatology, and Internal Medicine. As described above, genetic susceptibility 
plays an important role in the aetiology of IBD. Insight can provide a better under-
standing of the pathogenesis, and may lead to improvement of IBD therapy. The 
primary study goal of this thesis was to search of mutations in inflammation-related 
genes in patients with IBD. The study was approved by the Institutional Review Board 
of the Erasmus MC UMCR.
Participants
Patients meeting standard criteria of IBD 18 and attending the Erasmus MC UMCR, 
were systematically registered and asked whether they had IBD-affected relatives. 
In case of a positive family history, patients (probands), their affected relatives and 
some non-affected relatives were offered to participate in the study. Clinical infor-
mation was collected and a pedigree was drawn up based on a questionnaire, which 
was completed by the participants. Most of the affected relatives and a few probands 
did not attend the Erasmus MC, but other Dutch hospitals. Their diagnosis of IBD 
was verified, based on medical and surgical information supplied by their treating 
physician. Participants were asked to provide blood for DNA testing. All participants 
provided written informed consent. Also healthy anonymous Caucasian individuals 
were included, which served as non-related non-IBD-affected controls.
IBD database
From 1998 until the end of 2002, 1193 patients with IBD were included. Most of 
them were Caucasian (94.1%). Details are presented in Table 1.
Research methods
For the genetic study presented in chapters 2, a linkage analysis with candidate 
genes and microsatellite markers was used. We evaluated specifically individual sib-
pairs, focusing on those pairs who shared common alleles. In sib-pairs who share no 
alleles, it is unlikely that the gene of interest plays an (important) role in the disease 
pathogenesis. In contrast, the change of gene involvement in sib-pairs who share 
both alleles is a priori higher. In chapter 3, this concept (allele-sharing method) was 
used to search for mutations in the IL-10 gene by sequencing the IL-10 gene in the 
ʻhigh changeʼ sib-pairs. IL-10 is an IBD candidate gene because of its anti-inflam-
matory effect as discussed above.
The study methods presented in chapters 4, 6 and 7 are based on association 
analysis with candidate genes, i.e. the IL-10 and CARD15 genes.
In chapter 8, genetic anticipation is evaluated using standard statistical methods.
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OUTLINE OF THIS THESIS
This thesis includes molecular and clinical genetic studies in Dutch familiar and 
sporadic patients with IBD. Most of the chapters have been published or accepted as 
a scientific paper in established gastroenterology journals.
In chapter 2, a linkage analysis study is presented, including inflammation-
related cytokine genes in IBD-affected sib-pairs. The results were used for further 
detailed studies on IL-10 in those sib-pairs who showed allele-sharing.
Chapter 3 describes the finding of a Gly15Arg mutation in the IL-10 gene within 
a multiple CD-affected family. Its biological function was further evaluated in an in 
vitro stimulation test with mononuclear cells and a monocytic cell line. The mutation 
appeared to lead to a decreased IL-10 secretion.
In chapter 4, a multicentre survey is presented about the prevalence of the 
Gly15Arg mutation in a large group of Dutch patients with CD and in healthy unre-
lated controls.
Chapter 5 reviews the role of CARD15 in CD based on the literature published 
until 2002. An update of recent data is given in this chapter.
Chapter 6 focuses on the CARD15 3020insC (L1007fs) mutation, which is highly 
associated with CD. In the presented study, the prevalence of the mutation is evalu-
ated in IBD-affected families and healthy unrelated controls. One family is described 
in detail, as non-IBD-affected relatives appeared to be homozygous carriers of 
3020insC.
In chapter 7, the prevalence of the three common CD-associated CARD15 muta-
tions (R702W, G908R and L1007fs) is evaluated in a large group of multiple IBD-
affected families, sporadic IBD-affected patients and unrelated healthy controls.
Chapter 8 presents a study regarding genetic anticipation in patients with IBD.
Chapter 9 includes a summary and discussion of the presented studies. 
Furthermore, future perspectives are given. 
Chapter 10 includes a summary in Dutch of this thesis.
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Table 1.  Characteristics of the Rotterdam inflammatory bowel disease database
N or years of age (range)
Crohnʼs disease
    Males
    Females
    Mean age
Ulcerative colitis
    Males
    Females
    Mean age
Indeterminate colitis
    Males
    Females
    Mean age
Patients with familial IBD
    Confirmed familial disease
    Unconfirmed familial disease a
Sporadic patients with IBD b
269
441
44.3 (17.9 – 90.9)
239
191
45.9 (12.5 – 86.2)
22
31
45.9 (18.7 – 84.0)
138
127
928
a  IBD-affected relatives of which the diagnosis could not be confirmed as no medical 
and surgical information of their treating physician was available. 
b  Data also include probands which were not interviewed about familial disease 
(n = 33).
IBD, inflammatory bowel disease.
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Figure 1.  Endoscopic views of inflammatory bowel disease. A, early Crohnʼs disease 
of the colon with a small aphthous lesion. B, moderate severe active ulcerative coli-
tis, characterised by fragile continuous mucosal inflammation with loss of vascular 
pattern and with loss of haustration.
A B
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Figure 2.  Linkage areas in inflammatory bowel disease 64.
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Figure 3.  A schematic figure of the current genetic model in inflammatory bowel 
disease (IBD). Specific genes combined with environmental factors lead to either 
Crohnʼs disease (CD) or ulcerative colitis (UC). Other modifier genes are responsible 
for specific phenotypes once the disease is present 64, 66.
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ABSTRACT
Background
The pathogenesis of inflammatory bowel disease (IBD) 
is complex, multifactorial, and involves genetic predis-
position. This predisposition is likely to include various 
chromosomal loci, but simple Mendelian inheritance can-
not be excluded in a subset of families with IBD.
Methods
We evaluated allele-sharing in 17 sib-pairs with IBD 
as an approach to select candidate genes for further 
studies in individual families. It was determined whether 
each sib-pair had inherited the same alleles for inter-
leukin-2 (IL-2), IL-2 receptor β (IL-2Rβ), IL-4, IL-4R, 
IL-10, IL-10R, tumour necrosis factor α (TNFα), TNFα-
R1 and TNFα-R2.
Results
The results were very different per individual family. 
The estimated probability of sharing both alleles identi-
cal-by-descent at IL-4R, IL-10, IL-10R and TNFα were 
50%, 39%, 40%, and 33% respectively. The LOD score was 
significant for IL-4R (P = 0.04).
Conclusion
In this small group of sib-pairs with IBD a modestly 
increased allele-sharing was found for some inflamma-
tion-related genes. Different results per family may sug-
gest genetic heterogeneity. This method can be useful 
as a first step to further evaluation of specific candidate 
genes which may play a pathogenetic role in individual 
families.
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INTRODUCTION
The pathogenesis of inflammatory bowel disease (IBD) is complex and multifac-
torial. Besides imunological and environmental factors, genetic predisposition plays 
an important role in the susceptibility to the two major phenotypes of IBD, Crohnʼs 
disease (CD) and ulcerative colitis (UC). Epidemiological evidence for genetic involve-
ment includes ethnic differences in the frequency of disease and familial aggrega-
tion 1. The most convincing genetic evidence is a higher disease concordance rate in 
monozygotic twins than in dizygotic twins 2, 3.
The search for IBD susceptibility genes has been performed using either a 
genome-wide screening strategy or a candidate gene approach. Highly polymorphic 
anonymous genetic markers (microsatellite markers) are used to flag chromosomal 
regions of interest, which include susceptibility genes. In genome screens, multiple 
informative markers are used spanning (almost) the whole genome. In candidate 
gene studies, linkage is evaluated by using polymorphisms or microsatellite mark-
ers in or around susceptibility genes 4. In most studies affected sib-pairs are used, 
and in the analysis no restrictions are made regarding the mode of inheritance (non-
parametric). When a region or gene harbours a genetic factor involved in the aetiol-
ogy of the trait, affected sib-pairs will share more alleles identical-by-descent than 
under random segregation 5.
At present, the genetic aetiology of IBD is based on polygenic models of inheri-
tance with environmental stimuli. Although IBD is probably heterogenetic, simple 
Mendelian inheritance in subsets of IBD should not be precluded 6, 7. The results of 
genome studies in IBD, which are based on the overall data of many familial pairs 1, 
may blur the genetic impact of certain genomic regions and corresponding genes in 
individuals with IBD and their IBD-affected family members.
In IBD, mucosal inflammation is characterised by an exaggerated and sustained 
immune response due to a dysregulated production and interaction of pro-inflam-
matory and anti-inflammatory cytokines and cytokine receptors 8. In this study we 
evaluated identical-by-decent sharing of marker alleles at candidate cytokine (recep-
tor) genes in a relatively small group of IBD-affected sib-pairs.
MATERIALS AND METHODS
Patients
Dutch Caucasian families with two or more siblings with either CD or UC, and their 
non-affected parents were recruited by interviewing IBD-affected patients attend-
ing the Erasmus MC University Medical Centre Rotterdam (UMCR). When one or both 
parents were not available, non-affected siblings were included. Probands, affected 
relatives and non-affected relatives completed a questionnaire about IBD. Based 
on information supplied by their physician the diagnosis was verified according to 
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standard criteria 9. The study was approved by the Institutional Review Board of the 
Erasmus MC UMCR. All participants gave written informed consent.
DNA isolation
Genomic DNA was isolated from whole peripheral venous blood collected in eth-
ylenediaminetetraacetic acid anticoagulated tubes (Becton Dickinson, Leiden, The 
Netherlands) using standard techniques. In some instances DNA was isolated from 
Epstein-Barr virus transformed lymphoblastoid cell lines 10, derived from peripheral 
venous blood collected in acid citrate dextrose solution containing tubes (Becton 
Dickinson).
Genotyping
Nine well defined inflammation-related cytokine genes 8 and the IBD2 locus on 
chromosome 12 1, 11 were evaluated. The genes and locus are summarised in Table 1. 
To identify these genes for further statistical analysis, microsatellite markers located 
within or close to these genes were used. If the heterozygosity of a marker was 
< 0.80 or unknown, additional markers from the same region were tested if pos-
sible. For the interleukin-10 (IL-10) gene, only one marker was used with a hetero-
zygosity of 72%. Amplification of the microsatellite markers was performed by poly-
merase chain reaction (PCR) on a PCR thermocycler (PCT 200, Biozyme, Landgraaf, 
The Netherlands). PCR conditions were chosen according to the literature (see Table 
1), sometimes with minor modifications. PCR fragment analyses was performed with 
an ABI 310 Genetic Analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The 
Netherlands) supported by Genescan (version 2.1.1) and Genotyper (version 2.1) 
software program.
Allele-sharing and statistical analysis
For each pair of IBD-affected siblings the probability of sharing zero, one or two 
alleles identical-by-descent at the cytokine (receptor) gene was determined. When 
parental genotypes were missing, the allele frequencies estimated from the set of 
non-affected parents were used. Under random (Mendelian) segregation, the prob-
abilities of sharing zero, one or two alleles identical-by-descent are 25%, 50% and 
25%, respectively. For the IBD-affected sib-pairs in this study, the probabilities of 
sharing zero, one or two alleles identical-by-descent were estimated by maximising 
the log likelihood function under the possible triangle constraints using Mapmaker/
sibs software program 12, 13.
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RESULTS
Patients
Fifteen families including 17 IBD-affected sib-pairs were examined in this study. 
In five pairs both siblings had CD, in seven pairs both had UC, and in five pairs one 
individual had CD and the other UC (mixed families). One family included three UC-
affected siblings of which two females were a dizygous twin. Twenty-seven non-
affected parents and three non-affected siblings were included. The affected sib-
pairs are summarised in Table 2.
Allele-sharing of cytokine (receptor) genes
For each sib-pair the probability of sharing alleles at the nine cytokine (recep-
tor) genes and the IBD2 locus are presented in Table 2. As expected, the results 
appeared to vary between families. In Table 3 the maximum likelihood estimates 
of the probabilities of sharing alleles identical-by-descent are given for the tested 
markers. Here, IL-4 was excluded because it appeared to be non-informative. For IL-
4 receptor (IL-4R), IL-10, IL-10R and tumour necrosis factor α (TNFα) the probability 
of sharing two alleles identical-by-descent were higher than expected, namely 50%, 
39%, 40% and 33% respectively. In this group, only the IL-4R showed a significant 
LOD score of 0.95 (P = 0.04).
Allele-sharing of IBD2 locus
The allele-sharing results for the chromosomal marker D12S83, correspond-
ing with the IBD2 locus, was not different from what could be expected based on 
Mendelian inheritance.
DISCUSSION
The genetic basis of IBD is considered to be heterogeneous, meaning that involve-
ment of several altered genes or interaction between specific genes may lead to simi-
lar clinical phenotypes. The results of the recent published genome screens in IBD 
support this theory, and suggest that the pathogenesis is unlikely to be of monoge-
netic origin 1. The same conclusion can be drawn from the results of candidate gene 
studies in IBD, which are focused on the involvement of specific genes in the disease 
pathogenesis. Well studied genes are those of the major histocompatibility complex, 
including the human leukocyte antigen class II molecules and TNFα 14, and several 
pro-inflammatory and anti-inflammatory cytokine genes 15-18.
In this study, allele-sharing of four (anti-)inflammation-related cytokine genes 
and their receptors were evaluated in a relatively small group of 17 affected sib-
pairs with IBD. A low but near significant LOD score was found for the IL-4R gene. 
This gene is located within a pericentromeric locus on chromosome 16, which was 
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the first genomic susceptibility region of interest described by Hugot et al. in 1996. 
This so-called IBD1 locus appeared to be linked with CD 19. In candidate gene stud-
ies, however, the IL-4R gene did not appear to be associated with IBD 20-22. In the 
meantime, linkage of the IBD1 locus with CD has been found to be based on genetic 
alterations in the CARD15 gene 23, 24.
The allele-sharing method is based on the concept that when a gene is disease-
involved, sib-pairs will share more alleles identical-by-descent than under no asso-
ciation between disease and gene. Although the statistical power of this method is 
low, and hence a large group of sib-pairs is necessary to achieve statistical signifi-
cance, the individual results of sib-pairs may also give insight in the heterogenetic 
concept of the IBD pathogenesis. For example, in this study the allele-sharing results 
of the IL-10 gene (chromosome 1q) suggest a weak (non-significant) linkage with 
IBD. In 39% of the included sib-pairs both siblings shared two alleles (the maximum 
likelihood estimate under the triangle constraints). Although no significant LOD score 
was found for IL-10 in the whole group, it might still be worthwhile to look for muta-
tions in those sib-pairs who share both alleles. In these specific sib-pairs the chance 
of IL-10 involvement in the disease pathogenesis is relatively high. Otherwise, in 
those sib-pairs who do not share any allele it is unlikely that the IL-10 will play a 
pathogenetic role. Therefore, searching for mutations in these individual families is 
probably not worthwhile. By following this strategy, we recently found a functional 
IL-10 mutation in two multiple CD-affected families 25, 26.
In conclusion, this study evaluates allele-sharing of several cytokine (receptor) 
genes in a relative small group of IBD-affected sib-pairs. A significant increased 
identical-by-decent allele-sharing was found for IL-4R. By using this approach to 
select and further analyse candidate genes in individual multiple IBD-affected fami-
lies, it is possible to find (functional) mutations. The various results between sib-
pairs are suggestive for the presumed heterogenetic pathogenesis of IBD. In certain 
families, involvement of specific cytokine genes may be more important than in other 
families. Functional assays and detailed DNA analysis of corresponding candidate 
cytokines and their genes should be focused on sib-pairs who share both parental 
alleles.
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Table 1.  Evaluated chromosomal locus and candidate genes
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54%
80%
forward ʻ5-AAAGAGACCTGCTAACACA-3ʼ
reverse ʻ5-CCTATGTTGGAGATGTTTAT-3ʼ
forward 5ʼ-GAGAGGGAGGGCCTGCGTTC-3ʼ
reverse 5ʼ-CACCCAGGGCCAGATAAAGA-3ʼ
forward 5ʼ-CTCAAAGTGCTGGGATTAGC-3ʼ
reverse 5ʼ-AGCCATCTCGGTTGGATGGA-3ʼ
forward 5ʼ-ATGGCAGATAGGTCCACCGG-3ʼ
reverse 5ʼ-TCATCCTCATCTGTTGTAGC-3ʼ
forward 5ʼ-TGACTCTTTTCGTCAACACAGC-3ʼ
reverse 5ʼ-TATTCAAATACAAGCAACCGTG-3ʼ
forward 5ʼ-TTCCTCATGTATAAATTGGGTGTGGCCA-3ʼ
reverse 5ʼ-ACCTCCCGGCCCAATCCCAATGCTT-3ʼ
forward 5ʼ-GTCCTTCCCCAGGTAGAGCAACACTCC-3ʼ
reverse 5ʼ-CTCCCAAAGAAGCCTTAGTAGTGTTG-3ʼ
forward 5ʼ-TCAGTTTCCTCATCCACCAA-3ʼ
reverse 5ʼ-AAAAGCACATATTTTGCTCAGAGTC-3ʼ
forward 5ʼ-TGGCCTCTTGTCACTCCTA-3ʼ
reverse 5ʼ-TGCTCTTCAAAGCAAAATG-3ʼ
forward 5ʼ-GCTGAATGAGTCCTGAGTAATAA-3ʼ
reverse 5ʼ-GGCCTAGACGTTCTTTTGTG-3ʼ
forward 5ʼ-GCCTCTAGATTTCATCCAGCCACA-3ʼ
reverse 5ʼ-CCTCTCTCCCCTGCAACACACAC-3ʼ
forward 5ʼ-CATAGTGGACTCTGTCTCCAAAG-3ʼ
reverse 5ʼ-AGATCCTTCCCTGTGAGTTCTGCT-3ʼ
forward 5ʼ-GAGGTGCATTTTCCAGGG-3ʼ
reverse 5ʼ-GGGTCCAGCATGTTCATC-3ʼ
forward 5ʼ-TGTGAGCCACTGCACC-3ʼ
reverse 5ʼ-GCCTTCAAAACCATAGTACAATAAC-3ʼ
forward 5ʼ-AGCTAATTTACATTACCCAAAAAGA-3ʼ
reverse 5ʼ-GCAGGTGGCACAGTGA-3ʼ
forward 5ʼ-GTGATCTGCAAGATGAACTCAC-3ʼ
reverse 5ʼ-ACACCACGTCTGATGTTTCA-3ʼ
forward 5ʼ-TTTTTGGAAGTCTATCAATTTGA-3ʼ
reverse 5ʼ-TAGCAGAGAAAGCCAATTCA-3ʼ
27 
28 
29 
30 
31 
32 
33 
internet b
internet b
internet b
34 
34 
internet b
internet b
35 
35 
internet b
a IBD2, IBD2 locus; IL, interleukin; TNF, tumour necrosis factor; R, receptor.
b Website www.genethon.fr
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Table 2.    Allele-sharing identical-by-descent in sib-pairs with inflammatory bowel 
disease
Allele-sharing (%) in IBD-affected sib-pairs (n = 17) b
G
en
e 
/ 
lo
cu
sa
N
um
be
r 
of
  
sh
ar
ed
 a
lle
le
s
C
D
-C
D
C
D
-C
D
C
D
-C
D
C
D
-C
D
C
D
-C
D
U
C
-U
C
U
C
-U
C
U
C
-U
C
U
C
-U
C
U
C
-U
C
U
C
-U
C
U
C
-U
C
M
ix
ed
M
ix
ed
M
ix
ed
M
ix
ed
M
ix
ed
IL-2 0 19 0 9 0 0 0 0 0 100 0 0 0 100 0 100 0 0
1 81 11 91 100 100 100 100 100 0 50 50 50 0 100 0 1 0
2 0 89 0 0 0 0 0 0 0 50 50 50 0 0 0 0 100
IL-2Rβ 0 100 0 27 50 0 0 0 100 0 0 0 0 100 0 100 0 100
1 0 100 73 50 100 0 0 0 100 50 50 50 0 0 0 100 0
2 0 0 0 0 0 100 100 0 0 50 50 50 0 100 0 0 0
IL-4 0 24 24 20 25 25 25 25 50 50 25 25 25 50 50 25 25 50
1 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50
2 26 26 30 25 25 25 25 0 0 25 25 25 0 0 25 25 0
IL-4R 0 0 0 18 0 0 0 50 0 100 0 0 0 98 0 50 50 98
1 15 100 82 2 0 0 50 0 0 0 0 0 2 0 50 50 2
2 85 0 0 98 100 100 0 100 0 100 100 100 0 100 0 0 0
IL-10 0 0 0 26 0 100 0 50 100 50 0 0 0 0 0 25 100 100
1 100 34 74 100 0 0 50 0 50 0 0 0 0 0 50 0 0
2 0 66 0 0 0 100 0 0 0 100 100 100 100 100 25 0 0
IL-10R 0 - 82 8 2 0 0 0 0 0 0 0 0 0 0 - 0 -
1 - 18 92 98 100 100 2 100 100 0 100 100 100 0 - 98 -
2 - 0 0 0 0 0 98 0 0 100 0 0 0 100 - 2 -
TNFα 0 50 2 0 0 98 0 0 48 0 0 0 0 0 0 100 98 0
1 50 98 8 2 2 0 100 4 100 0 100 100 0 100 0 2 100
2 0 0 92 98 0 100 0 48 0 100 0 0 100 0 0 0 0
TNFαR1 0 0 10 20 98 76 86 0 88 88 0 98 98 0 0 0 77 0
1 100 90 80 2 22 14 0 12 12 2 2 2 98 12 50 22 50
2 0 0 0 0 2 0 100 0 0 98 0 0 2 88 50 1 50
TNFαR2 0 100 50 98 0 2 0 0 2 50 0 98 98 0 0 0 0 0
1 0 50 2 100 98 100 50 96 50 2 2 2 4 100 98 0 98
2 0 0 0 0 0 0 50 2 0 98 0 0 96 0 2 100 2
a IL, interleukin; TNF, tumour necrosis factor; R, receptor.
b  IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis; Mixed, one 
sibling affected with CD and the other with UC.
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Table 3.   Allele-sharing identical-by-descent in sib-pairs with inflammatory bowel 
disease (n = 17)
Genes a Allele-sharing (%) b LOD score
0 1 2
IL-2
IL-2Rβ
IL-4R
IL-10
IL-10R
TNFα
TNFαR1
TNFαR2
25
25
17
20
10
22
25
25
50
50
33
41
50
45
50
50
25
25
50
39
40
33
25
25
0
0
0.95
0.27
0.25
0.1
0
0
a IL, interleukin; TNF, tumour necrosis factor; R, receptor.
b  The probabilities of sharing zero, one or two alleles identical-by-descent were 
estimated by maximising the log likelihood function under the possible triangle 
constraints.
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CHAPTER 3
A Gly15Arg mutation in the interleukin-10 gene
reduces secretion of interleukin-10 
in Crohnʼs disease
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Meijssen, H.F.J. Savelkoul, J.H.P. Wilson, F.W.M. de Rooij
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ABSTRACT
Background
Genetic susceptibility, probably involving cytokines 
and their receptors, plays an important role in inflam-
matory bowel disease (IBD). In this study we examined 
the potential role of the interleukin-10 (IL-10) gene as a 
susceptibility gene in IBD.
Methods
We studied 17 sib-pairs with either Crohnʼs disease 
(CD) or ulcerative colitis. After microsatellite analy-
sis for allele-sharing, the IL-10 gene of sib-pairs who 
shared alleles was screened for nucleotide alterations 
in and around exons and the promoter region. The 
IL-10 promoter polymorphism at position -1082 was 
also determined. Function was evaluated by measuring 
IL-10 secretion by peripheral blood mononuclear cells 
stimulated with lipopolysaccharide or phorbol ester. The 
activity of recombinant immature wild-type and mutated 
IL-10 was tested in a proliferation assay with a human 
monocytic leukaemia cell line (HL60 cells).
Results
DNA sequencing revealed a G → A point mutation in 
exon 1 at base position 43 in one sib-pair, both affected 
with CD. It was also found in two of their healthy siblings, 
but not in 75 unrelated healthy controls. This mutation 
results in a glycine to arginine substitution at amino acid 
position 15 of the leader sequence (Gly15Arg). The in 
vitro IL-10 secretion by mononuclear cells of the IL-10 
Gly15Arg carriers was about 50% of healthy controls, 
matched for the -1082 polymorphism in the IL-10 pro-
moter region. Incubation of HL60 cells with recombinant 
mutated IL-10 showed a markedly reduced cell prolifera-
tion compared with wild-type IL-10.
Conclusion
A Gly15Arg mutation in the leader sequence of IL-10 
was found in a multiple CD-affected family. This altered 
leader sequence decreases IL-10 secretion, thereby 
reducing the anti-inflammatory effect.
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INTRODUCTION
Genetic predisposition plays an important role in the pathogenesis of chronic 
inflammatory bowel disease (IBD). It seems increasingly likely that IBD is not a single 
disease but rather a group of aetiologically and genetically distinct diseases that have 
similar clinical presentations 1. During past years, many attempts have been made to 
identify susceptibility loci for IBD, by using either a genome-wide linkage analysis 
with multiple highly polymorphic microsatellite markers, or association studies with 
candidate and positional genes 2. The available data suggest that genetic suscepti-
bility for IBD is heterogeneous, and probably not inherited in a simple monogenetic 
Mendelian fashion, although this type of inheritance might apply to subgroups 2, 3.
In IBD, the mucosal inflammation is associated with an exaggerated and prolonged 
immune response because of a dysregulated production and interaction of pro-
inflammatory and anti-inflammatory cytokines and their receptors 4. Interleukin-10 
(IL-10) inhibits the synthesis of several pro-inflammatory cytokines derived from acti-
vated monocytes and macrophages such as tumour necrosis factor alpha and IL-1 5. 
The IL-10 gene knock-out mouse spontaneously develops a chronic enterocolitis 6. 
The IL-10 gene is therefore of special interest for a candidate gene approach in 
IBD.
Linkage of the IL-10 gene with IBD was not demonstrated in a large group of 
sib-pairs 7. However, recently three biallelic polymorphisms have been identified 
within the IL-10 gene promoter region. One polymorphism was associated with 
either a high (-1082*G) or low (-1082*A) IL-10 production of in vitro stimulated 
peripheral lymphocytes 8. Tagore and co-workers found a decreased frequency of 
this high IL-10 producer allele in patients with IBD, and suggested that the lower 
IL-10 responses could contribute to the chronic intestinal inflammation 9. These 
results were not confirmed by others 10. Treatment with recombinant IL-10 does 
not appear to be effective 11-13. However, the possibility that mutations in the IL-10 
gene may play an important role in a small percentage of patients is not excluded 
by the above studies.
In the present study, we examined the potential role of the IL-10 gene in 17 IBD-
affected sib-pairs from 15 families. Sibs who share both alleles were considered to 
be the most likely candidates to harbour a mutation. After selecting suitable sib-
pairs by IL-10 allele-sharing based on microsatellite analysis, we screened for exon 
nucleotide alterations and promoter polymorphisms. We identified a guanine (G) to 
adenine (A) substitution in exon 1 of the IL-10 gene. The functional consequences of 
this genetic alteration were tested in vitro using recombinant IL-10 (both wild-type 
and Gly15Arg) in a proliferation assay with LPS-stimulated HL60 cells which express 
IL-10 receptors. Secretion of mutated IL-10 was evaluated in vitro by stimulating 
monocytes and lymphocytes obtained from patients and controls.
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MATERIALS AND METHODS
Patients and materials
Dutch Caucasian families with two or more siblings with either Crohnʼs disease 
(CD) or ulcerative colitis (UC) attending the Departments of Gastroenterology, Internal 
Medicine, and Surgery of the Erasmus MC University Medical Centre Rotterdam 
(UMCR) were recruited. Probands, affected siblings and non-affected first-degree 
relatives completed a questionnaire about IBD. Based on information supplied by 
their physician the diagnosis was verified according to standard criteria 14. Seventy-
five healthy Caucasian controls were also examined.
Genomic DNA was isolated from whole peripheral venous blood collected in eth-
ylenediaminetetraacetic acid anticoagulated tubes using standard techniques. Blood 
collected in acid citrate dextrose solution containing tubes (Becton Dickinson, Leiden, 
The Netherlands) was used for DNA and RNA isolation from Epstein-Barr virus trans-
formed lymphoblastoid cell lines 15. All DNA sequence and polymerase chain reaction 
(PCR) fragment analyses were performed using an ABI 310 Genetic Analyzer (Applied 
Biosystems, Nieuwerkerk aan de IJssel, The Netherlands) supported by Genescan 
(version 2.1.1) and Genotyper (version 2.1) software programs.
Peripheral blood mononuclear cells (PBMCs) were isolated from selected patients, 
their relatives and 22 healthy Caucasian controls for in vitro stimulation.
The study was approved by the Institutional Review Board of the Erasmus MC 
(UMCR). All participants gave written informed consent.
IL-10 genotyping
The microsatellite marker IL10.G was used for genotyping IL-10 alleles, as 
described by Eskdale and co-workers 16, with minor modifications in the PCR condi-
tions, using a PCR thermocycler (PCT 200, Biozyme, Landgraaf, The Netherlands).
IL-10 gene sequence analysis
IL-10 exons were screened for nucleotide alterations by comparing its DNA 
sequence with the IL-10 gene sequence deposited in the Genbank of the National 
Centre for Biotechnology Information (NCBI) with accession number U16720 (unpub-
lished data, internet http://www.ncbi.nlm.nih.gov). Primer pairs used to amplify the 
5 exons, including the flanking intronic regions, are listed in Table 1. PCR fragments 
of the exons were sequenced with the forward primer, using a BigDye Terminator 
sequencing kit (Applied Biosystems). As discussed below, in one multiple affected 
family with IBD a point mutation was found in exon 1. Other participants were 
screened for this specific mutation, using the Mae I restriction enzyme. The PCR 
product of exon 1 was incubated with 1 unit of Mae I (Boehringer Mannheim, Almere, 
The Netherlands) at 45 0C for 4 hours (h), and then analysed on a 2% agarose elec-
trophoresis gel. Bands were visualised with ethidium bromide staining.
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IL-10 promoter analysis
IL-10 high and low secretion genotypes were determined by screening for 
promoter polymorphisms at position -1082 relative to the transcriptional start 
site. Positions -819 and -592 were also evaluated 8. DNA amplification was per-
formed by PCR, using the forward primer 5ʼ-CCAAGACAACACTACTAAGGC-3ʼ, 
and the reverse primer 5ʼ-GTCTCTGGGCCTTAGTTTCC-3ʼ. This resulted in a PCR 
product of 629 base pairs, which was further sequenced with an internal reverse 
primer 5ʼ-AAGCTTCTGTGGCTGGAGTC-3ʼ to determine the -1082, and the 
5ʼ-GTCTCTGGGCCTTAGTTTCC-3ʼ reverse primer to determine positions -819 and 
-592.
Excretion of IL-10 protein in vitro by stimulated PBMCs
Blood samples were taken between 09.00 and 11.00 h to minimise circadian 
variation 17. PBMCs were prepared from heparinized blood within 3 h of venapuncture 
by Ficoll-Hypaque separation (Pharmacia, Uppsala, Sweden). PBMCʼs were cultured at 
106 cells/mL in RPMI 1640 medium (Bio Whittaker Europe, Verviers, Belgium) supple-
mented with 2 mM L-glutamine, 100 IU/mL penicillin, 50 µg/mL streptomycin, 1 mM 
pyruvate and 10% heat-inactivated foetal bovine serum (Gibco BRL Life Technologies, 
Breda, The Netherlands). Cells were stimulated in 24-well flat-bottom microtitre 
plates in triplicate separately with 1 µg/mL lipopolysaccharide (LPS) extracted from 
Escherichia (E.) coli O26:B6 bacteria (Difco, Detroit, Michigan, USA) and 10 ng/mL 
phorbol-12-myristate-13-acetate (PMA, Sigma, St. Louis, Missouri, USA) plus 1 µg/
mL ionomycine (Sigma). After 24 h of incubating at 37 0C and 5% CO2, the superna-
tants were collected and stored at -70 0C for IL-10 protein enzyme-linked immu-
nosorbent assay (ELISA, Biosource, Etten Leur, The Netherlands) or Western blotting 
18. 
LPS stimulates mainly monocytes 19, while PMA stimulation involves T cells 20. The 
total IL-10 protein production of stimulated PBMCs depends on the relative numbers 
of monocytes and T cells. To identify the PBMCs, two triple stainings were performed 
for immunophenotyping. PBMCs were first stained with fluorescein isothiocyanate 
labelled monoclonal antibodies (MoAbs) against CD3 (UCHT1, Immunotech, Marseille, 
France) or CD14 (Leu-M3, Becton Dickinson) for 15 minutes (min) at room tempera-
ture, to determine T cells and monocytes, respectively. After washing, the samples 
were further stained with phycoerythrin-conjugated MoAbs against CD25 (3G10, 
Sanbio, Uden, The Netherlands) and phycoerythrin-cyanine 5-conjugated MoAbs 
against CD45 (T29/33, Dako, Denmark) for 15 min at room temperature, to identify 
IL-2 receptor carrying cells and total leukocytes, respectively. After a second wash, 
cells were analysed for specific fluorescence by flow cytometry (FACScan, Becton 
Dickinson) using CellQuest software (Becton Dickinson). Appropriate controls were 
included to rule out non-specific fluorescence.
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Expression of IL-10 protein
Total RNA was isolated from lymphoblastoid cell lines using the Rneasy minikit 
(Qiagen, Leusden, The Netherlands). Complementary DNA (cDNA) was made using 
M-MLV reverse transcriptase (Gibco BRL Life Technologies) and hexamers (Promega, 
Leiden, The Netherlands). The full coding IL-10 sequence was amplified by reverse 
transcription PCR (RT-PCR) using the forward primer 5ʼ-CGGGATCCATGCACAGCT
CAGCACTGC-3ʼ, including a BamHI restriction site, and reverse primer 5ʼ-GGAATT
CTCAGTTTCGTATCTTCATTG-3ʼ, including an EcoRI restriction site. After digestion 
and purification, the RT-PCR fragments were ligated into the corresponding restric-
tion sites of the expression vector pRSET A (Invitrogen, Groningen, The Netherlands), 
and transformed into TOP10 E. coli bacteria (Invitrogen). Inserts were sequenced, 
and vectors with the appropriate insert were transferred into BL21 E. coli bacteria 
(Invitrogen) for recombinant human IL-10 (rIL-10) protein production. The rIL-10 
protein was demonstrated by ELISA (Biosource).
Effect of IL-10 protein in vitro on HL60 cells
HL60 cells (human monocytic leukaemia cell line) 21, 22 were cultured at 
106 cells/mL in 24-well plates in RPMI 1640 medium (Bio Whittaker Europe) supple-
mented with 2 mM L-glutamine, 100 IU/mL penicillin, 50 µg/mL streptomycin, 1 mM 
pyruvate, and 10% heat-inactivated foetal bovine serum (Gibco BRL Life Technologies). 
Cells were stimulated with 1 µg/mL LPS E. coli O26:B6 (Difco). After 16 h of incu-
bation at 37 0C and 5% CO2, [3H]-thymidine 0.5 µCi/well (Amersham, Aylesbury, 
UK) was added, and plates were incubated for an additional 8 h before harvesting. 
Measurement of [3H]-thymidine was performed with a BetaPlate (Pharmacia LKB, 
Turku, Finland). In addition, similar HL60 quadriplate cultures were incubated in 
serum-free medium according Yssel and co-workers 23 in the presence of serial dilu-
tions of equal amount of rIL-10 of mutated or wild-type origin obtained from trans-
fected E. coli. The cloned immature wild-type rIL-10 and mutated rIL-10 proteins 
were tested as lysates of phosphate-buffered saline sonificated recombinant E. coli. 
These cultures were allowed to incubate for 24 h, after which culture supernatants 
were collected and assayed for the production of IL-10 by ELISA (Biosource).
Statistics
Statistical analysis of microsatellite markers to determine IL-10 allele-sharing in 
affected sib-pairs was performed with Mapmaker/sibs software. The data were eval-
uated by a non-parametric two-point linkage analysis 24. The results of all IL-10 in 
vitro stimulation studies were expressed as mean values with standard errors of the 
mean (SEM). The data were analysed by the Mann-Whitney test using SPSS software 
version 8.0 (SPSS Inc., Chicago, Illinois, USA). Linear regression was evaluated using 
GraphPad Prism software version 3.0 (GraphPad Software, Inc., San Diego, California, 
USA). P values of 0.05 or less were considered to be statistically significant.
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RESULTS
Affected sib-pairs
Fifteen families including 17 sib-pairs affected by IBD were examined in this 
study for genomic alterations of the IL-10 gene. In five pairs both siblings had CD, 
in seven pairs both had UC, and in 5 pairs one individual had CD and the other UC. 
One family included three UC-affected siblings of which two females were dizygous 
twins. Twenty-seven non-affected parents and three non-affected siblings were 
also studied.
IL-10 allele-sharing
In seven IBD-affected sib-pairs out of five families, siblings shared both paren-
tal IL-10 alleles. One sib-pair included two patients with CD. In four sib-pairs both 
family members had UC, of which two patients were dizygous twins. In two pairs one 
sibling had CD and the other UC. The LOD score for involvement of the IL-10 gene in 
all included sib-pairs (n = 17) was low (0.27). The diverse allele-sharing between the 
sib-pairs suggests that the IL-10 gene is not involved in pathogenesis in all families, 
but may play a role in a subgroup.
IL-10 gene sequence analysis
DNA sequence analysis of all IL-10 exons was performed in those probands of 
affected sib-pairs who shared or were statistically likely to share both parental IL-10 
alleles, as the chance of finding gene alterations among these pairs is the highest. 
In one male proband with CD, a heterozygous point mutation (G → A) was found 
at position 43 of exon 1. This mutation was also present in his CD-affected sister 
and two unaffected sisters, but not in the father and another unaffected sister. The 
mother died several years ago, and could not be tested. On allele reconstruction, she 
most probably carried the mutated IL-10 allele. Unfortunately, no close relatives of 
the mother were available for testing. Two available sisters of the probandʼs father 
were tested for the mutation, but found to be negative. The pedigree is shown in 
Figure 1.
The heterozygous mutation at position 43 of exon 1 was confirmed in cDNA of 
the proband. According to NCBI U16720, the mutation results in a single amino acid 
change from glycine (Gly) to arginine (Arg) at position 15 of the 178 amino acids 
containing IL-10 protein. This position corresponds with the leader sequence of the 
immature IL-10 (position 1-18).
Subsequently, all other probands of affected sib-pairs who shared one or nei-
ther parental allele, and 75 unrelated controls were screened for this IL-10 exon 1 
Gly15Arg mutation, using digestion of exon 1 PCR fragments by Mae I endonuclease 
or DNA sequence analysis. In none of them was the mutation found.
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Clinical characteristics of two families with the IL-10 Gly15Arg mutation
Proband  This 37-year-old non-smoking male patient presented with abdomi-
nal pain, diarrhoea and fever in 1979. CD of the terminal ileum was diagnosed and 
confirmed during an ileocecal resection in 1980. Additional resections of stenotic 
small bowel were necessary in 1987, 1988, 1995 and 1999. Histology of the resected 
specimens showed transmural granulomatous inflammation. In 1987, mild disease 
activity was seen in the rectum at colonoscopy. He was treated with salazopyrine and 
steroids from 1979, changing to oral budesonide in 1997. He has had mild anterior 
uveitis and sacroiliitis.
Affected sibling  His 49-year-old smoking sister was diagnosed with CD in 1981, 
and underwent an ileocecal resection. Again in 1987 and 1993 small bowel resec-
tions followed because of recurrent stenotic inflammation around the anastomosis. 
Treatment included aminosalicylates from 1988 until 1997. She has not had extra-
intestinal manifestations.
Unaffected siblings  The proband has three sisters without IBD, born in 1953, 
1954 and 1959. None of them has had other diseases or uses medication.
Unaffected parents  Neither parent had a history of abdominal disorders. The 
father, born in 1924, died in 1999 of a myocardial infarction, some time after blood 
was taken for this study. The mother died at the age of 62 years due to metastatic 
cancer of unknown primary.
IL-10 gene promoter analysis
Promoter polymorphisms were examined in available individuals (n = 6) of 
the IBD family in which the IL-10 Gly15Arg substitution was found to determine 
whether they had a high or low IL-10 secretion genotype. The data are shown in 
the pedigree (see Figure 1). Only the -1082*A/A and -1082*G/A genotypes (low 
production) were found. IL-10 gene promoter polymorphisms were also analysed in 
22 healthy unrelated Caucasian controls (11 males and 11 females). Seven controls 
had the -1082*A/A genotype, 11 the -1082*G/A genotype, and four the -1082*G/G 
genotype.
IL-10 secretion of in vitro LPS- and PMA-stimulated PBMCs
PBMCs of the CD-affected sib-pair with the IL-10 Gly15Arg mutation and their 
available family members (n = 3) were stimulated in vitro with LPS and PMA, after 
which IL-10 secretion was determined by ELISA. PBMCs of the father unfortunately 
could not be studied. The amount of IL-10 protein was expressed per 106 mono-
cytes and T-cells.
As the number of individuals with the IL-10 mutation was low (n = 4), stimulation 
tests of these participants were performed twice with an interval of 6 weeks. These 
results were expressed as the mean of both tests and summarised in Table 2.
In the literature, both the -1082*G/A and -1082*A/A genotypes are reported to 
be associated with low IL-10 production. As shown in Figure 1, the mutation carri-
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ers had either the -1082*G/A or -1082*A/A genotype. Therefore, IL-10 secretion 
was evaluated in healthy controls with comparable promoter polymorphisms. In the 
control group, IL-10 secretion was not significantly different between -1082*G/A 
and -1082*A/A carriers, so both genotypes were pooled to form a single con-
trol group. The IL-10 Gly15Arg mutation was associated with a significantly lower 
IL-10 protein production by PBMCs after stimulation with LPS or PMA (P = 0.002 and 
0.033, respectively, see Table 2).
Western blot analysis of the IL-10 protein derived from LPS-stimulated PBMCs 
culture mediums of individuals with the IL-10 Gly15Arg mutation revealed only a 
single band of a molecular weight corresponding to the wild-type IL-10.
In vitro effect of wild-type rIL-10 and mutated rIL-10 on HL60 cells
Both the wild-type and mutated rIL-10 were recognised by the ELISA for IL-10. 
After incubation of LPS-stimulated HL60 cells with serial dilutions of rIL-10, we 
did not find a difference in the intrinsic release of IL-10 by HL60 cells comparing 
mutated rIL-10 with wild-type rIL-10. However, the mutated rIL-10 protein induced 
a significantly lower HL60 cell proliferation rate than the wild-type rIL-10 protein, 
as analysed by linear regression (P = 0.006, see Figure 2).
DISCUSSION
The IL-10 gene is an attractive candidate gene for susceptibility to IBD, as its 
product has important anti-inflammatory and immunomodulatory effects 4-6. 
However, a recent linkage study using microsatellite analysis in 198 pairs of sib-
lings with IBD failed to demonstrate an overall significant contribution of the IL-10 
gene to the risk of developing IBD 7. Assuming that IBD is a genetically heteroge-
neous disease, then failure to demonstrate a statistically significant linkage of the 
IL-10 gene with IBD in a large number of affected sib-pairs will not preclude a major 
importance of the IL-10 gene in a small portion of families. We therefore chose to 
look for functional mutations in the IL-10 gene in sib-pairs with IBD, selected on 
the base of allele-sharing.
The IL-10 gene was initially screened in sib-pairs who shared or were likely to 
share both parental alleles, as the chance of finding gene alterations among these 
pairs is the highest. In a sib-pair affected family with CD a point mutation was found 
in the IL-10 gene at position 43 of exon 1 (G → A). This mutation leads to the amino 
acid change Gly → Arg at position 15 of the leader sequence of the immature IL-10 
protein. We showed that this mutation was associated with about a 50% reduction in 
IL-10 protein secretion by PBMCs following stimulation with either LPS or PMA. This 
effect of the mutation on IL-10 secretion is not surprising in view of the size and 
charge differences between Gly and Arg. To standardise the comparison with the 
mutation carriers, all healthy controls were matched for the IL-10 promoter poly-
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morphism at position -1082 relative to the transcriptional start site, which has been 
found to be associated with the amount of IL-10 production 9.
Although it is likely that most IL-10 involved in the regulation of intestinal inflam-
mation is the mature protein, we cloned both mutant and wild-type IL-10 including 
the leader sequence. Both recombinant cytokines were tested in a proliferation assay 
with LPS-stimulated HL60 cells, a human leukaemia cell line of monocytic lineage. 
HL60 cells were used as they are a model for monocytes, and express IL-10 recep-
tors 22. The Gly15Arg rIL-10 was less active than the wild-type rIL-10. We propose 
that in the CD-affected family the Gly15Arg mutation in the leader sequence of 
IL-10 predisposes to the development of IBD by causing a reduced IL-10 response 
to intestinal inflammation.
The IL-10 Gly15Arg mutation was also present in healthy siblings of the pro-
band with CD. Although in many autosomal dominant hereditary disorders clinical 
expression is variable, we did consider the possibility that lack of symptoms might 
be due to differences in the promoter polymorphisms between the symptomatic and 
the non-symptomatic siblings. This was not the case, which suggests that in addi-
tion to the putative role of the IL-10 gene, other factors trigger the events to obtain 
clinically manifest IBD in this family.
Very recently, the IL-10 Gly15Arg mutation was reported as a very rare polymor-
phism in an extensive search for new IL-10 gene alterations in patients with myo-
cardial infarction 25, and in patients with IBD 10. None of these studies evaluated the 
biological effects of the mutated IL-10 protein. To what extent the IL-10 Gly15Arg 
mutation is associated with IBD or other chronic diseases, is at present unknown.
Our findings do have potentially important implications. So far, four multicen-
tre clinical trials have been published about the therapeutic effect of subcutaneous 
administered recombinant IL-10 in CD. Although treatment with IL-10 is safe and 
well tolerated, the overall effect was disappointing 11-13, 26. However, it is possible 
that IL-10 treatment could be beneficial in a subset of patients who have a genetic 
defect in IL-10 secretion or function.
The other implication of our findings is that IBD is a heterogeneous disease. 
Detailed examination of candidate genes in sib-pairs who share alleles of these 
genes in a relative small number of multiple affected families can provide further 
insight into the genetic aetiology of IBD. 
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Table 1.   Primers used in polymerase chain reaction amplifications of interleukin-10 
exons
Exon Nucleotides a Primer Sequence
1
2
3
4
5
3946-3965
4312-4331
4921-4942
5261-5282
5326-5345
5658-5677
6452-6472
6791-6810
7584-7603
7924-7946
1a forward
1b reverse
2a forward
2b reverse
3a forward
3b reverse
4a forward
4b reverse
5a forward
5b reverse
5ʼ-AGAGGCCTCCCTGAGCTTAC-3ʼ
5ʼ-TGTTGGGGATGGAGGTGGAG-3ʼ
5ʼ-TCCCATACTGTTGAATCCTCTG-3ʼ
5ʼ-TGCTGAGTTAACATCTTCCCAC-3ʼ
5ʼ-GGCTTCTGGTAAGGAGGATC-3ʼ
5ʼ-TGTCTGTGGATGTGAGTGTC-3ʼ
5ʼ-CATGGAAGCAGGGCTCAGTTC-3ʼ
5ʼ-GCAGCAGCTCCTAATGGCTG-3ʼ
5ʼ-CACAGCCTTTCCCAAGGCAG-3ʼ
5ʼ-AGGTACAATAAGGTTTCTCAAGG-3ʼ
a  Nucleotide number according to accession number U16720 of the NCBI  
(http://www.ncbi.nlm.nih.gov).
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Table 2.   Interleukin-10 secretion by LPS- and PMA-stimulated PBMCs of inter- 
leukin-10 Gly15Arg mutation carriers and non-carriers
LPS-stimulated PBMCs
(ng/mL per 106 monocytes 
± SEM)
PMA-stimulated PBMCs
(pg/mL per 106 T-cells  
± SEM)
Family with IL-10 Gly15Arg mutation a
carriers (n = 4)
non-carrier (n = 1)
Healthy controls b
-1082*A/A (n = 7)
-1082*G/A (n = 11)
-1082*A/A and -1082*G/A (n = 18)
5.05 ± 0.59 c
7.91
9.18 ± 1.97
10.44 ± 1.10
9.95 ± 0.99 c
175.40 ± 115.24 d
502.45
261.66 ± 67.77
400.03 ± 60.14
346.22 ± 46.89 d
a  Multiple affected family with inflammatory bowel disease, including a Crohnʼs dis-
ease-affected sib-pair (brother and sister) and two healthy sisters carrying the 
interleukin-10 (IL-10) Gly15Arg mutation, and one healthy sister with the wild-type 
IL-10 gene. The father and mother could not be tested. All tested family members 
had the low IL-10 producing promoter genotype (-1082*G/A or -1082*A/A relative 
to the transcriptional start site). 
b  Selected for IL-10 promoter polymorphism at position -1082 relative to the tran-
scriptional start site.
c  IL-10 secretion by lipopolysaccharide (LPS)-stimulated peripheral blood mononu-
clear cells (PBMCs) was significantly different between IL-10 Gly15Arg mutation 
carriers and carriers of the wild-type IL-10 gene (P = 0.002).
d  IL-10 secretion by phorbol-12-myristate-13-acetate (PMA)-stimulated PBMCs was 
significantly different between IL-10 Gly15Arg mutation carriers and carriers of the 
wild-type IL-10 gene (P = 0.033).
SEM = standard error of the mean.
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a
G / A
GCC / ATA
136 / 132
G / G
GCC / ACC
136 / 138
G / A
ACC / ATA
142 / 132
G / A
GCC / ATA
136 /132
G / A
ACC / ATA
138 / 132
G / A
GCC / ATA
136 / 132
G / G
GCC / ACC
136 / 142
Figure 1.  Pedigree of multiple affected family with Crohnʼs disease (CD) and the 
interleukin-10 (IL-10) Gly15Arg mutation. Tested individuals: n, CD-affected male; 
l, CD-affected female; ®, non-CD-affected male; °, non-CD-affected female; Ì, 
proband. Indicated data for each tested individual: first row, genotype of the IL-10 
gene at position 43 of exon 1; second row, IL-10 promoter polymorphism at posi-
tions -1082, -819 and -592 relative to the transcriptional start site, respectively; 
third row, lengths of the IL-10.G microsatellite marker polymerase chain reaction 
fragments.
a Genotypes of the deceased mother were reconstructed.
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Figure 2.  Proliferation rate of HL60 cells stimulated by lipopolysaccharide (LPS), and 
wild-type or mutated recombinant interleukin-10 (rIL-10). Open bar, added wild-
type rIL-10; black bar, added rIL-10 with Gly15Arg mutation. A significant differ-
ence (P = 0.006) was found between the slopes of both correlation curves, meaning 
that stimulation of HL60 cells with LPS and rIL-10 Gly15Arg (r = 0.95) induced a 
lower proliferation than stimulation with LPS and wild-type rIL-10 (r = 0.55). Data 
are expressed as a mean value of a quadruple measurement ± standard error of the 
mean.
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ABSTRACT
Background
Interleukin-10 (IL-10) is an anti-inflammatory and 
immunomodulatory cytokine. IL-10 deficient mice are 
prone to develop chronic colitis. Administration of 
recombinant human IL-10 has been proposed to have a 
beneficial effect in a subgroup of patients with Crohnʼs 
disease (CD). Recently, we found an IL-10 Gly15Arg 
mutation in a family with CD which is associated with 
reduced IL-10 secretion by in vitro stimulated monocytes 
and lymphocytes. We hypothesised that this IL-10 muta-
tion plays a role in maintaining the inflammatory process 
in CD in some families.
Methods
We evaluated IL-10 Gly15Arg in 379 patients with CD, 
and 75 unrelated healthy controls. Also first-degree fam-
ily members of IL-10 Gly15Arg carriers were evaluated. 
Additionally, mutation carriers and their relatives were 
evaluated for CARD15 R702W, G908R and L1007fs. 
Results
Two patients with CD were heterozygous for the IL-
10 Gly15Arg mutation. No homozygotes were found. The 
Gly15Arg mutation was not observed in the controls. In 
first-degree family members of the CD-affected IL-10 
Gly15Arg carriers, the mutation was found in CD-affected 
as well as in their apparently healthy individuals. All fam-
ily members carried one or two CARD15 mutation(s).
Conclusion
The IL-10 Gly15Arg mutation is rare in patients 
with CD, and is not associated with the disease in The 
Netherlands.
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INTRODUCTION
Interleukin-10 (IL-10) is considered to be an important cytokine for immune 
modulation in the gut. It has anti-inflammatory and immunomodulatory effects, 
and is considered to play a role in inflammatory bowel disease (IBD). This hypothesis 
is supported by the observation that IL-10 gene knock-out mice develop chronic 
enterocolitis resembling Crohnʼs disease (CD) 1.
IL-10 influences the expression of a variety of cytokines, soluble mediators, 
and cell surface molecules produced by activated monocytes and macrophages. 
IL-10 can down-regulate the production of IL-1 and tumour necrosis factor alpha 
(TNFα), which are first-line cytokines in a Th1-driven inflammatory response 2. 
Subcutaneously administered IL-10 has been evaluated in four clinical trials with 
CD-affected patients, with inconsistent results 3-6. It has been suggested that a sub-
group of CD patients might benefit from IL-10 administration 4.
Recently, we found an IL-10 single nucleotide gene alteration at position 43 in 
exon 1 (G → A) encoding for a Gly15Arg substitution in a family with multiple CD-
affected members. The nucleotide substitution was associated with a reduced IL-10 
protein secretion by in vitro stimulated monocytes and lymphocytes of IBD patients. 
Based on these findings we hypothesised that the IL-10 Gly15Arg mutation may play 
a role in the pathogenesis of IBD in this family, and that IL-10 administration could 
be useful in treating active CD in these patients 7.
CD is considered to be a polygenic disease with different genes contributing to 
susceptibility in different families and giving rise to differences in response to anti-
inflammatory agents 4. Recently, three coding polymorphisms R702W, G908R, and 
L1007fs in the CARD15 gene were shown to be independently associated with CD 8, 9. 
As the IL-10 Gly15Arg also appeared to be a coding nucleotide variation and there-
fore may have potential therapeutic implications, we evaluated the prevalence of this 
mutation in a large group of CD-affected patients with or without a positive family 
history of IBD.
MATERIALS AND METHODS
Patients and materials
Patients with CD of Dutch Caucasian origin were recruited from three Dutch uni-
versity referral centres. Patients were classified as familial CD if one or more first-, 
second- or third-degree relatives were known to have IBD. If the family history was 
negative or not clear, patients were considered sporadic CD or CD patients with an 
unknown family history. The diagnosis of CD was verified by each centre according 
to standard criteria 10. The age of the CD-affected participants was calculated on the 
date of entry, i.e. July 1st 2002. Initially, only the proband from a family was studied. 
Family members of selected participants were also subsequently examined.
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Seventy-five healthy Caucasian controls were included. These controls were 
recruited at the Erasmus MC University Medical Centre Rotterdam (UMCR), and the 
reports have been published previously 7.
Genomic DNA was isolated from whole peripheral venous blood using standard 
techniques.
The study was approved by the Institutional Review Board of the Erasmus MC 
UMCR. All participants provided written informed consent.
IL-10 Gly15Arg mutation analysis
Exon 1 of the IL-10 gene was amplified using the forward primer 5ʼ-
AGAGGCCTCCCTGAGCTTAC-3ʼ and reverse primer 5ʼ-TGTTGGGGATGGAGGTGGAG-
3ʼ resulting in a polymerase chain reaction (PCR) fragment of 386 base pairs (bp). The 
prevalence of the IL-10*G/A point mutation at base position 43 was evaluated with 
the restriction enzyme Mae I (Boehringer Mannheim, Almere, The Netherlands). After 
digestion with 1 unit of Mae I at 45 0C for 4 hours (h), the PCR fragment was analysed 
on a 2% agarose electrophoresis gel. Bands were visualised with ethidiumbromide 
staining. Wild-type PCR products resulted in fragments of 60 and 326 bp, while 
mutant PCR products gave fragments with a length of 60, 152 and 174 bp. Positive 
samples representing the IL-10 Gly15Arg mutation were confirmed by sequencing 
the 386 bp PCR fragments, using the forward primer 5ʼ-AGAGGCCTCCCTGAGCTTAC-
3ʼ and a BigDye Terminator sequencing kit (Applied Biosystems, Nieuwerkerk aan de 
IJssel, The Netherlands). All DNA sequences were performed using an ABI 310 Genetic 
Analyzer (Applied Biosystems) supported by Genescan (version 2.1.1) and Genotyper 
(version 2.1) software programs.
IL-10 haplotyping
Microsatellite markers IL-10.G and IL-10.R were used for haplotyping IL-10 
alleles. Both microsatellites have been evaluated in healthy Caucasian individuals by 
Eskdale et al. 11. The IL-10.G marker is highly polymorphic with a heterozygosity of 
around 72%. It is located in the promoter of the IL-10 gene 11. The IL-10.R marker 
is less informative, having a heterozygosity of 50% 12. PCR conditions were used as 
published in the literature with minor changes. An ABI 310 Genetic Analyzer (Applied 
Biosystems) was used for DNA sequencing.
CARD15 mutation analysis
CARD15 R702W and G908R were determined by means of restriction enzyme anal-
ysis. First, the DNA regions of interest containing the alteration were amplified by PCR. 
For R702W (2104C → T in exon 4) the forward primer 5ʼ-CAGCTGGGCAGCTTTGCTGC-
3ʼ and the reverse primer 5ʼ-CATGGCATGCACGCTCTTGG-3ʼ were used. The 448 bp 
was purified by phenol extraction followed by ethanol precipitation, after which the 
PCR fragment was digested with 8 units of Hpa II (New England BioLabs, Beverly, 
Massachusetts, USA) for 4 h at 37 0C. Bands were visualised after separation on a 
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2% agarose gel containing ethidium bromide. The wild-type exon 4 resulted in 
fragments of 29, 54, 76 and 289 bp, whereas the minor allele resulted in fragments 
of 29, 130, and 289 bp.
The G908R (2722G → C in exon 8) alteration was amplified using the 
forward primer 5ʼ-CACTTTGCTGGGACCAGGAG-3ʼ and reverse primer 
5ʼ-ACTCCATTGCCTAACATTGTGG-3ʼ. The 363 bp PCR product was digested 
immediately with 4 units HinP1 I (New England BioLabs) for 3 h at 37 0C followed 
by separation on a 2% agarose gel containing ethidium bromide. It resulted in one 
fragment of 363 bp in case of the wild-type, and in 168 and 195 bp fragments in 
case of the rare allele of the G908R polymorphism.
CARD15 L1007fs (3020insC in exon 11) was determined by means of an allele-
specific PCR reaction, followed by separation of PCR products on an agarose gel as 
described previously 9, 13.
When participants were positive for CARD15 R702W, G908R or L1007fs, sequenc-
ing of the corresponding PCR product was performed on an ABI 310 Genetic Analyzer 
(Applied Biosystems) to confirm the alteration.
Statistical analysis
Statistical analysis was performed by comparing the allele frequencies of the 
mutation in patients with CD and controls, using Fisherʼs exact test. The genotype 
frequencies in controls were tested for Hardy-Weinberg equilibrium (HWE) propor-
tions. The analyses were performed with SPSS software version 9 (SPSS Inc., Chicago, 
Illinois, USA).
RESULTS
Patients
Initially, 79 probands from separate families with CD were studied. Subsequently, 
300 CD patients with no or an unknown family history were investigated, giving a 
total of 379 patients with CD including 134 males and 245 females. Their mean age 
was 40.1 years (range: 18.7-81.6 years).
Prevalence of IL-10 Gly15Arg mutation
Two CD patients (0.5%) from two different multiple IBD-affected families were 
found to be heterozygous for the IL-10 Gly15Arg mutation (Figure 1). Both probands 
were from one centre (Erasmus MC UMCR). Homozygosity for the Gly15Arg mutation 
was not found. All other CD-affected patients and all 75 healthy controls carried the 
wild-type allele of the IL-10 gene.
 
Mutation analysis in family members of IL-10 Gly15Arg mutation carriers
First-degree family members of the two CD-affected IL-10 Gly15Arg mutation 
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carriers (probands) were evaluated for this mutation. In both families IL-10 haplo-
types were evaluated as well. The results are summarised in Figure 1. The reports of 
one family have been published recently 7. In the second family, in addition to the 
proband a niece of the probandsʼ father had CD. She was evaluated as well, and did 
not have the Gly15Arg mutation.
One CD-affected sibling and several non-IBD-affected family members were car-
riers of the IL-10 Gly15Arg mutation. In both families, the mutation was present on 
the haplotype IL-10.43*A−IL-10.G−131bp−IL-10.R-110 bp. Therefore, it is possible 
that these families have a common ancestor.
Clinical characteristics of two families with the IL-10 Gly15Arg mutation
Family 1  This family has been described in detail recently 7. In summary, the 
proband (born in 1963) has been known with CD since 1979. The disease is mainly 
located in the small bowel. He was treated with salazopyrine and steroids, and later 
budesonide. He underwent several resections for therapy resistance and stenotic 
lesions. The disease was complicated by uveitis and sacroiliitis. One female CD-
affected sibling (born 1952) was diagnosed in 1981. She also underwent several 
small bowel resections, mainly because of stenotic inflammation. She was treated 
with aminosalicylates until 1997, and experienced no extra-intestinal manifestations. 
The proband has three female healthy siblings (born in 1953, 1954, and 1959). Both 
parents (father born in 1924, mother born in 1926) have died, but were not known 
to have IBD. All family members were evaluated for CARD15 L1007fs, as previously 
published in part 13. The proband, the CD-affected sister, two non-IBD-affected sis-
ters, and the father were homozygous carriers. One non-IBD-affected sister, and the 
mother were heterozygous carrier of mutant L1007fs. The proband and the non-IBD-
affected sister which was heterozygous for L1007fs, were both negative for R702W 
and G908R. These mutations were not evaluated in the other family members.
Family 2  The proband is a non-smoking female patient born in 1977. She pre-
sented with weight loss, nausea, bloody diarrhoea, and abdominal pain in 1996. 
CD of the colon was diagnosed by endoscopy in 1996. Biopsies showed a chronic 
granulomatous inflammation with crypt abscesses. She was treated with prednison 
and subsequently budesonide until 1997, azathioprine until 2000 and mesalazine. 
Besides arthralgia, she had no serious extra-intestinal manifestations. Her sister, 
born in 1971, is healthy and has no abdominal complaints. Neither parent has a his-
tory of abdominal disorders. The father, born in 1949, is known to be affected with 
hypertension. The mother, born in 1951, is healthy and underwent a hysterectomy 
for a benign reason several years ago. A niece of her father, born in 1956, had been 
diagnosed as having CD of the colon in 1988. Her disease was complicated by peri-
anal fistulas. The proband, sister and father had genotypes CARD15 R702W/G908R. 
The mother and niece of the father were heterozygous for R702W. The proband and 
niece were also evaluated for L1007fs, which was negative.
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DISCUSSION
IL-10 has important anti-inflammatory and immunomodulatory effects making 
the IL-10 gene (chromosome 1q32.1) a good candidate for susceptibility to IBD 2, 14. 
Several studies with IL-10 deficient mice have shown that exogenous IL-10 is effec-
tive in preventing and treating spontaneous enterocolitis 1, 15, 16. In IBD patients, a 
lower frequency of the IL-10 -1082*G allele was found compared with controls 17. As 
this allele is associated with higher production of IL-10, the presence of this allele 
might protect against IBD 18. Genetic studies do not support a major role for IL-10 
mutations in human IBD. In a candidate gene study, no significant association was 
found between IBD and IL-10 gene polymorphisms 19. In a genome-wide screen sig-
nificant linkage was found at chromosome 1q31-q32 20. This region is at least 15 cM 
apart from the IL-10 gene, and therefore linkage dysequilibrium between the IL-10 
gene and 1q31-q32 is unlikely. This absence of significant linkage in large popula-
tion studies does not exclude an essential role for mutations in the IL-10 gene in a 
limited number of CD patients.
We have recently described the IL-10 Gly15Arg mutation in a single multiple 
CD-affected family. This mutation is located in the leader sequence of IL-10, and 
was associated with about a 50% reduction in IL-10 protein secretion by peripheral 
blood mononuclear cells after stimulation with lipopolysaccharide or phorbol-12-
myristate-13-acetate. This lead us to propose that the IL-10 Gly15Arg mutation 
might play an important role in the pathogenesis of CD in this specific family 7. This 
mutation also has potential therapeutic implications, as these CD patients could 
theoretically benefit from recombinant human IL-10 administration.
In the present study, we evaluated the prevalence of the IL-10 Gly15Arg muta-
tion in a large group of Dutch patients with CD. Only three patients in two families 
(Figure 1) were heterozygous carrier of this mutation (prevalence of 0.5%). The rela-
tive rarity of the IL-10 Gly15Arg mutation has been reported in two other studies. In 
a study of IL-10 gene polymorphisms, Klein et al. found the IL-10 Gly15Arg mutation 
in two out of 142 patients with CD and five out of 400 healthy controls 21. Donger et 
al. evaluated the prevalence of IL-10 Gly15Arg in patients with cardiovascular dis-
ease and healthy controls 22. The data are summarised in Table 1. Neither of these 
studies presented data evaluating the possible effect on functionality of this IL-10 
mutation.
In this study, 75 unrelated healthy controls were analysed for the IL-10 Gly15Arg. 
No carriage was found. We concluded that the IL-10 Gly15Arg mutation is not asso-
ciated with CD. Ideally, to evaluate the possibility of association, a much larger con-
trol group is necessary. However, as Klein et al. and Donger et aI. 21, 22 showed a very 
low prevalence of IL-10 Gly15Arg in a large set of controls, enlarging our control 
group is unlikely to change the conclusion of this study.
As healthy carriers of the mutation were found in both families, the presence of 
the IL-10 Gly15Arg mutation is not by itself sufficient to cause CD in these specific 
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families. We speculate that in a subgroup of CD patients, the reduction in IL-10 
production together with other yet unidentified predisposing genes involved in the 
immune response, may impair the capacity to appropriately overcome or down-regu-
late the inflammatory process in the gut. The finding that carriage of the mutation 
is not associated with CD, and the finding that within a family with two CD-affected 
relatives only one carries the mutation, does not exclude a pathogenetic role for this 
functional mutation. Similar disparities in association have for instance been reported 
for the CARD15 mutations in CD 8, 9, 13, 23. Moreover, there might be an epistatic inter-
action between IL-10 and CARD15 as in both families CD-affected individuals were 
found with both the IL-10 Gly15Arg as well as one or two CARD15 mutations. 
In conclusion, the prevalence of the IL-10 Gly15Arg mutation is very low (less than 
1%) and is only found in a small number of Dutch patients with CD. We postulate that 
this mutation in the gene encoding the anti-inflammatory cytokine IL-10, which we 
have previously shown results in an impairment of anti-inflammatory function 7, may 
play a role in a small number of individuals with CD. However, additional gene poly-
morphisms and/or triggering events are necessary to result in clinical manifest CD.
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Table 1.   European studies on the prevalence of the interleukin-10 Gly15Arg 
mutation
Study Crohnʼs disease (n) Cardiovascular disease (n) Healthy controls (n)
Gly15Arg + Gly15Arg - Gly15Arg + Gly15Arg - Gly15Arg + Gly15Arg -
Klein et al. 21 
Donger et al. 22
This study
Total a
Prevalence (%) a
2
-
2
4
0.8
140
-
377
517
99.2
-
7
-
7
0.7
-
1001
-
1001
99.3
5
5
0
10
0.7
395
987
75
1457
99.3
a  Statistical analysis of the combined data using Fisherʼs exact test showed no asso-
ciation between interleukin-10 (IL-10) Gly15Arg and Crohnʼs disease.
All IL-10 Gly15Arg positive individuals are heterozygous.
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a
1963
G | A
135 | 131
110 | 110
1924
G | G
137 | 135
108 | 110
1926
G | A
141 | 131
108 | 110
1952
G | A
135 | 131
110 | 110
1954
G | A
137 | 131
108 | 110
1953
G | A
135 | 131
110 | 110
1977
G | A
139 | 131
108 | 110
1949
G | G
131 | 139
108 | 108
1951
G | A
139 | 131
108 | 110
1971
G | G
139 | 139
108 | 108
1959
G | G
141 | 135
108 | 110
Family 1 Family 2
Figure 1.  Pedigrees of families with carriers of the interleukin-10 (IL-10) Gly15Arg 
mutation Tested individuals: n, Crohnʼs disease (CD)-affected male; l, CD-affected 
female; ®, non-CD-affected male; °, non-CD-affected female; Ì, proband. Indicated 
data for each tested individual: first row, year of birth; second row, position 43 in 
exon 1; third row, length of the IL-10.G microsatellite marker PCR fragments; fourth 
row, lengths of the IL-10.R microsatellite marker PCR fragments. 
a Haplotypes of the deceased mother in family 1 were reconstructed.
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CHAPTER 5
From gene to disease: frameshift mutation 
in the CARD15 gene and Crohnʼs disease
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ABSTRACT
A pericentromeric region on chromosome 16 (IBD1 
locus) has been linked with Crohnʼs disease (CD). 
Recently, three genetic variants in the CARD15 gene 
within the IBD1 locus have been identified which were 
highly associated with CD. Carriage increases the relative 
risk of developing CD. One specific mutation (3020insC) 
leads to a stop codon and truncation of the C-terminal 
tandem leucine-rich repeats (LRR) of the CARD15 pro-
tein. Of all patients with CD, 11-19% is heterozygous 
and 3-7% homozygous for this frameshift mutation. 
The CARD15 gene is expressed in monocytes. The LRR-
domain is thought to be involved in the binding of bac-
terial lipopolysaccharide (LPS) and subsequent activation 
of nuclear factor kappa-B (NFκB). NFκB plays a central 
role in the regulation of the expression of other genes 
involved in the inflammatory response. In vitro, embry-
onic kidney cells transfected with the CARD15 3020insC 
mutant showed a reduced activity of NFκB after exposure 
to LPS compared with cells transfected with the wild-type 
CARD15 gene. How the reduced response to LPS contrib-
utes to CD is not clear yet.
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THE DISEASE
Crohnʼs disease (CD) is a chronic inflammatory bowel disease (IBD). In The 
Netherlands the incidence is four to eight cases per 100,000 inhabitants per year. 
The prevalence is around 0.5% 1-3. The disease is characterised by a chronic or inter-
mittent transmural granulomatous inflammation of the gastrointestinal tract. It can 
affect any part of the gastrointestinal tract. The most common disease location is the 
ileocecal region (40%). Typical endoscopic features are presented in Figure 1. CD can 
be complicated by strictures and fistulas, such as perianal and enteroenteric fistulas. 
Furthermore, the disease can manifest outside the gastrointestinal tract, with signs 
including arthritis, erythema nodosum, pyoderma gangrenosum, and uveitis 4.
The disease cause is unknown, however, there is strong epidemiological evidence 
for genetic involvement in IBD. For example, Caucasians are more often affected 
than other ethnic groups. Especially, in American- and Europe-born Ashkenazi Jews 
a high prevalence of CD is reported 5. Four to 18% of patients with CD have a first-
degree relative with IBD 6. In twins with IBD, the concordance for CD is 42-58% in 
monozygotic twin and 0-12% in dizygotic twins 7, 8. High concordance rates for type 
of disease has also been found in families with two or more IBD-affected relatives 
other than twins 6, 9.
Non-genetic factors also play a role in the aetiology of CD. Several animal stud-
ies have demonstrated that an inflammatory bowel response occurs in the presence 
of bacterial flora, and not in a germ-free environment. In CD patients with severe 
perianal fistula, deviation of the faecal stream by means of an ileo- or colostomy 
can induce clinical improvement. Otherwise, antibiotic treatment can also reduce 
disease activity 10.
THE GENE
During the 1990s of the previous century, several research groups have searched 
for genes which might play a role in the pathogenesis of CD and ulcerative colitis 
(UC). The latter disease is also a major subtype of IBD 11. Linkage analysis in multiple 
IBD-affected families have revealed several putative IBD susceptibility chromosomal 
loci (Table 1) 12-18. The various results support the current hypothesis that IBD is a 
multigenetic disease 19.
The pericentromeric region of chromosome 16 (16q12 ) is the most documented 
locus. This so-called IBD1 locus showed linkage with CD 12, 20. In 2001, two research 
groups independently demonstrated that linkage was based on specific nucleotide 
variations within the caspase recruitment domain (CARD)-15 gene (formally named 
nucleotide binding oligomerization domain (NOD)-2 gene) 21, 22. So far, 67 nucleotide 
variations in the CARD15 gene have been identified 23. Only three of these variations 
appeared independently highly associated with CD in Caucasian populations from 
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North America and Europe; 2104C → T in exon 4 (Arg702Trp), 2722G → C in exon 
8 (Gly908Arg), and 3020insC in exon 11 (Leu1007fsinsC) 21, 23. Although all three 
nucleotide variations are considered as mutations, only the 3020insC mutation has 
shown a functional defect in vitro 22. This frameshift mutation includes a cytosine 
insertion at position 3020 in exon 11. It changes a leucine to a proline at position 
1007, and is followed by a stop codon. It results in a truncated CARD15 protein. This 
frameshift mutation is located in the distal part of the gene, which codes for the tail 
of the protein, the so-called C-terminal leucine rich repeats (LRR) region 21, 22, 24.
THE PROTEIN
The CARD15 protein contains 1,040 amino acids. Its structure resembles the 
well-known CARD4 (NOD1) protein. CARD15 consists of two CARDs at the N-ter-
minal site, a central nucleotide binding domain (NBD), and the LRR region at the 
C-terminal site 24. A schematic illustration of the CARD15 protein with the three 
CD-associated amino acid changes is presented in Figure 2. The CARD domains can 
interact with other CARD containing cytoplasmatic proteins, like several pro-caspases 
25. The NBD domain can bind adenosine triphosphate and guanosine triphosphate, 
and probably comprises oligomerization of protein molecules 26, 27. LRRs are found in 
proteins, which are involved in recognition of pathogens. Therefore, CARD15 might 
be a receptor for bacterial products, like lipopolysaccharide (LPS) which is a cell wall 
component of gram negative bacteria 24. 
The function of CARD15 is not fully elucidated. In vitro studies with CARD15 
cDNA transfected embryonal kidney cells (HEK293T) have shown that expression of 
the CARD15 protein leads to activation of the caspase cascade through the N-ter-
minal CARD leading to apoptosis (programmed cell death). Apoptosis is necessary 
for normal development and homeostasis of organs and tissues. Binding with inac-
tive pro-caspase-9 leads to conversion into active caspase-9 24, 25. Expression of 
CARD15 in HEK293T cells also leads to activation of nuclear factor kappa-B (NFκB). 
NFκB comprises a family of proteins which can induce transcription factors. It is 
an important regulator of immune- and inflammation-related genes of for exam-
ple pro-inflammatory cytokines, adhesion molecules, chemokines, growth factors, 
cyclo-oxygenase-2 and inducible nitric oxide synthase. NFκB proteins are localised 
in the cytoplasm as inactive dimers. Activation of NFκB is mediated by RICK (RIP-
like interacting CLARP kinase; RIP, receptor interacting protein; CLARP, caspase-like 
apoptosis regulatory protein), a CARD-containing kinase that associates with CARD 
of the CARD15 protein to a complex. The LRR domain is likely to be involved in the 
recognition of a wide array of pathogen components, and induction of a pathogen 
specific response. In case of CARD15, it is suggested that the LRR domain acts like 
an intracellular receptor for LPS. After binding (or interaction) of intracellular LPS with 
the LRR domain, cytoplasmatic NFκB becomes activated and subsequently translo-
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cates into the nucleus where it activates expression of specific genes 24, 28.
The CARD15 frameshift mutation leads to truncation of the LRR domain lacking 
the 33 distal amino acids. CARD15 frameshift mutation transfected HEK293T cells 
showed reduced NFκB activity 22. In contrast, patients with CD have increased expres-
sion of NFκB in the colon compared with healthy controls 29. Therefore, the exact 
role of the CARD15 frameshift mutation in the aetiology of CD is unclear, and there 
exists a discrepancy between experimental and clinical findings. Otherwise, while 
NFκB is considered to be a pro-inflammatory factor, NFκB-deficient mice sponta-
neously develop colitis 30. Together, the data have led to several hypotheses with 
respect to the relation between CARD15 mutations and the development of CD. As 
a consequence of altered (reduced) recognition of bacterial organisms the inflam-
matory response might become dysregulated. Otherwise, mutated CARD15 might 
lead to an inadequate anti-inflammatory response, for example through the anti-
inflammatory cytokine interleukine-10 22. A CARD15 mutation might also result in a 
reduced apoptotic signal leading to an abnormal inflammatory response.
THE CELL
The CARD15 protein is expressed in monocytes 24 and possibly in enterocytes 
as well 31. Monocytes are involved in non-specific cellular immunity and are precur-
sors of tissue-bound cells, like intestinal macrophages and dendritic cells. These 
antigen presenting cells are important for initiation an immune response after bind-
ing with specific intestinal antigens. The inflammatory response in CD is based on 
a dysregulated T-helper-1 response characterised by release of pro-inflammatory 
cytokines, like tumour necrosis factor-alpha and interferon-gamma 32. It is likely 
that CARD15 is also expressed in intestinal antigen presenting cells, however, this 
has not been proven.
THE POPULATION
The prevalence of the CARD15 frameshift mutation in patients with CD is 11-19% 
for heterozygous carriage, and three to seven percent for homozygous carriage. In 
patients with UC and in healthy controls only heterozygous carriage have been found 
in six to nine percent 21, 22. The prevalence in CD is equal in sporadic patients and in 
patients with IBD-affected relatives 23, 33, 34.
Carriage means an increased risk of developing CD. While heterozygous carriage 
is associated with a two- to three-fold increased risk, homozygous carriers have a 
17-42-fold increased risk for developing CD 21, 22, 33. These calculations are based on 
the original publications in which no healthy homozygous carriers had been found. In 
our own populations we did find homozygous carriage in individuals with a relatively 
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high age and without signs of CD.
Besides the frameshift mutation, carriage of the two other common CARD15 
mutations in exon 4 and 8 are also associated with an increased disease risk. None 
of the three mutations are located together on the same allele. In Table 2, the dis-
ease risks for developing CD are summarised for carriage of one or two of the three 
common CARD15 mutations 21. The population attributable risk (PAR) of the three 
CARD15 mutations is around 15-20%. The PAR estimates the proportion of a disease 
attributable to a specific risk factor 35.
DIAGNOSTICS
The diagnosis CD is based on clinical, radiological and endoscopic criteria. So 
far, CARD15 DNA testing has no consequences concerning the diagnostic work-
up and treatment of CD. It is also not accepted as a non-invasive screening test 
when considering the diagnosis CD in symptomatic patients. However, recent stud-
ies have shown that carriage of the CARD15 frameshift is associated with an early 
age of disease 36, disease localisation in the terminal ileum 34, 36-39, and a stenosing 
disease behaviour 36, 38, 39. One study reported association with fistula 38, another did 
not 36. These findings make it possible to subtype patients with CD. Maybe CARD15 
genotyping will become a clinical tool to predict the course and prognosis of the 
disease.
CONCLUSION
The discovery of the CARD15 gene is a milestone in the history of IBD. It will give 
new insights on the pathogenesis of CD. At the same time, an important conclusion 
is that CD is a complex genetic disorder of which one single risk factor is neither 
necessary nor sufficient to develop the disease.
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Table 1.  Review of genome screens in inflammatory bowel disease
Authors (year) reference Chromosome a Disease a
Hugot et al. (1996) 12
Satsangi et al. (1996) 13
Cho et al. (1998) 14
Hampe et al. (1999) 15
Ma et al. (1999) 16
Duerr et al. (2000) 17
Rioux et al. (2000) 18
16 (IBD1 locus)
12q (IBD2 locus), 7q, 3p
1p, 3q, 4q
16
1q, 6p (IBD3 locus), 22
10, 12, 16
4, X
12, 14q
14q (IBD4 locus)
3p, 5q (IBD5 locus), 6p, 19q
CD
CD and UC
CD and UC
CD
CD and UC
CD
UC
CD
CD
CD and UC
a IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis.
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Table 2.   Relative risk to develop Crohnʼs disease with respect to carriage of the 
three common CARD15 mutations 21
Carriage of mutations Relative risk Absolute risk (%)
None
One, heterozygous carriage
One, homozygous carriage
Two, compound heterozygous carriage  
(on two different alleles)
1
3
38
44
0.07
0.2
3
3
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Figure 1.  Endoscopic views of Crohnʼs disease. A, recurrent disease in the neo-
terminal ileum after ileocecal resection. The mucosa is red and swollen with several 
irregular longitudinal ulcers. B, severe Crohnʼs disease of the colon with multiple 
irregular deep longitudinal ulcers and disappearance of haustration.
BA
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CARD1 NBD   LRRCARD2
Arg702Trp
Leu1007insC
chromosome 16q
Gly908Arg
chromosome 16p
CARD15 gene
IBD1 locus
Figure 2.  A schematic illustration of the inflammatory bowel disease (IBD)-1 locus, 
the caspase recruitment domain (CARD)-15 gene, and the CARD15 protein with the 
three common amino acid changes which are associated with Crohnʼs disease. Only 
3020insC have demonstrated an in vitro functional defect. This frameshift mutation 
leads to truncation of the C-terminal protein by the change of leucine to proline 
at amino acid position 1007. NBD, nucleotide-binding domain; LRR, leucine-rich 
repeats.
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  LRRCARD1&2
LPS
pro-caspase-9
caspase-9
inactive NF B
apoptosis transcription of
inflammation-related 
genes
active NF B
Figure 3.  A schematic illustration of caspase recruitment domain (CARD)-15 depen-
dant inflammatory and apoptotic response. CARD1 and CARD2 are important for the 
initiation of apoptosis and activation of nuclear factor kappa-B (NFκB). Binding (or 
interaction) of lipopolysaccharide (LPS) with the leucine-rich repeats (LRR) domain 
leads to NFκB activation. Whether this is also the first step towards apoptosis is yet 
not known.
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ABSTRACT
Background
Single nucleotide variations in the CARD15 gene have 
recently been shown to be associated with Crohnʼs dis-
ease (CD). Of special interest is a cytosine insertion at 
position 3020 of exon 11 (3020insC), which leads to a 
stop codon, truncation of the CARD15 protein, and an 
altered function of CARD15. The aim of the study was 
to evaluate this frameshift mutation in Dutch multiple 
affected families with inflammatory bowel disease (IBD).
Methods
Ninety-three Caucasian multiple affected families 
with IBD were recruited by interviewing patients attend-
ing our department. Sixty-one probands had CD, and 32 
probands ulcerative colitis (UC). The diagnosis of pro-
bands and affected family members was verified accord-
ing to standard criteria. In addition, 81 healthy unre-
lated controls were included. Genomic DNA was isolated 
from venous blood of all participants to determine the 
CARD15 3020insC mutation by using an allele-specific 
polymerase chain reaction, followed by agarose gel elec-
trophoresis and DNA sequencing.
Results
Association with CARD15 3020insC was statistically 
significant for CD, but not for UC. In one of the multiple 
affected families, middle-aged and elderly homozygous 
carriers were identified without CD.
Conclusion
Although CARD15 3020insC appears to be aetiologi-
cally important in CD, homozygous carriage does not 
always lead to IBD. 
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INTRODUCTION
The aetiology of inflammatory bowel disease (IBD), a chronic recurrent gastro-
intestinal disease, is complex and largely unknown. Genetic susceptibility, how-
ever, plays an important role, as demonstrated by several epidemiological studies 1. 
Additionally, during the 1990s several genome-wide linkage analyses with mul-
tiple highly polymorphic microsatellite markers in multiple affected families with IBD 
have revealed putative disease loci. The results of these studies are summarised in 
Table 1 2-8.
A pericentromeric locus on chromosome 16 was the first genomic susceptibil-
ity region of interest, described by Hugot et al. in 1996. This so-called IBD1 locus 
appeared to be linked with Crohnʼs disease (CD) 2. The findings were replicated 
by others 4, 5, 9-17. Absence of linkage of CD with the IBD1 locus has also been 
reported 18, 19.
Linkage of CD with the IBD1 locus appears to be based on genetic alterations 
in the CARD15 gene. The CARD15 gene is located on chromosome 16q12 and was 
described by Ogura et al. in 2001 20. Three single nucleotide variants appeared to be 
highly associated with CD. One specific alteration involves a cytosine insertion at posi-
tion 3020 of exon 11, leading to a stop codon and truncation of the CARD15 protein. 
It affects the C-terminal leucine rich repeats (LRR), shortening this protein domain by 
33 amino acids. This 3020insC frameshift mutation showed preferential transmission 
in families with CD but not in families with ulcerative colitis (UC) 21, 22. The spectacular 
findings have been subsequently confirmed by several other groups 23-30.
The goal of this study was to evaluate the prevalence of CARD15 3020insC in 
Dutch IBD-affected probands and their (non-)IBD-affected family members.
MATERIALS AND METHODS
Patients and families
Multiple affected families with IBD were identified by interviewing IBD patients 
attending the Departments of Gastroenterology, Internal Medicine, and Surgery of 
the Erasmus MC University Medical Centre Rotterdam (UMCR). Probands, affected 
relatives, and available non-affected relatives completed a questionnaire about IBD 
and other diseases. Based on information supplied by their physician, the diagnosis 
was verified according to standard criteria 31.
The study was approved by the Institutional Review Board of the Erasmus MC 
UMCR. All participants gave written informed consent.
DNA isolation
Genomic DNA was isolated from whole peripheral venous blood collected in eth-
ylenediaminetetraacetic acid anticoagulated tubes (Becton Dickinson, Leiden, The 
Netherlands) using standard techniques. In some instances, DNA was isolated from 
Epstein-Barr virus transformed lymphoblastoid cell lines 32, derived from peripheral 
venous blood collected in acid citrate dextrose solution containing tubes (Becton 
Dickinson).
Genotyping
The CARD15 3020insC mutation was determined by means of an allele-specific 
polymerase chain reaction (PCR), followed by separation on agarose gels, as described 
by Ogura et al. 22. Briefly, a multiplex PCR with four primers was performed. Two con-
trol intronic primers were used, including forward 5ʼ-CTGAGCCTTTGTTGATGAGC-3ʼ 
and reverse 5ʼ-TCTTCAACCACATCCCCATT-3ʼ resulting in a 533 base pairs (bp) frag-
ment including position 3020 of exon 11. Two additional exonic primers were used 
to discriminate between the wild-type and 3020insC allele, including reverse 5ʼ-
CGCGTGTCATTCCTTTCATGGGGC-3ʼ and forward 5ʼ-CAGAAGCCCTCCTGCAGGCCCT-
3ʼ. These primers result in a 319 bp containing wild-type fragment, or a 214 bp 
fragment in the case of a 3020insC allele. The PCR products were identified by 
electrophoresis on a 2% agarose gel and ethidium bromide staining. When par-
ticipants appeared positive for CARD15 3020insC, the mutation was confirmed by 
DNA sequencing of a exon 11 PCR fragment amplified with the forward primers 5ʼ-
AGGATGTGTCTAAGGGACAG-3ʼ and reverse primer 5ʼ-CTGAATGTCAGAATCAGAAGG-
3ʼ. Sequencing was performed on an ABI 310 genetic analyzer (Applied Biosystems, 
Nieuwerkerk aan de IJssel, The Netherlands).
In one family, non-IBD homozygous CARD15 3020insC mutation carriers were 
found. To exclude these results to be caused by an unknown sequence variation in 
the binding site of the primers, a second confirmation test was used. Exon 11 was 
amplified and sequenced with the two control intronic primers mentioned earlier.
Statistics
Association was determined by comparing the frequencies of the CARD15 
3020insC frameshift mutation in cases with CD and controls, using the Fisher exact 
test. It was expressed as relative risk (RR) with a 95% confidence interval (CI). The 
genotype relative risk (GRR) was evaluated by comparing the genotype frequencies 
in cases and controls. For cases, the observed frequencies were used, whereas for 
controls the genotype frequencies were estimated assuming the genotypes to be in 
Hardy-Weinberg equilibrium proportions (i.e., assuming no selection against the 
homozygotes) 22. The analyses were performed with SPSS software version 8.0 (SPSS 
Inc., Chicago, Illinois, USA).
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RESULTS
Ninety-three IBD-affected probands with either CD (n = 61) or UC (n = 32), and 
with a positive family history for IBD were screened for the CARD15 3020insC frame-
shift mutation. In addition, 81 unrelated healthy controls were examined.
Fourteen (23%) probands with CD, one (3%) proband with UC, and three (4%) 
healthy controls were carriers of the mutation. Three CD-affected probands were 
homozygous for the frameshift mutation. All other carriers, including UC-affected 
probands and controls were heterozygous. The allele frequency of the CARD15 
3020insC among patients with CD was 14%, and approximately 2% in UC-affected 
patients and in controls. The frequency of the frameshift mutation was significantly 
higher in CD-affected patients than in controls (P < 0.0001, Fisher exact test). No 
association was found with UC.
In probands with CD and heterozygous for CARD15 3020insC, the GRR was 6.1 
(95% CI = 1.6−23.7). As the CARD15 3020insC genotype frequencies in controls 
were assumed to be in Hardy-Weinberg equilibrium proportions (P = 0.87), we could 
estimate the expected frequency of homozygous frameshift carries in the control 
population. We used this to calculate the GRR for the homozygous carriers, which 
was 178 (95% CI = 0−∞).
Subsequently, available IBD-affected relatives of the 14 probands with CD who 
were positive for CARD15 3020insC were screened for the mutation. The data are 
summarised in Table 2. Most affected relatives were concordant for disease as well 
as for carriage of the mutation.
In addition, available non-IBD-affected relatives were screened for carriage of 
CARD15 3020insC when the proband had the frameshift mutation. In one family with 
a homozygous CD-affected proband, two sisters, the father and an aunt (sister of 
the father) were also homozygous carriers. Except for one sister, all these relatives 
had no symptoms or signs of IBD or other major gastrointestinal health problems. 
One relative (sister) was diagnosed with irritable bowel syndrome, based on a normal 
colonoscopy and blood tests. Follow-up of these non-IBD-affected family members 
was available until the beginning of 2002 (range of age: 42−83 years). The pedigree 
of the family is shown in Figure 1. Individual details are given in Table 3. In another 
family with a CARD15 3020insC homozygous CD-affected proband, the father was 
heterozygous for the mutation but appeared to have UC.
DISCUSSION
The CARD15 (formerly NOD2) gene is a recently described gene 20. Functionally, 
the CARD15 gene product has been predicted to have similar activity to the apoptotic 
protease activating factor-1, which is a regulator of apoptosis 33. The structure of the 
CARD15 protein is similar to that of CARD4 (formerly NOD1) 20. CARD15 is located 
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on chromosome 16q12 within the IBD1 locus. It seems to play an important role in 
the aetiology of CD, as three single nucleotide variants are highly independently 
associated with the disease 21, 26.
CARD15 is a cytosolic protein expressed in monocytes. Its C-terminal region is 
presumed to be involved in recognition of bacterial lipopolysaccharide (LPS) through 
the LRR. Binding or interaction of LPS with the LRR domain triggers activation of the 
transcription factor nuclear factor kappa-B (NFκB) through two N-terminal caspase 
recruitment domains (CARD). NFκB is an important regulator of genes involved in a 
pro-inflammatory response 34.
One of the three CD-associated nucleotide variants is a 3020insC in exon 11, 
which results in a truncated CARD15 protein missing the final 33 amino acids of the 
LRR. It probably leaves the CARD motifs and the centrally located nucleotide binding 
domain functionally intact 21, 22. Embryonic kidney cells (HEK293T) transfected with 
3020insC-mutated CARD15 plasmids showed a reduced activity of NFκB after expo-
sition to LPS from various bacteria, compared with wild-type CARD15 transfected 
cells 22. Based on these experiments, the CARD15 frameshift mutation is thought to 
result in an altered monocytic response to bacterial components in CD. Whether this 
reduced NFκB response to LPS under artificial circumstances is relevant to the patho-
genesis of CD is not clear, as colonic tissue from CD patients has been found to have 
increased rather than decreased NFκB activity compared with that of controls 35.
Carriage of the CARD15 3020insC mutation results in an increased RR of develop-
ing CD and appears to be a risk factor for early onset of disease 24, location of dis-
ease in the small bowel 24, 25, 28-30, and development of stenosis 24, 26, 28, 29. Whether car-
riage is also associated with fistulas is not yet clear 24, 28. In the initial studies on the 
prevalence of CARD15 3020insC mutation in IBD, no homozygous healthy controls 
have been detected. In these studies, the RR of homozygous CD-affected individuals 
was estimated to be as much as 18-42-fold, assuming that the genotype frequen-
cies in controls were in Hardy-Weinberg equilibrium proportions 22, 23. In this study 
also no unrelated homozygous controls were found. However, we did find homo-
zygous carriers of CARD15 3020insC within a family of two CD-affected siblings. 
These homozygous relatives had never had important gastrointestinal complaints or 
features suggesting IBD. They remained asymptomatic 27−67 years beyond the age 
of diagnosis of the proband. Searching the literature for other reports on non-IBD-
affected homozygous carriers, we found only one other study on the prevalence of 
CARD15 in psoriasis, which reported a 60-year-old healthy homozygous carrier in 
the control group 36. These results demonstrate that homozygosity does not neces-
sarily lead to manifest IBD, even at older age.
If the mutation by itself would be a major determinant of CD, one would expect, 
by analogy with other genetic diseases, homozygosity to result in a more severe 
phenotype. Other factors, both genetic and environmental, must be involved in the 
pathogenesis of CD. As CARD15 mutations have only been found in a minority of 
patients with CD patients 21-23, it is likely that IBD is not a single disease but rather 
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a group of aetiologically and genetically distinct diseases with similar clinical pre-
sentations. The various results of genome-wide linkage studies in IBD (Table 1) also 
support this multigenetic pathogenesis. 
In conclusion, this study confirms the association of CARD15 3020insC with CD. 
Homozygous carriage, however, does not always lead to disease. Further studies on 
the function of both wild-type and truncated CARD15 protein will help unravel the 
role of this frameshift mutation in CD.
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Table 1.  Summary of genome screens in inflammatory bowel disease
Authors (year) reference
Significant results of linkage analysis 37
Chromosome a Disease a
Hugot et al. (1996) 2 
Satsangi et al. (1996) 3
Cho et al. (1998) 4
Hampe et al. (1999) 5
Ma et al. (1999) 6 
Duerr et al. (2000) 7
Rioux et al. (2000) 8
16 (IBD1 locus)
12q (IBD2 locus), 7q, 3p
1p, 3q, 4q
16
1q, 6p (IBD3 locus), 22
10, 12, 16
4, X
12, 14q
14q (IBD4 locus)
3p, 5q (IBD5 locus), 6p, 19q
CD
CD and UC
CD and UC
CD
CD and UC
CD
UC
CD
CD
CD and UC
a IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis.
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Table 2.    CARD15 genotype of inflammatory bowel disease-affected relatives of 
probands with Crohnʼs disease who carried the CARD15 3020insC frame-
shift mutation
CD-affected relatives a UC-affected relatives a
Familial relation to 
proband with CD a
3020insC
positive
3020insC
negative
3020insC
positive
3020insC
negative
First-degree 4 1 1 0
Second-degree 1 1 0 1
Third-degree 4 2 0 0
> Third-degree 3 3 0 3
Not available 1 b 1 c
a CD, Crohnʼs disease; UC, ulcerative colitis.
b A third-degree family member was not available for testing.
c A second-degree family member died before starting this study.
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Table 3.   Characteristics of an inflammatory bowel disease family with affected and 
non-affected homozygous CARD15 3020insC frameshift mutation carriers
Year of birth
(year of death)
CARD15 
3020insC 
genotype
Age of 
diagnosis 
CD (yrs) a 
Location of 
CD a
Other relevant  
diseases a
Proband 1963 + / + 16 (1979)
small bowel, 
rectum
uveitis, sacroiliitis
Sister of proband 1952 + / + 29 (1981) small bowel
Sister of proband 1953 + / +
IBS, normal colonic 
barium study in 1995
Sister of proband 1954 + / -
IBS, endoscopy at early 
adolescence was normal
Sister of proband 1959 + / +
Father of proband 1924 (1999) + / +
no history of abdominal 
disorders, died of 
an acute myocardial 
infarction
Mother of proband 1926 (1988) + / - b
no history of abdominal 
disorders, died due to 
metastatic cancer of 
unknown primary
Sister of father 1916 (2000) + / +
no history of abdominal 
disorders, known with 
cardiovascular disease, 
diabetes mellitus,
and chronic obstructive 
pulmonary disease
Sister of father 1917 (2000) - / -
IBS, normal colonoscopy 
in 1997, known with 
cerebral vascular 
accident
a CD, Crohnʼs disease; IBS, irritable bowel syndrome.
b Reconstructed.
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            a
1963
 +/+
1924
 +/+
1926
 +/-
1952
 +/+
1954
 +/-
1953
 +/+
1959
 +/+
1917
 -/-
1916
 +/+
Figure 1.  A multiple IBD-affected family with healthy homozygous CARD15 3020insC 
carriers. n, CD-affected male; l, CD-affected female; ®, non-IBD-affected male; 
°, non-IBD-affected female; Ì, proband; + / +, homozygous carriage of CARD15 
3020insC; + / -, heterozygous carriage of CARD15 3020insC; - / -, homozygous 
carriage of wild-type CARD15. Row below individuals, year of birth. a Reconstructed 
genotype.
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ABSTRACT
Background
The single nucleotide variations R702W, G908R and L1007fs in the 
CARD15 gene have been found to be independently associated with 
Crohnʼs disease (CD). The aim of this study was to evaluate the preva-
lence of these gene variations in Dutch multiple inflammatory bowel 
disease (IBD)-affected families, in sporadic IBD-affected patients and 
in healthy controls.
Methods
Dutch Caucasians from multiple IBD-affected families were recruited, 
including 78 probands with CD, 34 probands with ulcerative colitis (UC) 
and 71 IBD-affected and 100 non-IBD-affected family members. In 
addition, 45 sporadic IBD patients (36 CD and nine UC) and 77 unrelated 
healthy controls were included. Genomic DNA was isolated to determine 
CARD15 R702W, G908R and L1007fs. For these mutations, we evaluated 
disease susceptibility and correlation with IBD phenotypes.
Results
In all included unrelated IBD-affected probands, the R702W, G908R 
and L1007fs allele frequencies were 8.8, 6.1 and 11.0%, respectively, 
for CD, and 4.7, 0 and 2.3% for UC. In controls, the allele frequencies 
were 5.9, 0.7, and 1.9%, respectively. G908R and L1007fs were associ-
ated with CD (P = 0.006 and 0.001, respectively). Compound hetero-
zygotes for any of the three mutations were 11 (9.2%) in CD patients, 
but none in UC patients or controls. Carriage of CARD15 mutations 
was not associated with familial disease (P ≥ 0.38). IBD-affected fam-
ily members of CD-affected probands carrying L1007fs, however, were 
significantly more often carrier of L1007fs than expected (P < 0.001). 
In CD-affected patients, a significant trend was found between carriage 
of at least one CARD15 mutation, and between carriage of L1007fs and 
behaviour of disease, including more carriers with stricturing and even 
more with penetrating disease (P = 0.006 and 0.017, respectively).
Conclusion
In the Dutch population, CARD15 G908R and L1007fs are associ-
ated with CD. Although no difference was found between sporadic and 
familial cases, in L1007fs positive multiple affected families the IBD-
affected relatives are more likely than expected to carry this mutation. 
In CD, carriage of at least one CARD15 mutation is associated with a 
more complicated disease behaviour.
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INTRODUCTION
Genetic susceptibility plays an important role in the aetiology of inflamma-
tory bowel disease (IBD). Several epidemiological studies have in particular shown 
high concordance rates of Crohnʼs disease (CD) in monozygotic twins 1, 2. Molecular 
genetic association studies including candidate gene and genome-wide screening 
studies have suggested that several immune and inflammation-related genes con-
tribute to the pathogenesis of IBD 3, 4.
In 2001, two groups reported the first susceptibility gene in CD, originally called 
NOD2 and more recently CARD15. The gene is located on chromosome 16q12 and its 
discovery was based on the linkage analysis of genome screening in IBD 5, 6. CARD15 
is expressed in monocytes, macrophages and intestinal epithelial cells 7-10. CARD15 
is a member of the Ced4 superfamily that includes apoptotic protease activating 
factor-1 11 and CARD4 12, 13.
So far, more than 100 single nucleotide polymorphisms (SNPs) and mutations 
have been described in the CARD15 gene (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?CMD=search&DB=snp). Only three mutations are independently associated 
with CD in Caucasian populations, 2104C → T in exon 4 (SNP8, R702W, Arg702Trp), 
2722G → C in exon 8 (SNP12, G908R, Gly908Arg), and 3020insC in exon 11 (SNP13, 
L1007fs, Leu1007fsinsC) 14. Several studies from different countries have been pub-
lished on the prevalence of these three mutations in IBD. The results from European 
countries are summarised in Table 1 5, 15-55. CD is most consistently associated with 
CARD15 L1007fs. One study also demonstrated a significantly increased prevalence 
of L1007fs in ulcerative colitis (UC) compared with controls 39. 
While simple heterozygous carriage of R702W, G908R or L1007fs is associated 
with about a three-fold increased relative risk for CD, compound heterozygous car-
riage or homozygous carriage results in a CD genotype relative risk (GRR) of 23-44 
5, 55, 56. All three nucleotide changes are considered to be disease-associated muta-
tions. Especially L1007fs has been demonstrated in vitro to be associated with a 
reduced activation of transcription factor nuclear kappa-B (NFκB) in mononuclear 
cells 6, 57, 58. Recent data in a L1007fs knock-in mouse model, however, showed that 
carriage of L1007fs is associated with an elevated NFκB activity 59. This mouse model 
is more in line with the clinical observation of elevated NFκB activity in patients with 
active CD 60.
CARD15 is expressed in Paneth cells, which are specialised epithelial cells located 
in the mucosal crypts of Lieberkühn, and which are thought to play a protective role 
in the host against enteric flora 61. While a high CARD15 expression has been dem-
onstrated in CD-affected ileal Paneth cells, only weak expression was seen in normal 
ileal mucosa of CD and non-IBD-affected individuals 10. An antimicrobial defence 
mechanism of Paneth cells is secretion of antimicrobial peptides defensin-5 and 
defensin-6, which is diminished in CD-affected ileal Paneth cells. CARD15 L1007fs 
carriage showed a further defensin deficiency 27, 62. Intestinal barrier function can also 
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be harmed due to an increased intestinal permeability, which is found in patients 
with CD and in their healthy relatives. Carriage of CARD15 L1007fs appeared to be 
associated with an increased intestinal permeability in these healthy first-degree 
relatives 63, 64, except for one study 65.
In multiple IBD-affected families, there is a high concordance rate for type of 
disease 66, 67. Not much is known about the concordance rate of CARD15 mutation 
carriage in familial IBD. Recently, we have published our data about CARD15 L1007fs 
in familial CD. CD-affected relatives were more often concordant for L1007fs car-
riage than UC-affected relatives 68. Otherwise, a Finnish study demonstrated in CD 
probands an association between CARD15 L1007fs carriage and familial IBD 20. 
The goal of this study was to determine the prevalence of the three CARD15 
mutations R702W, G908R and L1007fs in Dutch patients, with either familial or 
sporadic IBD. In familial IBD, CARD15 mutations were examined in IBD-affected and 
non-IBD-affected relatives. Moreover, a correlation with clinical phenotypes in IBD 
probands was sought.
MATERIALS AND METHODS
Patients, families and controls
Caucasian patients with IBD, meeting standard criteria 69 and attending the 
Erasmus MC University Medical Centre Rotterdam (UMCR), were recruited for this 
study. Patients were classified as familial IBD if one or more relatives were known to 
have IBD. Probands, available affected relatives and non-affected relatives completed 
a questionnaire about IBD and other diseases. On the basis of the information sup-
plied by their physician, the diagnosis was verified 69. The disease phenotype of CD 
probands was classified according to the Vienna classification for CD 70. UC-affected 
probands were phenotyped according to the age at onset (< 40 and ≥ 40 years) and 
the location of the disease (proctitis, left-sided colitis and extended or pancolitis). 
Some patients and their relatives have been included in other studies 68, 71. Caucasian 
controls were recruited at the Erasmus MC UMCR and have been described before 
68, 71. The study was approved by the Institutional Review Board of the Erasmus MC 
UMCR. All participants provided written informed consent.
DNA isolation
Genomic DNA was isolated from whole peripheral venous blood collected in 
ethylenediaminetetraacetic acid anticoagulated tubes (Becton Dickinson, Leiden, 
The Netherlands) using standard techniques. In some cases, DNA was isolated from 
Epstein-Barr virus transformed lymphoblastoid cell lines, derived from peripheral 
venous blood collected in acid citrate dextrose solution containing tubes (Becton 
Dickinson) 72.
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Genotyping
CARD15 R702W and G908R were determined by means of restriction enzyme 
analysis. First, the DNA regions of interest containing the mutation were ampli-
fied by polymerase chain reaction (PCR). For R702W (2104C → T in exon 4), the 
forward primer 5ʼ-CAGCTGGGCAGCTTTGCTGC-3ʼ and the reverse primer 5ʼ-
CATGGCATGCACGCTCTTGG-3ʼ were used. The R702W PCR product (448 base pairs 
(bp)) was purified by phenol extraction followed by ethanol precipitation, after which 
the PCR fragment was digested with 8 units of Hpa II (New England BioLabs, Beverly, 
Massachusetts, USA) for 4 hours (h) at 37 0C. Bands were visualised after separation 
on a 2% agarose gel containing ethidium bromide. The wild-type exon 4 resulted 
in fragments of 29, 54, 76 and 289 bp, while the R702W polymorphism resulted 
in fragments of 29, 130, and 289 bp. The G908R (2722G → C in exon 8) mutation 
was amplified using the forward primer 5ʼ-CACTTTGCTGGGACCAGGAG-3ʼ and the 
reverse primer 5ʼ-ACTCCATTGCCTAACATTGTGG-3ʼ. The G908R PCR product (363 
bp) was not further purified, and digested immediately with 4 units HinP1 I (New 
England BioLabs) for 3 h at 37 0C followed by separation on a 2% agarose gel contain-
ing ethidium bromide. It resulted in one fragment of 363 bp in case of the wild-type 
allele, and in fragments of 168 and 195 bp in case of the G908R mutation.
CARD15 L1007fs (3020insC in exon 11) was determined by means of an allele-
specific PCR reaction, followed by separation of the amplicons on an agarose gel as 
described previously 6, 68.
When participants were found to be positive for CARD15 R702W, G908R or 
L1007fs, DNA sequencing of the corresponding PCR product was performed to 
confirm the mutation. Available relatives of these probands were screened for 
the same CARD15 mutation by DNA sequencing. Sequencing was performed on 
an ABI 310 Genetic Analyzer (Applied Biosystems, Nieuwerkerk aan de IJssel, The 
Netherlands).
Statistics
Allele and genotype frequencies in CD, UC cases and in controls were deter-
mined. Associations were tested by comparing the allele frequencies of the CARD15 
R702W, G908R and L1007fs mutations in cases with IBD and controls, using Fisherʼs 
exact test. The genotype frequencies in controls were tested for Hardy-Weinberg 
equilibrium (HWE) proportions. In case of association, the GRR and 95% confidence 
interval (CI) in heterozygous and homozygous carriers were estimated by compar-
ing the genotype frequencies in cases and controls, and expressed as an odds ratio. 
When homozygous carriers were observed among the cases but not among the 
controls, the GRR in homozygous carriers versus non-carriers was computed using 
the expected number of homozygous carriers in controls based on HWE. A compari-
son of genotype frequencies between different groups was evaluated using Fisherʼs 
exact test 6.
In familial IBD, the frequency of CARD15 mutations in affected family members 
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was evaluated. We computed the expected number of carriers among affected rela-
tives of probands carrying the mutation under Mendelian transmissions and assum-
ing a small allele frequency. Taking ʻpʼ as the allele frequency in the population, then 
the probability of carrying the mutation for first-degree relatives is ½ + p, and for 
second-degree relatives this probability is ¼ + 1½p, etc. In this formula, the first 
term is the probability that relatives carry the same allele as the proband, and the 
second term is the probability that relatives carry another allele of the mutation. As 
an estimate of ʻpʼ, we used the observed frequency in the controls. We tested whether 
the observed number of carriers differed from the expected number of carriers. To 
this end, the variance of the observed number of carriers taking into account the cor-
relation among affected relatives of one proband was computed. We used a normal 
distribution to derive a P value.
Associations between genotypes and IBD phenotypes were evaluated by χ2 sta-
tistics. For ordinal variables, we also applied the χ2 statistics for trend. In the case of 
small numbers, exact P values were computed.
Mean follow-up between groups was evaluated by Studentʼs t test.
All analyses were performed with SPSS software version 9.0 (SPSS Inc., Chicago, 
Illinois, USA).
RESULTS
Patients, families and controls
In this retrospective study, 114 unrelated Caucasian patients with CD (46 men 
and 68 women, mean age at end of follow-up: 41.4 years, range: 21.8-78.8 years) 
and 43 with UC (21 men and 22 women, mean age at end of follow-up: 45.8 years, 
range: 28.0-71.5 years) were screened for CARD15 mutations. Their phenotypes 
are demonstrated in Tables 3 and 4. Seventy-eight (68%) CD- and 34 (79%) UC-
affected patients had a positive family history for IBD. From these families, 45 CD-
affected, 26 UC-affected, 100 non-IBD-affected blood-related and 19 non-IBD-
affected non-blood-related family members were included. In addition, 77 unrelated 
healthy Caucasian adults were included as controls.
CARD15 mutations in patients with inflammatory bowel disease and controls
R702W  Twenty (17.5% of 114) patients with CD, four (9.3% of 43) with UC 
and nine (11.8% of 76) healthy controls (one control not tested) were carriers of 
the CARD15 R702W mutation. All mutation carriers were heterozygous. In controls, 
the genotype frequencies were in HWE (P = 0.59). The allele frequency of CARD15 
R702W among patients with CD was 8.8%, 4.7% in UC patients and 5.9% in controls. 
The frequency of this missense mutation was not statistically different (P = 0.33) 
between patients with CD and controls, nor between patients with UC and controls 
(P = 0.77).
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G908R  CARD15 G908R was found in 14 (12.3% of 114) patients with CD and in 
one (1.3% of 76) healthy individual (one control not tested). Only heterozygous car-
riers were found. In controls, the genotype frequencies were in HWE (P = 0.95). No 
UC-affected carriers were found. The allele frequency of the G908R mutation was 
6.1% in CD-affected patients and 0.7% in controls, which was significantly different 
(P = 0.006). The GRR for CD in G908R carriers versus non-carriers was 10.5 (95% CI 
1.4–81.6, P = 0.005).
L1007fs  We found carriage of CARD15 L1007fs in 22 (19.3% of 114) patients 
with CD, in two (4.7% of 43) UC-affected patients, and in three (3.9% of 77) healthy 
controls. Three (2.6%) CD-affected patients were homozygous carriers. In controls, 
the genotype frequencies were in HWE (P = 0.86). The allele frequency was 11.0% 
in CD-affected patients, 2.3% in UC-affected patients and 1.9% in healthy controls. 
CARD15 L1007fs was associated with CD (P = 0.001), but not with UC (P = 1.0). 
The GRR for CD of heterozygous compared with wild-type carriers was 5.1 (95% CI 
1.5–17.9, P = 0.005). On the basis of HWE, the estimate for the number of homo-
zygous carriers in controls was 0.029, which yields a GRR for CD of homozygous 
versus wild-type carriers of 83.2 (95% CI = 0.31-∞, P = 0.26).
Combined carriage of CARD15 mutations in patients with inflammatory 
bowel disease and controls
The prevalence of CARD15 compound heterozygosity in CD-affected probands 
was 2.6% (n = 3) for R702W/G908R, 3.5% (n = 4) for R702W/L1007fs and 0.9% (n = 1) 
for G908R/L1007fs. In patients with UC and controls, no combined mutation car-
riage was found. The GRR for CD in patients with carriage of one mutation (R702W, 
G908R or L1007fs) versus wild-type carriers was 2.8 (95% CI = 1.3–5.7, P = 0.007). 
The GRR for CD of compound heterozygous or homozygous versus wild-type carri-
ers was 17.8 (95% CI 1.23–258.0, P = 0.001).
Prevalence of CARD15 mutations in familial and non-familial inflammatory 
bowel disease-affected patients
Carriage of CARD15 R702W, G908R and L1007fs in CD-affected probands with a 
positive familial history of IBD was 15.4, 14.1 and 20.5%, respectively. In CD-affected 
probands with a negative familial history, the prevalences were 22.2, 8.3 and 16.7%, 
respectively. Although the G908R and L1007fs were more and the R720W was less 
prevalent in CD-affected probands with a positive familial history than in sporadic 
CD-affected probands, these differences were not statistically significant (P = 0.43, 
0.54 and 0.80, respectively). Carriage of CARD15 R702W and L1007fs in UC-affected 
probands with a positive familial history of IBD was 11.8 and 2.9%, respectively. 
Prevalences in sporadic UC-affected probands were 0 and 11%, respectively. None 
of the prevalences between the two UC groups was significant different (P = 0.56 
and 0.38, respectively).
As the group sizes of CD-affected probands with a negative family history (n = 36), 
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UC-affected probands with a negative family history (n = 9) and UC-affected pro-
bands with a positive family history (n = 34) are quite small, we also analysed the 
combined data. In familial IBD-affected probands (n = 112), carriage of CARD15 
R702W, G908R and L1007fs was 14.3, 9.8 and 15.2%, respectively. In sporadic IBD-
affected probands (n = 45), the prevalences were 17.8, 6.6 and 15.6%, respectively. 
These differences were not significant (P = 0.63, 0.54 and 1.0, respectively).
Prevalence of CARD15 mutations in patients and relatives with inflammatory 
bowel disease
Available IBD-affected and unaffected relatives (up to the sixth-degree) of pro-
bands positive for CARD15 R702W, G908R or L1007fs were screened for the muta-
tion. Among first-degree IBD-affected relatives of CD-affected probands carrying 
R702W, G908R and L1007fs mutations, the number of carriers with the same muta-
tion was three out of six (50%), one out of four (12%) and five out of six (80%), 
respectively. Among IBD-affected relatives of CD-affected probands carrying CARD15 
L1007fs (n = 6), carriage of CARD15 L1007fs was significantly more frequent than 
expected (P < 0.001). Carriage of CARD15 R702W and G908R mutations in IBD-
affected relatives was not different from what was expected. The pedigrees of the 
families with the L1007fs mutation are illustrated in Figure 1, and the statistical 
results are summarised in Table 2. The number of available families of UC-affected 
probands was too low to perform statistical analysis.
Genotype-phenotype correlation
Carriage of CARD15 mutations and clinical phenotypes of all CD- and UC-affected 
probands were established. The results are summarised in Tables 3 and 4. In CD, 
an association was found between carriage of at least one CARD15 mutation and 
disease behaviour (P = 0.023). Carriage of L1007fs was almost significant associ-
ated with disease behaviour (P = 0.052). In fact, in carriers of at least one CARD15 
mutation and in carriers of L1007fs, a significant linear effect (trend) was found for 
inflammatory (B1), stricturing (B2) and penetrating (B3) disease (P = 0.006 and 0.017, 
respectively). For B1 disease eight (25.0% of 32), for B2 disease 10 (37.0% of 27) and 
for B3 disease 30 (54.5% of 55) patients were carrier of at least one mutation. Two 
(6.3%), five (18.5%) and 15 (27.3%) patients were carriers of L1007fs, respectively. It 
means that these carriers often show B2 disease, and even more often B3 disease. 
The mean follow-up of patients with B1 disease (12.4 years), however, was signifi-
cantly shorter than patients with B3 disease (7.3 years, P = 0.016). Between B1 and 
B2 disease, and between B2 and B3 disease no significant differences were found 
for follow-up duration (P = 0.20 and 0.23, respectively). For UC, no association was 
found between CARD15 mutations and any phenotype (P ≥ 0.57).
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DISCUSSION
The CARD15 gene has recently been described as the first susceptibility gene for 
CD 5, 6. The CARD15 protein is mainly expressed in phagocytic cells. The CARD15 
protein is able to induce NFκB after recognition of intracellular bacterial peptido-
glycan 57, 73. NFκB is an important regulator of genes involved in a pro-inflammatory 
response 74.
Three mutations in the CARD15 gene have been reported to be independently 
associated with CD, including R702W, G908R and L1007fs 5, 53. In this study, the allele 
and genotype frequencies of these three common CARD15 mutations are comparable 
with those found in several other European studies (Table 1). We found associations 
with CD only for G908R and L1007fs. Two other Dutch studies have been published 
about the prevalence of CARD15 mutations in IBD 43, 44. We observed higher allele 
frequencies of G908R and L1007fs in CD than that found by Murillo et al. 43 and 
Linskens et al. 44 (6.0 versus 4.2-4.3 and 10.8 versus 7.9-8.4, respectively). These 
authors also found an association between the L1007fs mutation and CD, but not 
between CD and the G908R mutation. Neither of them evaluated the R702W muta-
tion.
Carriage of two CARD15 mutations, either two alike (homozygosity) or two differ-
ent (compound heterozygosity), has been reported in IBD as well. We found frequen-
cies of homozygous and compound heterozygous carriership in CD comparable to 
those mentioned in the European literature (see references in Table 1). No combined 
carriage was found in UC and healthy controls, which is also in accordance with the 
literature.
As CARD15 mutations have only been found in a minority of patients with CD, 
it is likely that IBD is not a single disease but rather a group of genetically dis-
tinct diseases with similar clinical presentations 14. Moreover, we recently reported 
homozygous carriage of L1007fs mutations in unaffected first- and second-degree 
relatives of a CD-affected sib-pair, suggesting that in these individuals the CARD15 
mutation does not play a pathogenetic role 68. In Figure 2, families are presented in 
which closely related CD-affected relatives differ in CARD15 mutation carriership sta-
tus. It is therefore unlikely that the CARD15 mutations detected in the IBD-affected 
probands contribute to the pathogenesis in the other IBD-affected family members. 
These individual families are clear examples of the complex multifactorial origin of 
IBD, in which no single genetic or environmental factor is necessary nor sufficient 
to cause disease 75. Here, other (private) CARD15 mutations or mutations in other 
genes may be causative as recently reviewed. For example, nucleotide variations in 
the SLC22A4 and SLC22A5 genes (chromosome 5q31), and the DLG5 gene (chromo-
some 10q23) have also been found to be associated with CD 76.
A positive family history is reported in about 5-30% of IBD cases, especially in 
CD 1. Reports regarding an association between CARD15 mutations and a positive 
family history for IBD are, however, not consistent. While some studies reported a 
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significant association 20, 40, 42, 55, 77, most studies did not 15, 25, 33, 38, 41, 43, 53, 78-82. In this 
study, we also found no association between CARD15 carriage and a positive familial 
history, although the number of patients without a familial history was relatively low 
compared with the group of familial patients.
Associations have been reported between CARD15 mutations and CD phenotypes, 
including stricturing disease 19-21, 23, 37, 41, 47, 53, 80, 83, early onset disease 19, 26, 33, 34, 41, 
53, 77, 80, 82, 84, ileal and ileocolonic disease 19-23, 25, 26, 33, 34, 37, 41, 47, 49, 55, 78-80, 82, penetrat-
ing disease 23, 34, 80 in some, but not in all studies 43, 44, 85. In this study, an associa-
tion was found only between the behaviour of disease in CD and carriage of at least 
one of the three common CARD15 mutations. CD behaviour was almost significant 
associated with carriage of the L1007fs mutation. Carriers of at least one CARD15 
mutation and carriers of L1007fs also showed a significant trend for stricturing and 
even more for penetrating disease behaviour. This may be a true phenomenon, but 
we cannot exclude the possibility that the observed differences were partly related 
to difference in follow-up between the groups, as changing patterns of disease have 
been observed 86.
Not much is known about the carriage of CARD15 mutations in IBD-affected 
family members. By using an approach in which calculated allele frequencies were 
corrected for familial genetic dependency, we found that IBD-affected family mem-
bers of CD-affected probands with CARD15 L1007fs were carriers of this mutation 
significantly more often than expected. The statistical analysis for unaffected rela-
tives is much harder to interpret as these relatives may still develop IBD in the future. 
Some authors have reported a higher frequency of CARD15 mutations in unaffected 
first-degree relatives of familial CD-affected cases than in unrelated healthy controls 
15, 38, 87. These results can be criticised as multiple related healthy and CD-affected 
relatives were included, which may yield a deflated P value.
We found statistically significant higher concordance rates for carriage of CARD15 
L1007fs in CD-affected probands and their IBD-affected family members. On the 
other hand, the prevalence of L1007fs in probands with a positive family history was 
similar to probands with a negative family history. This may be due to small sample 
sizes or to the used definition of a positive family history. Larger families and fami-
lies with more relatives of age near 30 years (median age of diagnosis of IBD in The 
Netherlands is 28-29 years 66) are more likely to be positive a priori.
In conclusion, we evaluated the CARD15 R702W, G908R and L1007fs mutations 
in Dutch IBD patients, and we confirmed the association of G908R and L1007fs with 
the susceptibility of CD. The prevalence of the three common mutations did not differ 
between familial and sporadic IBD cases. Homozygosity and compound heterozygous 
carriage of the mutations was only found in CD (and not in UC). IBD-affected family 
members of L1007fs positive CD-affected probands were positive for L1007fs more 
often than expected. In CD, carriers of at least one CARD15 mutation and carriers of 
L1007fs were more likely to have stricturing and penetrating disease, which however 
might be the result of differences in follow-up duration.
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Table 1.   Allele frequencies of CARD15 R702W, G908R and L1007fs in European 
adult patients with inflammatory bowel disease
R702W G908R L1007fs
At least one 
mutation
European 
population
Authors (year) reference CD UC C CD UC C CD UC C CD UC C
Belgium
Esters et al. (2004) 15 12.9 7.8 5.8 6.0 3.2 1.8 8.6 1.4 3.0 46.3 22.0 20.6
Vermeire et al. (2004) 16 a 16.7 - 6.4 3.8 - 1.9 12.7 - 2.3 51.4 - 19.7
Vander Cruyssen et al. (2005) 17 15.1 - - 5.5 - - 8.7 - - 49.3 - 21.8
Denmark Vind et al. (2005) 18 0 - 1.5 2.6 - 1.0 16.4 - 2.1 22.4 - 9.3
England Ahmad et al. (2002) 19 12.5 - 5.2 3.3 - 1.4 9.4 - 1.6 38.5 - 15.8
Finland Heliö et al. (2003) 20 3.3 1.5 1.8 0.6 0 0 4.8 3.0 1.7 15.5 9.1 6.7
France Heresbach et al. (2004) 21 11.5 - 4.7 3.7 - 1.6 9.0 - 4.2 38.0 - 20.0
Germany
Hampe et al. (2002) 22 10.5 - 4.8 5.2 - 0.7 14.5 - 4.1 - - -
Radlmayr et al. (2002) 23 - - - - - - 13.9 2.1 1.7 - - -
Mascheretti et al. (2002) 24 b 6.7 - - 1.7 - - 13.9 - - 36.1 - -
Sun et al. (2003) 25 c 14.0 - - 5.0 - - 26.0 - 2.0 56.4 - 4.0
Büning et al. (2004) 26 7.2 2.1 3.6 4.2 2.1 2.1 12.2 4.3 2.1 35.6 14.3 15.5
Wehkamp et al. (2004) 27 4.4 - - 2.9 - - 13.2 - - 27.9 - -
Greece
Roussomoustakaki et al. (2003) 28 - - - - - - 2.7 0 1.5 - - -
Gazouli et al. (2005) 29 10.0 7.1 1.0 14.2 13.5 3.5 17.9 3.5 6.0 81.7 47.0 21.0
Hungary
Büning et al. (2005) 30 7.1 3.1 2.6 3.0 1.6 1.2 10.8 2.3 2.2 32.4 13.2 11.5
Lakatos et al. (2005) 31 7.3 - 3.0 6.3 - 1.8 10.9 - 2.5 35.1 - 16.5
Iceland Thjodleifsson et al. (2003) 32 0 - - 0 - - 0 - - - - -
Ireland
Bairead et al. (2003) 33 7.0 - 4.0 3.0 - 1.0 4.0 - 1.0 27.4 - -
Arnott et al. (2004) 34 9.7 - 5.1 2.2 - 0.9 3.0 - 0.9 27.4 - 11.4
Italy
Palmieri et al. (2003) 35 11.0 3.0 6.0 9.0 3.0 2.0 10.0 3.0 1.0 - - -
Annese et al. (2003) 36 15.0 7.0 6.0 9.0 2.0 2.0 11.0 2.0 1.0 45.3 22.6 18.5
Giachino et al. (2004) 37 9.0 10.9 5.9 4.3 2.7 1.4 6.3 0.5 2.3 33.1 25.0 18.7
Annese et al. (2004) 38 d 9.0 - 5.0 5.5 - 2.0 7.7 - 1.3 22.0 - 6.9
Andruilli et al. (2004) 39 - 2.9 4.0 - 1.6 2.0 - 2.5 0.7 - 8.8 6.9
Vavassori et al. (2004) 40 1.2 - 0.8 5.2 - 2.0 11.2 - 1.2 27.9 - 8.0
Annese et al. (2005) 41 8.7 - 4.1 7.3 - 2.7 9.3 2.7 0.7 38.2 13.7 15.1
Laghi et al. (2005) 42 10.0 - - 4.6 - - 7.7 - - 33.0 - -
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R702W G908R L1007fs
At least one 
mutation
European 
population
Authors (year) reference CD UC C CD UC C CD UC C CD UC C
Netherlands
Murillo et al. (2002) 43 e - - - 4.3 - 3.0 8.5 - 1.0 23.1 - 7.9
Linskens et al. (2004) 44 - - - 4.2 - - 7.9 - - 21.3 - -
This study 8.8 4.7 5.9 6.1 0 0.7 11.0 2.3 1.9 42.1 14.0 16.9
Norway Hampe et al. (2002) 22 4.3 - 2.8 0.9 1.2 2.6 - 1.2 - - -
Portugal
Ferreira et al. (2005) 45 12.2 - 4.0 2.8 - 1.3 6.8 - 1.6 34.6 - 12.9
Vind et al. (2005) 18 12.1 - 6.3 1.7 - 0.5 0 - 2.9 20.7 - 15.5
Scotland
Arnott et al. (2004) 34 7.2 2.6 5.5 1.8 2.0 0.2 4.6 3.0 1.4 22.8 - 13.1
Russell et al. (2004) 46 7.1 - - 1.8 - - 4.7 - - - - -
Spain
Mendoza et al. (2003) 47 6.9 - 2.9 4.2 - 1.4 8.6 - 2.9 32.8 - 10.7
Núñez et al. (2004) 48 6.7 - 5.8 4.5 - 1.0 4.5 - 1.0 27.9 - 15.2
Alvarez-Lobos et al. (2005) 49 - - - - - - - - - 30.5 - -
Barreiro et al. (2005) 50 - - - - - - - - - 27.9 - -
Switzerland Ruegg et al. (2004) 51 5.7 - - 2.8 - - 4.7 - - 22.8 - -
Belgium, 
Denmark, 
France, 
Ireland, Spain, 
Sweden
Hugot et al. (2001) 5 f 11.0 3.0 4.0 6.0 0 1.0 12.0 1.0 2.0 42.9 8.7 14.6
England, 
Germany, 
Netherlands
Hampe et al. (2001) 52 f - - - - - - 16.0 3.1 4.4 - - -
Belgium, 
Denmark, 
France, 
Germany, 
Ireland, Italy, 
Spain, Sweden
Lesage et al. (2002) 53 f 10.8 3.1 4.4 6.1 0.3 1.0 10.6 1.3 1.9 37.7 8.8 14.6
Belgium, 
France, 
Luxembourg
Vermeire et al. (2002) 54 b,f 10.0 - 2.1 4.7 - 0.5 5.3 - 1.1 32.6 - 15.0
England, 
Germany, 
Netherlands
Cuthbert et al. (2002) 55 f 9.1 3.7 3.5 3.4 1.6 0.6 6.6 1.5 2.1 35.8 14.3 13.6
a Unclear whether CD-affected relatives were included.
b Patients treated with infliximab.
c Data of controls only for L1007fs.
d Combined data of several centres.
e Data only for G908R and L1007fs.
f Combined data of several countries.
CD, Crohnʼs disease; UC, ulcerative colitis; C, controls.
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Table 2.   Frequency of CARD15 mutations in inflammatory bowel disease-affected 
relatives
Mutation Proband
Observed IBD-
affected patients 
with mutation
Expected IBD-
affected patients 
with mutation
P a
R702W
CD 5 4.8 0.9
UC 4 1.7 -
G908R
CD 4 2.9 0.4
UC 0 - -
L1007fs
CD 13 6.6 < 0.001
UC 0 - -
 a Statistical analysis for UC was not possible because of too low numbers.
IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis.
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Table 3.  Crohnʼs disease phenotypes and CARD15 mutations
Carriage frequency (%)
Probands (n) R702W G908R L1007fs
At least 
one 
mutation
Two 
mutations
Age at diagnosis
  A1 (< 40 years)
  A2 (≥ 40 years)
Location of disease
  L1 (terminal ileum)
  L2 (colon)
  L3 (ileocolon)
  L4 (upper gastrointestinal)
Behaviour of disease a
  B1 (inflammatory)
  B2 (stricturing)
  B3 (penetrating)
102
12
32
27
47
8
32
27
55
17.6
16.7
15.6
18.5
21.3
0
12.5
22.2
18.2
12.7
8.3
15.6
11.1
10.6
12.5
9.4
7.4
16.4
17.6
33.3
31.3
7.4
21.3
0
6.3
18.5
27.3
41.2
50.0
56.3
33.3
42.6
12.6
25.0
37.0
54.5
9.8
8.3
12.5
7.4
10.6
0
3.1
11.1
12.7
a  An association was found between carriage of at least one CARD15 mutation and 
disease behaviour (P = 0.023). Carriage of L1007fs was almost significant asso-
ciated with disease behaviour (P = 0.052). Carriers of at least one mutation and 
carriers of L1007fs showed a significant trend for behaviour of disease (P = 0.006 
and P = 0.017, respectively), including often stricturing and even more often pen-
etrating disease.
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Table 4.  Ulcerative colitis phenotypes and CARD15 mutations
Carriage frequency (%)
Probands (n) R702W G908R L1007fs At least one mutation
Age at diagnosis
  A1 (< 40 years)
  A2 (≥ 40 years)
Location of disease
  Proctitis
  Left-sided colitis
  Extended or pancolitis
30
13
3
14
26
10.0
7.7
0
7.1
11.5
0
0
0
0
0
6.7
0
0
0
7.7
16.7
7.7
0
7.1
19.2
 No association was found between any phenotype and carriage of CARD15 muta-
tions.
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Figure 1.  In these six multiple inflammatory bowel disease (IBD)-affected fami-
lies, in which the proband was positive for CARD15 L1007fs, carriage of CARD15 
L1007fs in the IBD-affected relatives was significantly more frequent than expected 
(P < 0.001). - | -, Homozygous carriage of wild-type allele; + | -, heterozygous car-
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riage of mutation; + | +, homozygous carriage of mutation; , male with Crohnʼs 
disease (CD); , female with CD; , male with ulcerative colitis (UC); , female with 
UC; ®, non-IBD-affected male; °, non-IBD-affected female; Ì, proband.
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1927
+ | -
1929
- | -
1957
Family with L1007fs Family with R702W
Family with G908R
- | -
1968
+ | -
1947
- | -
1947
+ | -
1972
- | -
1970
- | -
1954
- | -
1946
+ | -
1953
+| -
1941
- | -
1952
- | -
1979
+ | -
1968
- | -
1969
+ | -
Figure 2.  In these three families, it is demonstrated that common CARD15 muta-
tions do not segregate with the disease. It is therefore likely that in these families 
other genes than CARD15 contribute to the pathogenesis. - | - , Homozygous car-
riage of wild-type; + | - , heterozygous carriage of mutation; + | + , homozygous 
carriage of mutation; , male with Crohnʼs disease (CD); , female with CD; , male 
with ulcerative colitis (UC); , female with UC; ®, non-IBD-affected male; °, non-
IBD-affected female; Ì, proband.
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No evidence for genetic anticipation 
in Dutch familial infl ammatory bowel disease
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ABSTRACT
Background
Genetic predisposition plays an important role in 
inflammatory bowel disease (IBD). Some non-controlled 
studies suggested genetic anticipation in IBD, including 
disease onset in children at an earlier age than in parents. 
This study was planned to evaluate the existence of genetic 
anticipation in Dutch familial IBD-affected patients.
Methods
Forty familial IBD-affected parent-child pairs and 40 
control IBD-affected parent-child pairs were studied. The 
control pairs included sporadic patients matched for age, 
sex and type of IBD, either Crohnʼs disease (CD), ulcer-
ative colitis (UC) or indeterminate colitis (IC). Age at onset 
of first symptoms, age at diagnosis and disease sever-
ity, including the extent of inflammation, use of steroids, 
number of bowel resections and number of reported 
symptoms at onset of disease, were evaluated within and 
between the familial and control parent-child pairs.
Results
In IBD-IBD, CD-CD and UC-UC parent-child pairs, chil-
dren presented symptoms and were diagnosed at a sig-
nificant earlier age than their parents (P = 0.01 and 0.003, 
respectively). The same significant findings were present 
in control parent-child pairs. Moreover, in familial and 
control pairs the age at presenting first symptoms and the 
diagnosis was significantly correlated with the age at start 
of follow-up (P < 0.0001). In CD-CD and UC-UC pairs, no 
differences were found for number of symptoms, number 
of bowel resections, steroid use and extent of inflamma-
tion between familial and control pairs.
Conclusion
Genetic anticipation in IBD is very unlikely as age dif-
ferences between affected parents and children for onset 
of symptoms and diagnosis was similar in familial and 
matched control pairs. Also no differences were found for 
disease severity. The most probable cause of these results 
is ascertainment bias. 
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INTRODUCTION
Inflammatory bowel disease (IBD), including Crohnʼs disease (CD), ulcerative 
colitis (UC) and indeterminate colitis (IC), has a complex multifactorial pathogen-
esis. Genetic predisposition plays an important role in the disease susceptibility. 
Epidemiological evidence for genetic involvement includes ethnic differences in the 
frequency of disease and familial clustering up to 20% of the patients 1. Convincing 
evidence for a genetic role in IBD also comes from the observed higher concordance 
rate of disease in monozygotic twins than in dizygotic twins, especially in CD 2. 
Also high concordance rates for type, location and behaviour of disease have been 
described in multiple IBD-affected families other than twins 3. More recently, the 
CARD15 gene has been identified as the first susceptibility gene in CD 4, 5. The patho-
genetic role of the CARD15 in IBD has now extensively been evaluated, especially its 
role in the activation of transcription factor nuclear kappa-B 6.
Early non-controlled clinical studies, demonstrated that CD-affected children 
have a lower age at diagnosis than their CD-affected parents, suggesting the exis-
tence of genetic anticipation 7, 8. This age difference was also found in UC-affected 
parent-child pairs 9, and can in both conditions even reach 15 to 17 years. Genetic 
anticipation is defined as disease manifestation in offspring at an earlier age and/or 
with a more severe course than their affected parents 10. It is thought that expan-
sion of unstable trinucleotide repeats in the disease-causing gene in subsequent 
generations can be the biological basis for genetic anticipation 11. Expansion of such 
DNA triplet repeats has been described in some classic Mendelian monogenetic 
neurological diseases, such as Huntingtonʼs disease, Friedreichʼs ataxia and Fragile 
X-syndrome 12. There is some preliminary evidence that CAG repeats are involved in 
a subset of CD-affected families 13. Whether genetic anticipation is present in IBD is 
doubtful, as IBD is a polygenic disease with a non-Mendelian inheritance pattern 14. 
Moreover, studies about genetic anticipation are often systematically biased in that 
disease-affected parent-child pairs are by definition characterised by a young onset 
in affected children. However, as IBD is a heterogenetic disease simple Mendelian 
susceptibility might be true for a subset of IBD-affected patients 14. This may imply 
that anticipation perhaps is only present in such a subgroup.
The aim of this study was to evaluate clinical data of Dutch IBD-affected parent-
child pairs in order to evaluate the existence of genetic anticipation.
PATIENTS AND METHODS
Patients and controls
Between July 1998 and October 2002, patients with IBD attending the Erasmus 
MC University Medical Centre Rotterdam (UMCR) were registered. The diagnosis of 
IBD was based on standard criteria 15. At the end of the inclusion period, the registry 
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included 694 patients with CD, 406 with UC and 67 with IC. A positive family history 
for IBD, meaning one or more relatives affected with IBD, was reported in 291 cases. 
IBD-affected relatives were offered to participate in this study. Completely docu-
mented IBD-affected parent-child pairs (familial pairs) were included for this study. 
In those cases in which one of the affects did not attend the Erasmus MC UMCR but 
another Dutch (non-academic) hospital, medical and surgical information of these 
ʻunknownʼ relatives were supplied by their treating physician. Based on this informa-
tion the diagnosis was verified to the same criteria 15.
To evaluate genetic anticipation, familial parent-child pairs were compared with 
control IBD-affected parent-child pairs, including sporadic patients matched for age, 
sex and type of IBD. All matched controls were retrieved from the IBD registry of the 
Erasmus MC UMCR.
The study was approved by the Institutional Review Board of the Erasmus MC 
UMCR. All participants provided written informed consent.
Clinical data
All clinical data were retrieved from medical hospital records and from a ques-
tionnaire, which was completed by most patients. A few patients were interviewed 
by phone instead. We evaluated age at onset of first symptoms, age at diagnosis 
and disease severity. Disease severity was based on the extent of inflammation, use 
of steroids, number of bowel resections, and number of reported symptoms at the 
onset of disease. These symptoms included weight loss, nausea, vomiting, diarrhoea, 
rectal blood loss, rectal mucus loss, abdominal pain, arthralgia, eye symptoms and 
skin problems. The extent of bowel inflammation in UC was classified as proctitis 
(involving rectum only), left-sided colitis (involving rectum, sigmoid and descending 
colon) or pancolitis (involving inflammation beyond the splenic flexure). In CD, more 
severe extended inflammation was classified as disease involving the colon, small 
intestine or both, respectively. When the exact day or month was uncertain, day 15th 
and July 1st was chosen, respectively.
Statistics
Clinical characteristics between parents and children, and between parent-
child pairs were evaluated by using Studentʼs t test or χ2 statistics. A P value of 
0.05 or less was considered statistically significant. When data were significant 
while multiple tests were performed, the analysis was corrected using the formula 
Pcorr  = 1 – (1 - P)
N (N, number of performed tests; P, the significant P value to be 
corrected) 16. All analyses were performed with SPSS software version 9.0 (SPSS Inc., 
Chicago, Illinois, USA).
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RESULTS
Characteristics of parent-child pairs with inflammatory bowel disease
Forty familial IBD-affected parent-child pairs were included, retrieved from thirty-
nine families. One family included a CD-affected parent and two CD-affected chil-
dren, resulting in two parent-child pairs. Parents and children were concordant for 
CD in 19 pairs, and for UC in 13 pairs. In eight pairs the parent and child were dis-
cordant for type of disease (mixed pairs). The familial patientsʼ characteristics are 
summarised in Table 1.
Seventy-nine sporadic matched control IBD-affected patients were included. The 
mean age of the control parents and children was 58.9 years (range: 39.0–86.0 years) 
and 33.6 years (range: 9.6–68.9 years), respectively. In five control parents and five 
control children, the difference of age between the matched familial patients was 
more than one year (range: 1.0–9.1 years). However, the mean age of the familial 
parents and children was not different from controls (P = 0.86 for parents and P = 
0.94 for children).
Age at onset of symptoms and diagnosis
In the familial parent-child pairs, 80% (n = 32) of the children presented with 
symptoms of IBD at an earlier age than their affected parents (range: 1.1–37.4 years). 
In 85% (n = 34) children are diagnosed with IBD earlier than their parents (range: 
1.3–52.4 years). In the matched control parent-child pairs, children presented in 93% 
(n = 37) with symptoms and in 98% (n=39) with the diagnosis at an earlier age than 
their affected parents (range: 91 days–35.8 years and 2.1–38.5 years, respectively). 
With respect to age at diagnosis, more children from control pairs than children 
from familial pairs were younger than their parents, however, this was borderline 
significant (P = 0.05).
In familial pairs, the mean age at onset of symptoms and diagnosis was significant 
lower in children than in their affected parents (P ≤ 0.01 and ≤ 0.01, respectively). 
These data are summarised in Table 2. Similar significant data were found for control 
pairs (Table 2). The age differences between familial and sporadic parent-child pairs 
for onset of symptoms and diagnosis are summarised in Table 3. No significant dif-
ferences were found between the two groups (P = 0.6 and 0.2, respectively).
In familial patients, a significant linear correlation was found between start of fol-
low-up (age at inclusion) and age at onset of symptoms (P < 0.0001), and between 
age at diagnosis (P < 0.0001, Figure 1). The same significant correlations were found 
for control patients (P < 0.0001).
Disease severity
In familial parent-child pairs, the number of reported symptoms at onset 
of disease was significantly higher in parents than in their children (P = 0.04, 
Table 4). It became not significant (P = 0.39) after correcting for multiple testing 
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(n = 12 tests). No significant differences were found for number of resections (Table 
4). In the IBD-affected and CD-affected control parent-child pairs, a significant 
higher use of steroids was found in children (P = 0.004 and 0.006, respectively, 
Table 4). After correcting this findings for multiple testing (n = 12 tests), the differ-
ence is steroid use between CD-affected control parents and children lost signifi-
cance (P = 0.07). In the IBD-affected control pairs, a higher steroid use in children 
remained borderline significant (P = 0.05). The parent-child differences for number 
of symptoms at onset and steroid use between familial and sporadic pairs was not 
significantly different (P = 0.1 and 0.7, respectively).
The extent of disease as a parameter of disease severity was evaluated in the 
CD-CD (n = 19) and UC-UC parent-child pairs (n = 13). The data are summarised 
in Tables 5 and 6. In CD-CD pairs, concordance for extent of disease between par-
ents and children was found in 47% (n = 9) familial pairs and in 37% (n = 7) control 
pairs, which was not significantly different (P = 0.5, not shown in Table 5). In UC-UC 
parent-child pairs, concordance rates were 39% and 23%, respectively (P = 0.4, not 
shown in Table 6).
DISCUSSION
Studies on genetic anticipation in IBD were initiated based on positive findings 
in some monogenetic neurological diseases, like Huntingtonʼs disease, Friedreichʼs 
ataxia and fragile X-syndrome 12. Several studies in familial IBD have shown a lower 
age of disease onset in children compared with their parents. This was in particular 
explained as genetic anticipation in two studies evaluating CD-affected parent-child 
pairs 7, 8. One of these studies also showed more extensive disease in offspring com-
pared with their parents 7. However, the results were based on the comparison of 
mean ages between patients from two different generations, and without including 
a control group.
In this study, we therefore compared clinical data of IBD-affected parent-child 
pairs with control IBD-affected parent-child pairs. These control pairs included age, 
sex and type of IBD matched patients with a negative family history. Similar to other 
studies 7-9, 16-22, we found in the familial pairs that children presented at a significantly 
lower age with their first symptoms of IBD, and also were diagnosed at a significantly 
younger age than their IBD-affected parents. However, the same results were found 
in the control IBD-affected parent-child pairs.
The initial studies suggesting anticipation in IBD 7, 8, have been criticised as the 
observations were probably caused by ascertainment bias. Ascertainment bias means 
that in case of retrospective cross-sectional disease-affected parent-child studies 
both generations are included at different ages, which leads to preferential inclusion. 
Therefore, the parent and child have a different completed risk period for their dis-
ease. This type of study does not include unaffected children who may still develop 
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their disease after the inclusion date, which will lead to a false lower age of disease 
in children compared with their affected parents 23-25.
To study the role of ascertainment bias several methods have been used. Some 
authors studied the age of diagnosis in relation to the age of birth in IBD-affected 
parent-child pairs and sporadic IBD-affected patients. They found a significant lin-
ear correlation, in which the age at diagnosis decreased with later birth cohorts 16, 
20, 26. The same analysis was done in this study and presented in Figure 1. Instead of 
date of birth, we chose the age at start of follow-up (age at the time of inclusion). 
Evaluating the parental age at diagnosis and the number of ʻanticipation yearsʼ (age 
at diagnosis of the parent minus age of diagnosis of the child) also showed a signifi-
cant linear correlation 18. Otherwise, the age at onset of symptoms in (first-degree) 
parent-child pairs has been compared with the age of onset in uncle/aunt-nephew/
niece pairs, which showed comparable significant age differences 19, 22. In grandpar-
ent-grandchild pairs, even a higher age difference was found 22.
In all these analyses, the time of follow-up from birth to date of inclusion in 
IBD-affected children is lower than in their affected parents. This will lead to an 
artificial lower age of diagnosis in the children. To overcome his inadequate fol-
low-up time, the age at diagnosis in children has been compared with age matched 
affected parents and sporadic affected patients. This also showed a significant linear 
correlation, in which the age at diagnosis decreased in younger birth cohorts 16. A 
similar analysis but based on age stratification (child ≥ or < 45-years-old at time 
of survey) showed the same results 22. Another study evaluated the age of diagnosis 
in a subgroup of CD-affected patients, who had lived for at least 40 years and had 
received their diagnosis by 40 years of age. In this subgroup in which the observa-
tion time was equal for each patient, a minimal decreasing lower age at diagnosis per 
10 year birth cohort was found 26. The method we used in this study has not been 
used before in genetic anticipation IBD studies, although it is somewhat similar to 
the method described by Hampe et al., as described above 16. None of the genetic 
anticipation studies in IBD have included healthy but future IBD-affected individu-
als. This requires a prospective study and probably will increase the mean age of 
diagnosis, especially in children.
In this study, we also evaluated disease severity in familial and control parent-
child pairs based on the number of patientsʼ reported symptoms at onset of dis-
ease, the number of resections, the use of steroids and the extent of disease. No 
significant differences were found, except for steroid use in IBD-affected control 
parent-child pairs. Steroid use in CD- and UC-affected pairs was not different. We 
found high concordance rates for extent of disease, which is in accordance with the 
literature 8, 9. Concordance rates for surgery need are variable 8, 9.
All together, there are no strong arguments to assume that genetic anticipation 
plays a role in IBD. The age differences between parents and children are most prob-
ably caused by ascertainment bias. Moreover, other forms of bias can play a role, 
such as recall bias and truncation bias 25, 26. A long-term prospective study is prob-
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ably the best way to evaluate whether anticipation is present in IBD or not. However, 
even the results of such a study can be influenced by confounding factors, like age 
effect, cohort effect and period effect 25, 26.
In conclusion, in this study we demonstrated that IBD-affected children have a 
significant lower age at onset of symptoms and diagnosis than their IBD-affected 
parents. Similar results were found in matched control IBD-affected parent-child 
pairs. Also no major differences were found between familial and control parent-
child pairs for disease severity. These observations argue against genetic anticipation 
and are most likely to be caused by ascertainment bias.
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Table 1.  Familial parent-child pairs with inflammatory bowel disease
Familial pairs
Parents
n = 39
Children
n = 40
Sex (n)
   Males
   Female
Age (mean years, range)
Type of IBD (n) a 
   CD
   UC 
   IC
14
25
59.4 (39.3 – 95.1)
19
19
1
20
20
33.4 (11.1 – 68.6)
25
15
0
a CD, Crohnʼs disease; UC, ulcerative colitis; IC, indeterminate colitis.
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Table 2.   Age differences in familial and control parent-child pairs with inflamma-
tory bowel disease
Familial pairs Control pairs
Parents Children P Parents Children P
Age at onset of symptoms 
(mean years, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
Age at diagnosis  
(mean years, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
32.5 (13.1)
28.3 (12.4)
37.5 (12.7)
33.9 (13.6)
36.4 (14.1)
32.8 (12.5)
39.9 (11.4)
39.0 (20.1)
20.3 (7.3)
19.8 (5.9)
22.3 (8.5)
18.3 (8.5)
22.8 (6.8)
22.4 (6.1)
24.2 (7.3)
21.3 (8.2)
< 0.001
0.01
0.001
0.02
< 0.001
0.003
< 0.001
0.04
36.2 (14.5)
30.3 (9.3)
43.4 (16.3)
37.7 (17.2)
40.7 (14.0)
36.4 (10.1)
47.6 (14.0)
39.3 (18.5)
22.3 (10.8)
20.4 (3.8)
25.6 (16.8)
21.1 (9.5)
23.2 (10.6)
21.5 (3.4)
26.2 (16.7)
22.1 (9.6)
< 0.001
< 0.001
0.01
0.3
< 0.001
< 0.001
0.002
0.4
a  IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis; IC, 
indeterminate colitis; mixed pairs, parent and child discordant for type of IBD; SD, 
standard deviation.
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Table 3.   Age differences between familial and control parent-child pairs with inflam-
matory bowel disease
Differences between parents and children
Familial pairs Control pairs P
Age at onset (mean years, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
Age at diagnosis (mean years, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
12.2 (13.2)
8.6 (10.8)
15.2 (14.6)
15.7 (15.5)
13.5 (13.3)
10.2 (11.1)
15.6 (12.5)
17.7 (18.7)
13.5 (11.2)
9.3 (10.6)
17.7 (9.7)
16.6 (12.6)
17.4 (10.7)
14.7 (9.4)
21.3 (10.5)
17.2 (13.2)
0.6
0.8
0.6
0.9
0.2
0.2
0.2
1.0
a  IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis; IC, 
indeterminate colitis; mixed pairs, parent and child discordant for type of IBD; SD, 
standard deviation.
140 Chapter 8
Table 4.   Disease severity in familial and control parent-child pairs with inflamma-
tory bowel disease
Familial pairs Control pairs
Parents Children P Parents Children P
Mean number of symptoms (mean n, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
Number of bowel resections (mean n, SD) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
Use of steroids (%) a
   IBD-IBD pairs (n = 40)
   CD-CD pairs (n = 19)
   UC-UC pairs (n = 13)
   Mixed pairs (n = 8)
5.7 (1.9)
6.1 (1.9)
4.7 (1.4)
6.4 (2.1)
1.0 (1.4)
1.7 (1.7)
0.4 (0.7)
0.4 (0.7)
77
83
69
75
4.8 (1.9)
5.2 (2.1)
4.5 (1.8)
4.4 (1.7)
0.6 (0.9)
0.7 (1.2)
0.4 (0.8)
0.5 (0.5)
68
68
69
63
0.04
0.2
0.7
0.5
0.1
0.06
1.0
0.7
0.4
0.3
1.0
0.6
4.9 (2.2)
5.3 (2.5)
4.7 (1.9)
4.5 (1.9)
1.0 (1.3)
1.3 (1.5)
0.5 (0.8)
0.9 (1.1)
67
67
62
75
4.7 (1.8)
4.6 (1.9)
4.5 (1.0)
5.4 (2.5)
0.8 (1.3)
1.1 (1.3)
0.4 (0.8)
0.8 (1.8)
93
100
85
88
0.7
0.4
0.7
0.4
0.5
0.5
0.8
0.9
0.004
0.006
0.2
0.5
a  IBD, inflammatory bowel disease; CD, Crohnʼs disease; UC, ulcerative colitis; IC, 
indeterminate colitis; mixed pairs, parent and child discordant for type of disease; 
SD, standard deviation.
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Table 5.  Extent of disease in parent-child pairs with Crohnʼs disease
Familial pairs Control pairs
Parents
(n=18)
Children
(n=19)
Parents
(n=18)
Children
(n=19)
Colon (n)
Small intestine (n)
Both (n)
5
6
7
6
3
10
4
8
6
3
5
11
Table 6.  Extent of disease in parent-child pairs with ulcerative colitis
Familial pairs Control pairs
Parents
(n=13)
Children
(n=13)
Parents
(n=13)
Children
(n=13)
Proctitis (n)
Left-sided colitis (n)
Pancolitis (n)
2
6
5
6
5
2
4
6
3
2
4
7
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Figure 1.  Correlation between the age at follow-up and the age at diagnosis of 
parents and their children both affected with inflammatory bowel disease (P < 0.001, 
r = 0.5).
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SUMMARY AND GENERAL DISCUSSION
The goal of this thesis is to explore aspects of the genetic susceptibility in inflam-
matory bowel disease (IBD), which is considered to be a major factor in the aetiology 
of IBD. This thesis started with creating a clinical and DNA database including mul-
tiple IBD-affected families and sporadic affected patients. The subsequent genetic 
studies mainly focused on the caspase recruitment domain 15 (CARD15) and inter-
leukin-10 (IL-10) genes.
Evidence for a genetic role in the aetiology of IBD comes from epidemiological 1, 2 
and basic molecular studies 3. The current hypothesis includes a complex multigenic 
disease, in which several gene mutations combined with environmental factors can 
lead to IBD, either Crohnʼs disease (CD) or ulcerative colitis (UC) 4. These two disease 
entities are the major subtypes of IBD 5. Probably some disease-causing genes are 
related to both CD and UC, while others are disease-specific 3.
The genome scans in IBD, based on linkage analysis using the allele-sharing 
method in multiple affected families, have revealed several IBD-linked loci (IBD1-9), 
which are likely to contain susceptibility genes 6. Some of these genes have been 
discovered by either fine mapping or using a candidate gene strategy 7. The CARD15 
gene is the first discovered IBD gene. This gene is located on chromosome 16q12 
within the IBD1 locus 7.
The IL-10 gene is not part of any IBD linkage locus. Interest in this gene in rela-
tion to IBD is based on its anti-inflammatory function 8. Therefore, the IL-10 gene 
is a candidate gene in the search for susceptibility genes in a complex multigenic 
disorder like IBD.
In chapters 1 and 5, a review of the epidemiology, pathogenesis and genetics 
of IBD is presented.
Genetic heterogeneity can be part of complex multigenic disorders. It is thought 
that multiple (mutated) genes with a low penetrance lead to similar phenotypes 4. 
Genetic heterogeneity in IBD is demonstrated in chapter 2. In this chapter a linkage 
study is described in a small group of 17 IBD-affected sib-pairs. Several inflamma-
tory and anti-inflammatory cytokine and cytokine receptor candidate genes were 
evaluated for allele-sharing. As expected, the results were quite different per indi-
vidual sib-pair. A significant LOD score (outcome of linkage studies) was only found 
for the IL-4 receptor (IL-4R), which is located within the IBD1 locus. However, it is 
unlikely that this gene is an important disease-causing gene as in other studies no 
association with IBD was found 9-12. Linkage is also not caused by carriage of CARD15 
mutations. While nine (out of 17) sib-pairs (four CD-CD pairs and five UC-UC pairs) 
showed allele-sharing for the IL-4R gene, only one CD-affected proband carried 
CARD15 mutations (compound heterozygous R702W/L1007fs). One female UC-
affected proband was not tested, however, her twin sister and brother both affected 
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with UC carried no CARD15 mutations (these data have not been published). These 
findings are in accordance with another Dutch study 12.
Although linkage analysis and candidate gene association studies can exclude 
involvement of a specific gene in a large group of IBD patients, (low level) involve-
ment in some individual affected families is not excluded. Even simple Mendelian 
inheritance, based on a major single gene mutation among several other involved 
genes might be the case 13. This hypothesis was worked out in chapters 3 and 4 for 
the IL-10 gene. Sib-pairs who shared both IL-10 alleles were considered to be most 
likely to harbour a (major or minor) mutation. The IL-10 gene of these sib-pairs 
was screened for exon and promoter nucleotide alterations. We identified a point 
mutation Gly15Arg in exon 1 in one CD-affected sib-pair. The mutation was also 
found in their non-IBD-affected first-degree relatives. Additionally, the prevalence 
of IL-10 Gly15Arg was evaluated in 379 CD-affected patients recruited from our 
own Erasmus MC IBD database and from two other Dutch academic hospitals. One 
additional patient with CD and a related healthy parent were found to be heterozy-
gous for Gly15Arg. No carriage among 75 healthy controls was found. On the basis 
of these data, IL-10 Gly15Arg appeared to be not associated with CD. However, IL-
10 secretion is likely to be reduced in carriers of IL-10 Gly15Arg, which was dem-
onstrated by an in vitro stimulation test with human peripheral blood mononuclear 
cells. Moreover, the secreted IL-10 protein also showed functional impairment, as 
was shown by an experiment using an IL-10 dependent HL60 cell line (human leu-
kaemia cell line of monocytic lineage). We have concluded that in IL-10 Gly15Arg 
positive CD-affected families, the Gly15Arg may predispose to the development of 
IBD by causing a reduced IL-10 response to intestinal inflammation.
A major genetic breakthrough was the identification of the CARD15 gene in 
2001. Three common mutations in this gene, i.e. R702W, G908R and L1007fs are 
independently associated with CD, meaning that carriage increases the risk of devel-
oping this disease 14-16. Meanwhile, the (dys)function of CARD15 and its mutations 
are widely explored. At the moment, there are two opposite hypotheses about the 
function of CARD15. Carriage of CARD15 mutations shows a reduced transcription 
factor nuclear kappa-B (NFκB) activity in human studies (ʼloss-of-functionʼ). In con-
trast, in animal studies mutated CARD15 leads to a defective down-regulation of 
NFκB (ʻgain-of-functionʼ) and subsequently a pro-inflammatory cytokine response 
17. The latter is more in line with the clinical observation of elevated NFκB activity in 
patients with active CD 18.
In chapters 6 and 7, the presence of the three common CARD15 mutations 
are evaluated in Dutch Caucasian familial and sporadic IBD patients, and in healthy 
controls. We found allele and genotype frequencies comparable with other European 
studies. Around 40% of patients with CD appeared to be carrier of at least one 
of the three mutations. In UC-affected patients and healthy controls carriage was 
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found in about 15%. Association with CD was found for G908R and L1007fs, but 
not for R702W. Association was also found between carriage of at least one of the 
three CARD15 mutations and disease behaviour, especially for carriage of L1007fs. 
Patients carrying L1007fs were more likely to have intestinal strictures and fistula 
formation. These findings, however, are not completely in line with the literature. 
A meta-analysis and a recent pooled analysis showed that carriage of at least one 
CARD15 variant is in particular associated with small bowel disease and to a lesser 
extent with stricturing disease 19, 20. 
We did not find an association between carriage of a common CARD15 muta-
tion and familial IBD. However, carriage of CARD15 L1007fs in IBD-affected rela-
tives of L1007fs-positive CD-affected probands occurred significantly more often 
than expected. In other studies, increased carriage of L1007fs was also found in 
unaffected first-degree relatives of CD-affected probands compared with healthy 
unrelated controls 21-23. Although healthy relatives can still develop IBD it is unlikely 
that carriage of the L1007fs mutation leads per se to IBD. In chapter 6, we have 
demonstrated this by a multiple IBD-affected family in which several first- and sec-
ond-degree relatives of a homozygous L1007fs CD-affected sib-pair also showed 
homozygous carriage of this mutation but yet had not developed CD even at very 
high age. In this specific family, the CARD15 mutation probably does not play an 
(important) role in the disease pathogenesis.
In the literature, CD-affected sib-pair families have been described which show 
linkage with the IBD1 locus, but without segregation of one of the three CARD15 
mutations 14, 24-26. There is evidence for the existence of a second IBD gene on the 
proximal region of chromosome 16p 24, as the IBD1 locus contains at least a second 
linkage peak not corresponding with the CARD15 gene 24, 27. Otherwise, in families 
with more than two affected sibs a decreased linkage with the IBD1 locus 27 and a 
lower frequency of CARD15 mutations 22 was found. As discussed before, in chapter 
2 linkage between the IL-4R gene and IBD has been found in 17 affected sib-pairs. 
The IL-4R gene is located on chromosome 16p12.1-p11.2 (MIM 147781), which is 
close to the second linkage peak 16p13.1-p13.3 within the IBD1 locus 6. Although 
not tested, this might explain the linkage result between IL-4R and IBD.
CD is a T-helper-1 cell driven disease, characterised by increased secretion of 
pro-inflammatory cytokines 28. In contrast, IL-10 is an anti-inflammatory cytokine, 
however, it may play a significant role in the pathogenesis of CARD15 mutation 
positive CD-affected patients. IL-10 secretion by human mononuclear cells of CD-
affected patients homozygous for L1007fs is significantly reduced after stimulation 
with a toll-like receptor 2 (TLR-2) agonist compared with CD-affected patients and 
healthy controls homozygous for wild-type CARD15. In contrast, no difference was 
seen in IL-10 secretion after stimulation with a TLR-4 agonist like lipopolysaccha-
ride (LPS) 29.
The family members carrying the IL-10 Gly15Arg mutation, as described in chap-
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ter 3, were also carrier of CARD15 L1007fs (three homozygotes and one heterozy-
gote, chapter 6). In these family members, it is unlikely that the observed reduced 
IL-10 secretion is caused by L1007fs carriage as we have performed the stimulation 
tests with LPS. We also performed cell stimulation with phorbol-12-myristate-13-
acetate, which is an agonist of intracellular protein kinase C that does not follow 
the TLR-signalling pathway 30. Stimulation with phorbol-12-myristate-13-acetate 
also showed a reduced IL-10 secretion of mononuclear cells from carriers of IL-10 
Gly15Arg. Therefore, our hypothesis that the nucleotide variation Gly15Arg in the 
IL-10 gene is functional and may predispose to the development of CD in patients 
carrying this mutation remains valid.
In chapter 8, a study is presented on genetic anticipation. This phenomenon is 
defined as disease manifestation in offspring at an earlier age and/or with a more 
severe course than in their affected parents 31. Genetic anticipation in IBD was sug-
gested by some uncontrolled studies. In our study, we compared clinical data of 
familial parent-child pairs with those from control parent-child pairs, including spo-
radic IBD-affected patients matched for age, sex and type of disease. We confirmed 
that children presented with symptoms of IBD and are diagnosed significantly ear-
lier than their IBD-affected parents. As this finding was also present in the control 
pairs, we concluded that genetic anticipation in IBD is very unlikely. Moreover, also 
no major differences were found for several clinical parameters involving the sever-
ity of the disease. The results regarding differences in age at onset of symptoms 
and age at diagnosis are probably caused by ascertainment bias. Our conclusion is 
in accordance with the literature 32. In fact, studies about genetic anticipation based 
on parent-offspring pairs are by definition characterised by a relative young onset 
in affected children as future IBD-affected individuals are not included. A long-term 
prospective study including a large cohort of IBD-affected patients may give a defini-
tive answer whether genetic anticipation in IBD exists.
FUTURE PERSPECTIVES
Due to its genetic complexity and heterogeneity it will probably take many years 
to discover all the IBD genes. However, new genetic technology involving a very 
large amount of single nucleotide polymorphisms (SNPs) to perform genome screens 
(linkage analysis) in multiple affected families or genome-wide association studies 
in multiple case-control pairs, might increase the progress of gene finding 33. Very 
recently, the first genome-wide association study in IBD was published, showing a 
highly significant association between CD and the IL-23R gene 34.
The discovery of new IBD genes will initiate additional research on their biologi-
cal (dys)function, hopefully leading to a better understanding of the pathogenesis. 
This has nicely been demonstrated for the CARD15 gene, which provided insight into 
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mechanisms of bacteria recognition in CD. However, the paradox whether CARD15 
mutations lead to ʻgain-of-functionʼ or ʻloss-of-functionʼ with respect to cytokine 
production is still unresolved 17.
Based on the results of genetic research, new treatment strategies can be devel-
oped. It may also lead to the development of clinical genetic tests, for example to 
confirm the diagnosis in IBD-affected patients 35, or it may provide a screening test 
in symptomatic individuals. Otherwise, genotyping in patients diagnosed with IBD 
may be useful as a prognostic test concerning the disease course and response to 
therapy 36, 37.
151Summary, general discussion and future perspectives
REFERENCES
1. Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin 
Gastroenterol 2004; 18: 463-479.
2. Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 2004; 18: 525-539.
3. Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharma-
cogenetics of IBD. Gastroenterology 2004; 126: 1533-1549.
4. Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel 
disease. Aliment Pharmacol Ther 2001; 15: 731-748.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
6. Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, meth-
odology, and present status of the field. Inflamm Bowel Dis 2004; 10: 300-311.
7. Wild GE, Rioux JD. Genome scan analyses and positional cloning strategy in IBD: successes and limi-
tations. Best Pract Res Clin Gastroenterol 2004; 18: 541-553.
8. Moore KW, de Waal Malefyt R, Coffman RL, OʼGarra A. Interleukin-10 and the interleukin-10 receptor. 
Annu Rev Immunol 2001; 19: 683-765.
9. Olavesen MG, Hampe J, Mirza MM, Saiz R, Lewis CM, Bridger S, et al. Analysis of single-nucleotide poly-
morphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease. 
Immunogenetics 2000; 51: 1-7.
10. Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of single nucleotide polymorphisms in 
the interleukin-4 gene and interleukin-4 receptor gene with Crohnʼs disease in a British population. 
Genes Immun 2001; 2: 44-47.
11. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, et al. Interleukin-4 and interleukin-4 recep-
tor gene polymorphisms in inflammatory bowel diseases. Genes Immun 2001; 2: 287-289.
12. de Jong DJ, Franke B, Naber AH, Willemen JJ, Heister AJ, Brunner HG, et al. No evidence for involvement of 
IL-4R and CD11B from the IBD1 region and STAT6 in the IBD2 region in Crohnʼs disease. Eur J Hum 
Genet 2003; 11: 884-887.
13. Yang H, Rotter JI. The genetics of ulcerative colitis and Crohnʼs disease. In: Kirsner JB, editor. Inflammatory 
bowel disease. 5th ed. Philadelphia, Pennsylvania: W.B. Saunders Company; 2000. p. 250-279.
14. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich 
repeat variants with susceptibility to Crohnʼs disease. Nature 2001; 411: 599-603.
15. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 
associated with susceptibility to Crohnʼs disease. Nature 2001; 411: 603-606.
16. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis 
and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum 
Genet 2002; 70: 845-857.
17. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for 
complex diseases? Lancet 2006; 367: 1271-1284.
18. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 
1998; 42: 477-484.
19. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on 
Crohnʼs disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 
152 Chapter 9
99: 2393-2404.
20. Oostenbrug LE, Nolte IM, Oosterom E, van der Steege G, Te Meerman GJ, van Dullemen HM, et al. CARD15 
in inflammatory bowel disease and Crohnʼs disease phenotypes: An association study and pooled 
analysis. Dig Liver Dis 2006; 38: 834-845.
21. Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, et al. Frequency of NOD2/CARD15 
variants in both sporadic and familial cases of Crohnʼs disease across Italy. An Italian Group for 
Inflammatory Bowel Disease Study. Dig Liver Dis 2004; 36: 121-124.
22. Tukel T, Shalata A, Present D, Rachmilewitz D, Mayer L, Grant D, et al. Crohn disease: frequency and 
nature of CARD15 mutations in Ashkenazi and Sephardi/Oriental Jewish families. Am J Hum Genet 
2004; 74: 623-636.
23. Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, et al. Transmission of CARD15 
(NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 2004; 
99: 299-305.
24. Hampe J, Frenzel H, Mirza MM, Croucher PJ, Cuthbert A, Mascheretti S, et al. Evidence for a NOD2-inde-
pendent susceptibility locus for inflammatory bowel disease on chromosome 16p. Proc Natl Acad Sci 
U S A 2002; 99: 321-326.
25. Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, OʼCallaghan NJ, Rodgers HJ, et al. CARD15/NOD2 risk alleles 
in the development of Crohnʼs disease in the Australian population. Ann Hum Genet 2003; 67: 35-41.
26. Sugimura K, Taylor KD, Lin YC, Hang T, Wang D, Tang YM, et al. A novel NOD2/CARD15 haplotype con-
ferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 2003; 72: 509-518.
27. Cavanaugh J, Consortium tIIG. International collaboration provides convincing linkage replication in 
complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. 
Am J Hum Genet 2001; 68: 1165-1171.
28. Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflamma-
tory bowel disease. Curr Opin Gastroenterol 2006; 22: 361-364.
29. Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, Naber TH, et al. NOD2 mediates anti-inflam-
matory signals induced by TLR2 ligands: implications for Crohnʼs disease. Eur J Immunol 2004; 34: 
2052-2059.
30. Wang Y, Biswas G, Prabu SK, Avadhani NG. Modulation of mitochondrial metabolic function by phorbol 
12-myristate 13-acetate through increased mitochondrial translocation of protein kinase Calpha in 
C2C12 myocytes. Biochem Pharmacol 2006; 72: 881-892.
31. Harper PS, Harley HG, Reardon W, Shaw DJ. Anticipation in myotonic dystrophy: new light on an old 
problem. Am J Hum Genet 1992; 51: 10-16.
32. Hampe J, Heymann K, Kruis W, Raedler A, Folsch UR, Schreiber S. Anticipation in inflammatory bowel dis-
ease: a phenomenon caused by an accumulation of confounders. Am J Med Genet 2000; 92: 178-183.
33. Craig DW, Stephan DA. Applications of whole-genome high-density SNP genotyping. Expert Rev Mol 
Diagn 2005; 5: 159-170.
34. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study 
identifies IL23R as an inflammatory bowel disease gene. Science 2006; in press.
35. Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want 
genetic testing? Inflamm Bowel Dis 2006; 12: 497-502.
153Summary, general discussion and future perspectives
36. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol 2004; 18: 
569-575.
37. Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. 
Inflamm Bowel Dis 2005; 11: 56-61.
154 Chapter 9
CHAPTER 10
Samenvatting, algemene discussie 
en toekomstperspectief
156 Chapter 10
SAMENVATTING EN ALGEMENE DISCUSSIE
Dit promotieonderzoek richt zich op genetische factoren die van invloed zijn 
op het ontstaan van inflammatoire darmziekten (IBD), zoals de ziekte van Crohn en 
colitis ulcerosa 1. Gestart is met de opbouw van een dataset bestaande uit klinische 
gegevens en DNA materiaal van patiënten met IBD, met en zonder een positieve 
familieanamnese voor dit complex van aandoeningen. Vervolgens heeft het onder-
zoek zich toegespitst op de caspase recruitment domain 15 (CARD15) en interleu-
kine-10 (IL-10) genen.
Epidemiologisch 2, 3 en moleculair biologisch onderzoek 4 heeft aangetoond dat 
erfelijke factoren een belangrijke rol spelen bij het ontstaan van IBD. Waarschijnlijk 
leiden bepaalde genen (in combinatie met omgevingsfactoren zoals roken) tot zowel 
Crohn als colitis ulcerosa, terwijl andere genen juist specifiek zijn voor het ontstaan 
van een van beide aandoeningen 4, 5. Genoomscans hebben door middel van koppe-
lingsonderzoek (linkage analyse) bij families met IBD aangetoond dat er tenminste 
negen chromosoomgebieden (IBD1 tot en met IBD9 locus) zijn waarop IBD-genen 
kunnen liggen 6. Met behulp van ʻfine mappingʼ en de kandidaat-gen methode zijn 
deze IBD-gebieden verder onderzocht en is op chromosoom 16 in het IBD1 locus 
het CARD15 gen ontdekt. Dit is het eerste gen waarvan is aangetoond dat het een 
belangrijke rol speelt bij het ontstaan van de ziekte van Crohn 7.
In tegenstelling tot het CARD15 gen maakt het IL-10 gen geen deel uit van een 
IBD locus. Het IL-10 gen heeft een ontstekingsremmende (anti-inflammatoire) werk-
ing en kan daardoor ook van invloed zijn op het ontstaan van IBD 8. Het IL-10 gen 
is dus als kandidaat-gen geschikt voor verdere genetische studies in de zoektocht 
naar genen die van invloed zijn op het ontstaan van complexe multigen ziekten 
zoals IBD.
In de hoofdstukken 1 en 5 wordt een overzicht gegeven van de epidemiologie, 
pathogenese en genetica van IBD.
Genetische heterogeniteit kan een rol spelen bij complexe ziektebeelden. Dit 
betekent dat meerdere (gemuteerde) genen kunnen leiden tot het ontstaan van een-
zelfde (uitingsvorm van een) ziekte 5. Genetische heterogeniteit bij IBD komt aan de 
orde in hoofdstuk 2. In dit hoofdstuk wordt een koppelingsonderzoek beschreven 
bij een relatief kleine groep sib-paren (broer/zus relatie) met IBD, waarin verschil-
lende inflammatoire en anti-inflammatoire cytokine en cytokinereceptor kandidaat-
genen zijn geëvalueerd. Daarbij is specifiek gekeken naar overeenkomstige allelen 
per sib-paar. Zoals verwacht is de uitkomst van deze zogenaamde ʻallele-sharingʼ 
methode heel verschillend per sib-paar. Voor de hele groep is alleen voor het IL-4 
receptor (IL-4R) gen een significante LOD score (uitkomst van koppelingsonderzoek) 
gevonden. Het IL-4R gen maakt deel uit van het IBD1 locus, echter het is niet waar-
schijnlijk dat dit gen een belangrijke rol speelt bij het ontstaan van IBD. In andere 
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studies is namelijk geen associatie aangetoond tussen dit kandidaat-gen en IBD 9-12. 
De significante LOD score, zoals hiervoor beschreven, is waarschijnlijk ook niet 
veroorzaakt door dragerschap van CARD15 mutaties in de onderzochte sib-paren. 
Namelijk van de zeventien onderzochte sib-paren zijn er negen sib-paren (vier paren 
met de ziekte van Crohn en vijf paren met colitis ulcerosa) die IL-4R allelen delen. 
Daarvan blijkt slechts één patiënt (proband met de ziekte van Crohn) drager te zijn 
van CARD15 mutaties (dubbel heterozygoot R702W/L1007fs). Een vrouwelijke pro-
band met colitis ulcerosa is niet getest, doch haar tweelingzus en broer met colitis 
ulcerosa zijn geen drager van CARD15 mutaties (niet gepubliceerde data). Deze 
bevindingen zijn in overeenstemming met een andere Nederlandse studie 12.
Binnen een grote onderzoeksgroep kan met koppelingsonderzoek en de kandi-
daat-gen methode worden aangetoond dat een bepaald gen geen rol speelt bij het 
ontstaan van de onderzochte ziekte. Met deze onderzoeksmethoden is echter niet 
uitgesloten dat het onderzochte gen toch betrokken is bij het ontstaan van de ziekte 
in individuele gevallen en/of families. Het is zelfs niet uitgesloten dat in bepaalde 
families IBD wordt veroorzaakt door één belangrijk gen wat overerft volgens de 
wetten van Mendel 13. In hoofdstuk 3 en 4 is van deze hypothese uitgegaan in het 
onderzoek naar het IL-10 gen. Sib-paren met volledig overeenkomstige IL-10 alle-
len werden geacht de hoogste kans te hebben op een IL-10 mutatie. Het IL-10 gen 
van deze sib-paren is gescreend op nucleotide veranderingen van de exonen en de 
promotorgebieden. Door middel van DNA-sequencing is de puntmutatie Gly15Arg 
gevonden in één sib-paar met de ziekte van Crohn. De mutatie werd ook aangetrof-
fen bij eerstegraads famileleden zonder IBD. Daarnaast is het voorkomen van deze 
mutatie bestudeerd in 379 patiënten met de ziekte van Crohn, afkomstig uit de 
Rotterdamse IBD database en de databases van twee andere Nederlandse academi-
sche ziekenhuizen. In dit onderzoek is bij nog één patiënt en haar gezonde ouder de 
IL-10 Gly15Arg mutatie gevonden. Deze mutatie komt niet voor in de controlegroep 
van 75 personen. Geconcludeerd is dat de IL-10 Gly15Arg mutatie niet geassocieerd 
is met de ziekte van Crohn. De mutatie is overigens wel functioneel; bij dragers blijkt 
de secretie van IL-10 verlaagd. Dit is aangetoond in een in vitro stimulatietest met 
humane perifere mononucleaire cellen. In een tweede experiment waarbij gebruik 
is gemaakt van een IL-10 afhankelijke HL60 cellijn (humane leukemie cellijn), blijkt 
de werking van het gemuteerde IL-10 eiwit ook veranderd. Geconcludeerd is dat in 
families met de ziekte van Crohn de IL-10 Gly15Arg mutatie kan bijdragen aan het 
ontstaan van de ziekte vanwege een verminderde IL-10 respons bij een ontsteking 
van het maag-darmkanaal.
Een belangrijke doorbraak in het genonderzoek bij IBD was de ontdekking van 
het CARD15 gen in 2001. Drie belangrijke mutaties in dit gen - te weten R702W, 
G908R en L1007fs - zijn onafhankelijk van elkaar geassocieerd met de ziekte van 
Crohn. Dit betekent dat dragerschap van één of meerdere van deze mutaties leidt 
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tot een verhoogd risico op het krijgen van de ziekte 14-16. Intussen is er veel onder-
zoek gedaan naar het biologische effect van CARD15 mutaties. Dit heeft geleid tot 
twee tegengestelde hypothesen. In onderzoek op menselijk materiaal leidt de aan-
wezigheid van CARD15 mutaties tot een verlaagde activiteit van het transcription 
factor nuclear kappa-B (NFκB). Dit betekent functieverlies van het gen (ʼloss-of-
functionʼ) waardoor er geen ontstekingsproces in gang wordt gezet. Daarentegen 
heeft onderzoek op dierlijk materiaal aangetoond dat gemuteerd CARD15 juist leidt 
tot een verminderde down-regulatie van NFκB. Deze ʻgain-of-functionʼ zorgt voor 
een verhoogde NFκB activiteit. Dit leidt tot toename van ontstekingsbevorderende 
cytokinen en daarmee tot het juist wel in gang zetten van een ontstekingsproces 17. 
 De laatste hypothese is meer in overeenstemming met klinische bevindingen bij 
patiënten met de ziekte van Crohn. Patiënten met Crohn hebben namelijk een ver-
hoogde NFκB activiteit in de darm 18.
In de hoofdstukken 6 en 7 zijn onderzoeken beschreven naar het voorkomen 
van de drie hiervoor genoemde CARD15 mutaties in een groep Nederlandse patiënten 
met IBD en een gezonde controlegroep. De gevonden allel- en genotypefrequenties 
komen overeen met de resultaten van andere Europese studies. Ongeveer 40% van 
de patiënten met de ziekte van Crohn blijkt drager te zijn van tenminste één van 
de drie mutaties. Bij patiënten met colitis ulcerosa en in de gezonde controlegroep 
blijkt dit 15% te zijn. De mutaties G908R en L1007fs zijn geassocieerd met de ziekte 
van Crohn. Daarnaast is associatie gevonden tussen dragerschap van tenminste één 
van de drie mutaties en het ziektegedrag van Crohn. Dit verband is het sterkst voor 
de L1007fs mutatie. Zo hebben patiënten met L1007fs mutatie een groter risico op 
darmstricturen en fistels. Deze bevindingen zijn niet volledig in overeenstemming 
met de literatuur. Twee grote studies hebben namelijk aangetoond dat dragerschap 
van tenminste één van de drie CARD15 mutaties in patiënten met de ziekte van 
Crohn is geassocieerd met lokalisatie van de ziekte in de dunne darm en daarnaast 
(in mindere mate) met darmstricturen 19, 20. 
Bij patiënten met de ziekte van Crohn is er geen associatie tussen dragerschap 
van één van de drie CARD15 mutaties en het hebben van een positieve familieanam-
nese voor IBD. Daarentegen blijkt wel dat bij patiënten met de ziekte van Crohn én 
de CARD15 L1007fs mutatie, familieleden met IBD significant vaker dan verwacht 
ook drager zijn van deze mutatie. Ander studies vonden ook een hoger percen-
tage dragerschap van de L1007fs mutatie in gezonde eerstegraads familieleden van 
patiënten met Crohn in vergelijking met gezonde (niet-bloedverwante) controles 21-23. 
Hoewel gezonde familieleden nog IBD kunnen ontwikkelen, blijkt uit dit onderzoek 
(hoofdstuk 6) dat het niet waarschijnlijk is dat dragerschap van L1007fs per defi-
nitie leidt tot het krijgen van IBD. Bij familieleden van een sib-paar met de ziekte 
van Crohn én homozygoot drager van CARD15 L1007fs, blijken meerdere eerste- 
en tweedegraads familieleden ook homozygoot drager van deze mutatie. Echter zij 
hebben tot op hoge leeftijd geen kenmerken van de ziekte van Crohn vertoond. In 
deze specifieke familie speelt het CARD15 gen waarschijnlijk geen (belangrijke) rol 
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bij het ontstaan van de ziekte.
In de literatuur zijn sib-paren met de ziekte van Crohn beschreven waarbij kop-
peling met het IBD1 locus niet blijkt te berusten op dragerschap van één van de drie 
CARD15 mutaties 14, 24-26. Het koppelingsonderzoek wijst uit dat er waarschijnlijk 
naast het CARD15 gen nog een tweede IBD gen op het IBD1 locus ligt 24, aangezien 
er twee koppelingspieken zijn gevonden binnen dit locus 24, 27. In families met meer 
dan twee aangedane sibs (broer/zus relatie) is een minder sterke koppeling gevon-
den met het IBD1 locus 27. In dergelijke families komt dragerschap van CARD15 
mutaties ook minder voor 22. In hoofdstuk 2 en zoals hiervoor beschreven, wordt in 
dit onderzoek bij zeventien sib-paren koppeling aangetoond tussen het IL-4R gen 
en IBD. Het IL-4R gen ligt op chromosoom 16p12.1-p11.2 wat dicht in de buurt ligt 
van de tweede koppelingspiek 16p13.1-p13.3 binnen het IBD1 locus 6. Hoewel dit 
niet verder is uitgezocht, kan dit verklaren waarom er koppeling is gevonden tussen 
het IL-4R gen en IBD bij de zeventien sib-paren.
Bij de ziekte van Crohn speelt de T-helper-1 cel een belangrijke rol. Deze cel 
produceert ontstekingsbevorderende cytokines 28. Daarentegen is IL-10 een ontste-
kingsremmende cytokine. Laatstgenoemde cytokine kan ook een belangrijke rol spe-
len bij patiënten met de ziekte van Crohn en drager zijn CARD15 mutaties. Stimulatie 
van humane mononucleaire cellen via de toll-like receptor 2 (TLR-2) van patiënten 
met de ziekte van Crohn en homozygoot drager van de CARD15 L1007fs mutatie, 
leidt tot een verlaagde IL-10 secretie ten opzichte van patiënten met de ziekte van 
Crohn en gezonde controles die drager zijn van het niet gemuteerde CARD15 gen. 
Daarentegen is geen verschil gezien in IL-10 secretie na celstimulatie via de TLR-4 
met lipopolysaccharide (LPS) 29.
De familieleden met de IL-10 Gly15Arg mutatie (hoofdstuk 3) blijken in dit 
onderzoek ook drager te zijn van de CARD15 L1007fs mutatie. Drie personen zijn 
homozygoot en één persoon is heterozygoot drager (hoofdstuk 6). De celstimulatie-
test zoals beschreven in hoofdstuk 3 is uitgevoerd met LPS. Daarom is het onwaar-
schijnlijk dat de verlaagde IL-10 secretie bij de bovenstaande familieleden het gevolg 
is van de CARD15 L1007fs mutatie. In het onderzoek is ook celstimulatie verricht 
met phorbol-12-myristate-13-acetaat (hoofdstuk 3), wat ook een verlaagde IL-10 
secretie toont. Stimulatie met phorbol-12-myristate-13-acetaat loopt via een andere 
route dan de toll-like receptoren 30. De hiervoor genoemde hypothese blijft daarom 
gehandhaafd; de nucleotideverandering Gly15Arg in het IL-10 gen betreft een func-
tionele mutatie en kan bijdragen aan het ontstaan van de ziekte van Crohn.
In hoofdstuk 8 wordt een studie beschreven naar genetische anticipatie bij IBD. 
Dit betekent dat de ziekte zich in opeenvolgende generaties op steeds jongere leef-
tijd en/of met een steeds ernstiger beloop manifesteert 31. Genetisch anticipatie bij 
IBD is gesuggereerd in enkele studies zonder een controlegroep. In dit onderzoek 
zijn klinische kenmerken vergeleken tussen ouders en hun kinderen met IBD en een 
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controlegroep. De controlegroep bestond uit volwassen en kinderen met IBD van 
dezelfde leeftijd en hetzelfde geslacht als de onderzoeksgroep, maar zonder een 
positieve familieanamnese voor IBD. Geconcludeerd is dat kinderen met een positieve 
familieanamnese op significant jongere leeftijd symptomen ontwikkelen en ook op 
jongere leeftijd worden gediagnosticeerd met IBD dan hun aangedane ouders. Echter 
dezelfde bevindingen zijn gevonden in de controlegroep. Op grond hiervan is gecon-
cludeerd dat genetische anticipatie bij IBD waarschijnlijk niet bestaat. Verder zijn er 
ook geen relevante verschillen gevonden tussen de onderzoeksgroep en controlegroep 
wat betreft klinische parameters die de ernst van de ziekte bepalen. Waarschijnlijk 
wordt het verschil in leeftijd waarop symptomen optreden en de diagnose kan worden 
gesteld, veroorzaakt door ascertainment bias (inclusie-bias). Deze conclusie komt 
overeen met de bevindingen in andere studies 32. Onderzoek naar genetische antici-
patie waarbij gebruik wordt gemaakt van aangedane ouder-kind paren wordt per defi-
nitie gekenmerkt door een relatief jonge leeftijd waarop de ziekte zich manifesteert bij 
de kinderen. In dergelijke onderzoeken worden namelijk geen familieleden onderzocht 
die mogelijk erfelijk belast zijn en dus in de toekomst de ziekte nog kunnen ontwik-
kelen. Een langdurig lopend prospectief onderzoek bij een grote groep patiënten met 
IBD kan mogelijk uitwijzen of genetische anticipatie bij IBD werkelijk voorkomt.
TOEKOMSTPERSPECTIEF
De genetische achtergrond van IBD is complex en heterogeen. Het zal waarschijn-
lijk nog vele jaren duren voordat alle IBD genen zijn ontdekt. Nieuwe genetische 
onderzoekstechnologieën die gebruik maken van zeer grote aantallen enkelvoudige 
nucleotideveranderingen (SNP, single nucleotide polymorphism) voor de uitvoering 
van koppelings- en associatieonderzoek van het gehele menselijke genoom, kunnen 
de zoektocht naar IBD genen een impuls geven 33. Op deze manier is heel recent het 
IL-23 receptor (IL-23R) gen aangetoond. Het IL-23R gen blijkt sterk geassocieerd 
te zijn met de ziekte van Crohn 34.
De ontdekking van (nieuwe) IBD genen maakt het mogelijk om meer inzicht 
te krijgen in het ontstaan van de ziekte. Een goed voorbeeld is het CARD15 gen. 
Uitgebreid onderzoek naar de functie van CARD15 heeft meer inzicht gegeven in 
herkenningsmechanismen van bacteriën bij de ziekte van Crohn. Echter er zijn nu 
twee plausibele, doch tegenstrijdige hypothesen (ʻgain-of-functionʼ versus ʻloss-of-
functionʼ) over de rol van het gemuteerde CARD15 gen bij een darmontsteking 17.
Verder genetisch onderzoek kan de behandelmogelijkheden van patiënten met 
IBD in de toekomst verbeteren. Tevens kan onderzoek de ontwikkeling van klinische 
gentesten mogelijk maken. Deze testen kunnen een waardevolle aanvulling zijn bij 
het stellen van de diagnose 35 en bepalen van de prognose 36, 37 van IBD. Een derge-
lijke test zou ook ingezet kunnen worden om mensen met klachten verdacht voor 
IBD te diagnosticeren. 
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te Los Angeles (USA). 
In 1994 neemt Van der Linde zijn artsenbul in ontvangst en begint 
als arts-assistent Interne Geneeskunde in het Drechtsteden ziekenhuis te 
Dordrecht (thans Albert Schweitzer ziekenhuis). Nog datzelfde jaar wordt 
hij daar toegelaten tot de zesjarige opleiding tot internist (opleider Dr. 
B. Hazenberg, later Dr. A.J.M. van Vliet). De laatste twee opleidingsjaren 
werkt Van der Linde in het Erasmus MC Universitair Medisch Centrum 
Rotterdam (opleider Prof. J.H.P. Wilson). Aansluitend volgt hij in datzelfde 
ziekenhuis de driejarige opleiding maag-, darm- en leverziekten (opleider 
Prof.dr. S.W. Schalm, later Prof.dr. E.J. Kuipers). 
Naast de opleiding start hij in 1998 zijn promotieonderzoek naar gene-
tische factoren die van invloed zijn op het ontstaan van inflammatoire 
darmziekten. 
Januari 2003 begint Van der Linde als maag-darm-leverarts in het 
Medisch Centrum Leeuwarden. Daar heeft hij de afgelopen jaren de gas-
trointestinale endo-echografie geïntroduceerd. 
Hij is getrouwd met Hanneke Schuiringa. Ze hebben drie jongens: 
Gaaike, Jelte en Siert. Het gezin woont met veel plezier in de Friese 
Trynwâlden.
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